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A B S T R A C T
Background
Non-alcohol related fatty liver disease (commonly called non-alcoholic fatty liver disease (NAFLD)) is liver steatosis in the absence of
significant alcohol consumption, use of hepatotoxic medication, or other disorders affecting the liver such as hepatitis C virus infection,
Wilson’s disease, and starvation. NAFLD embraces the full spectrum of disease from pure steatosis (i.e. uncomplicated fatty liver)
to non-alcoholic steatohepatitis (NASH), via NASH-cirrhosis to cirrhosis. The optimal pharmacological treatment for people with
NAFLD remains uncertain.
Objectives
To assess the comparative benefits and harms of different pharmacological interventions in the treatment of NAFLD through a network
meta-analysis and to generate rankings of the available pharmacological treatments according to their safety and efficacy. However,
it was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did not
perform the network meta-analysis, and instead, assessed the comparative benefits and harms of different interventions using standard
Cochrane methodology.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded,
the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.com to August 2016.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in participants with NAFLD.
We excluded trials which included participants who had previously undergone liver transplantation. We considered any of the various
pharmacological interventions compared with each other or with placebo or no intervention.
Data collection and analysis
We calculated the odds ratio (OR) and rate ratio with 95% confidence intervals (CI) using both fixed-effect and random-effects models
based on an available participant analysis with Review Manager. We assessed risk of bias according to the Cochrane risk of bias tool,
controlled risk of random errors with Trial Sequential Analysis, and assessed the quality of the evidence using GRADE.
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Main results
We identified 77 trials including 6287 participants that met the inclusion criteria of this review. Forty-one trials (3829 participants)
provided information for one or more outcomes. Only one trial was at low risk of bias in all domains. All other trials were at high risk
of bias in one or more domains. Overall, all the evidence was very low quality. Thirty-five trials included only participants with non-
alcohol related steatohepatitis (NASH) (based on biopsy confirmation). Five trials included only participants with diabetes mellitus;
14 trials included only participants without diabetes mellitus. The follow-up in the trials ranged from one month to 24 months.
We present here only the comparisons of active intervention versus no intervention in which two or more trials reported at least one
of the following outcomes: mortality at maximal follow-up, serious adverse events, and health-related quality of life, the outcomes that
determine whether a treatment should be used.
Antioxidants versus no intervention
There was no mortality in either group (87 participants; 1 trial; very low quality evidence). None of the participants developed serious
adverse events in the trial which reported the proportion of people with serious adverse events (87 participants; 1 trial; very low quality
evidence). There was no evidence of difference in the number of serious adverse events between antioxidants and no intervention (rate
ratio 0.89, 95% CI 0.36 to 2.19; 254 participants; 2 trials; very low quality evidence). None of the trials reported health-related quality
of life.
Bile acids versus no intervention
There was no evidence of difference in mortality at maximal follow-up (OR 5.11, 95% CI 0.24 to 107.34; 659 participants; 4 trials;
very low quality evidence), proportion of people with serious adverse events (OR 1.56, 95% CI 0.84 to 2.88; 404 participants; 3 trials;
very low quality evidence), or the number of serious adverse events (rate ratio 1.01, 95% CI 0.66 to 1.54; 404 participants; 3 trials;
very low quality evidence) between bile acids and no intervention. None of the trials reported health-related quality of life.
Thiazolidinediones versus no intervention
There was no mortality in either group (74 participants; 1 trial; very low quality evidence). None of the participants developed serious
adverse events in the two trials which reported the proportion of people with serious adverse events (194 participants; 2 trials; very
low quality evidence). There was no evidence of difference in the number of serious adverse events between thiazolidinediones and no
intervention (rate ratio 0.25, 95% CI 0.06 to 1.05; 357 participants; 3 trials; very low quality evidence). None of the trials reported
health-related quality of life.
Source of funding
Twenty-six trials were partially- or fully-funded by pharmaceutical companies that would benefit, based on the results of the trial.
Twelve trials did not receive any additional funding or were funded by parties with no vested interest in the results. The source of
funding was not provided in 39 trials.
Authors’ conclusions
Due to the very low quality evidence, we are very uncertain about the effectiveness of pharmacological treatments for people with
NAFLD including those with steatohepatitis. Further well-designed randomised clinical trials with sufficiently large sample sizes are
necessary.
P L A I N L A N G U A G E S U M M A R Y
Medical treatment for people with non-alcohol related fatty liver disease
Review question
We aimed to assess different medications to treat people with non-alcohol related fatty liver disease.
Background
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat in the liver in people who have no history of significant alcohol
consumption, use of medicines, diseases such as hepatitis C virus infection, or other conditions such as starvation that can damage
the liver. Fatty liver can lead to liver damage resulting in inflammation (non-alcohol related steatohepatitis or NASH) or liver scarring
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(liver cirrhosis). The best way to treat people with NAFLD is not clear. We sought to resolve this issue by searching for existing trials
on the topic.
Selection criteria and date of search
We included all randomised clinical trials (clinical studies where people are randomly put into one of two or more intervention groups)
reported to August 2016.
Study characteristics
We included 77 randomised clinical trials that involved a total of 6287 participants. Of these, 41 trials (3829 participants) provided
information for one or more outcomes for this review. Thirty-five trials only included participants with NASH; five included only
people with diabetes mellitus; and 14 included only people who did not have diabetes mellitus. The average follow-up period in the
trials ranged from one month to two years in the trials that reported this information. We excluded trials in which participants with
NAFLD had undergone liver transplantation before the trial. As well as conducting standard Cochrane analysis, we also planned to
conduct network meta-analysis (a technique that enables comparison of different treatments that are not directly compared to each
other in the trials). However, the nature of available information meant we could not determine if the network meta-analysis results
were reliable.
Specific outcomes we looked for were numbers of deaths, adverse events, and assessment of health-related quality of life.
Study funding sources
Twelve trials did not receive any additional funding or were funded by sources with no vested interest in the results; 26 were funded by
drug companies that could potentially benefit from trial results; and the funding source was not available from 39 trials.
Key results
Included trials compared drug treatments such as bile acids, antioxidants, phosphodiesterase type 4 inhibitor, glucocorticosteroid
inhibitor, anti-cholesterol drugs and anti-diabetes drugs with a fake treatment (placebo) or no treatment.
Antioxidants versus no intervention
There were no deaths in either group (87 participants, 1 trial). None of the participants developed serious adverse events in the trial
which reported the percentage of people with serious adverse events (87 participants, 1 trial). There was no evidence of difference in
the number of serious adverse events between antioxidants and no intervention (254 participants, 2 trials).
Bile acids versus no intervention
There was no evidence of difference in deaths at maximal follow-up (659 participants, 4 trials), percentage of people with serious
adverse events (404 participants, 3 trials), or the number of serious adverse events (404 participants, 3 trials) between bile acids and no
intervention. None of the trials reported health-related quality of life.
Thiazolidinediones versus no intervention
There were no deaths in either group (74 participants, 1 trial). None of the participants developed serious adverse events in the two trials
which reported the percentage of people with serious adverse events (194 participants, 2 trials). There was no evidence of difference
in the number of serious adverse events between thiazolidinediones and no intervention (357 participants, 3 trials). None of the trials
reported health-related quality of life.
We found no evidence of benefit from any of the compared interventions in people with fatty liver disease. There is significant
uncertainty in this issue, and we need further high quality randomised clinical trials with sufficiently large group of participants.
Quality of evidence
Evidence quality was very low overall, and there was a high risk of bias. This means there is a possibility of making conclusions that
wrongly interpret benefits or harms of treatments because of the ways the studies were conducted.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antioxidants versus no intervention for non-alcohol related fatty liver disease
Patient or population: part icipants with non-alcohol related fatty liver disease (NAFLD)
Settings: secondary or tert iary care
Intervention: ant ioxidants
Control: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Antioxidants
M ortality
Follow-up: 12 months
There were no events in either group 87
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
Follow-up: 12 months
There were no events in either group 87
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number of events)
Follow-up: 12 months to 22
months
101 per 1000 90 per 1000
(36 to 221)
rate ratio 0.89
(0.36 to 2.19)
254
(2 trials)
⊕©©©
very low1,2,4
Health- related quality of
life
None of the trials reported this outcome
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level for risk of bias because of the high risk of bias in the trial(s).
2 Downgraded one level for imprecision because of sample size.
3 Downgraded one level for imprecision because of lack of events.
4 Downgraded one level for imprecision because of wide conf idence intervals.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Fatty liver disease is steatosis (accumulation of fat - usually triglyc-
erides) in the liver parenchymal cells (NCBI 2014). Non-alco-
hol related fatty liver disease (also called non-alcoholic fatty liver
disease (NAFLD)) is liver steatosis in the absence of significant
alcohol consumption; use of medications such as methotrexate,
tamoxifen, or steroids; or other disorders such as hepatitis C virus
infection, Wilson’s disease, starvation, and lecithin cholesterol
acyltransferase (LCAT) deficiency that result in fat accumulation
(Chalasani 2012). Fatty liver disease includes a spectrum of dis-
orders ranging from simple steatosis or non-alcoholic fatty liver
(NAFL) (fat accumulation without evidence of liver parenchy-
mal cell injury), non-alcoholic steatohepatitis (NASH) (fat accu-
mulation with liver parenchymal injury but without cirrhosis), to
NASH cirrhosis (advanced liver fibrosis with current or previous
NAFL or NASH) to cirrhosis (Chalasani 2012; Rinella 2015).
The prevalence of NAFLD varies between 19% and 33% in differ-
ent populations, depending upon ethnicity, region of origin (also
among people of similar ethnicity), being overweight or obese,
and having other disorders such as diabetes mellitus or hyper-
tension (Bedogni 2005; Park 2006; Dassanayake 2009; Koehler
2012; Lazo 2013; Fleischman 2014; Li 2014; Shen 2014; Nishioji
2015). The major risk factors associated with increased prevalence
of NAFLD are beingmale, increasing age, ethnicity (e.g.Mexican-
Americans have higher prevalence of fatty liver than other eth-
nic groups), hypertension, hypercholesterolaemia, diabetes mel-
litus, lower socio-economic level, lower level educational attain-
ment, and lower physical activity (Bedogni 2005; Park 2006;
Dassanayake 2009; Koehler 2012; Lazo 2013; Fleischman 2014;
Shen 2014; Lonardo 2015).
The mean age of people with NAFLD varies between 40 years
and 60 years (Bedogni 2005; Dassanayake 2009; Shen 2014). In
studies with long-term follow-up, the mean age of people with
NAFLD ranged between 45 years and 50 years (Adams 2005;
Bedogni 2007; Soderberg 2010; Onnerhag 2014). After a mean
follow-up period of 8 years to 28 years, the presence of NAFLD in-
creased overall long-termmortality compared to the general popu-
lation without NAFLD (Adams 2005; Bedogni 2007; Ong 2008;
Soderberg 2010; Onnerhag 2014).
People with NAFLD are at risk of dying before reaching the mean
life expectancy at birth (Adams 2005; Bedogni 2007; Ong 2008;
Soderberg 2010; Onnerhag 2014). It is widely believed that peo-
ple with simple steatosis rarely progress to advanced liver disease
but people with NASH may develop cirrhosis (Chalasani 2012).
It has been reported that in people with NAFLD, liver fibrosis
was the only histological feature associated with increased mortal-
ity and requirement for liver transplantation (Angulo 2015). In a
trial that followed people with simple steatosis and NASH for a
mean of 28 years, similar rates of mortality were observed between
participants in the intervention and control groups (Soderberg
2010). However,mortality was higher than the general population
mortality rate. It is noteworthy that NAFLD is associated with
metabolic syndrome (presence of three of the following factors:
hypertension, raised triglycerides, lowered high-density lipopro-
tein cholesterol, raised fasting glucose, and central obesity; Alberti
2009) (Ballestri 2016). Therefore, increased mortality in people
with NAFLD may be related to metabolic syndrome rather than
NAFLD per se.
Fat accumulates within the liver cells when there is an imbalance
between the mechanisms that reduce fat in cells (such as oxidation
of fatty acids or secretion of lipoproteins) and mechanisms that
increase fat in cells (such as increased uptake of fat and increased
production of fat). The accumulation of fat leading to NAFLD
is believed to be mediated by insulin resistance because insulin
resistance increases the breakdown of peripheral adipose tissue
with resultant increased influx of free fatty acids (FFA), promotes
the synthesis of new triglycerides within the liver, and decreases
the oxidation of FFAs (Abdelmalek 2007). The accumulation of
fat in the liver causes injury due to pro-inflammatory cytokines (
Riley 2007). However, themechanism by which only a proportion
of people develop advanced liver fibrosis or primary liver cancer
(hepatocellular cancer or HCC) is unclear (Abdelmalek 2007).
Ultrasound is a widely usedmethod for screening the general pop-
ulation for NAFLD; however, it is operator-dependent (Hernaez
2011), and may miss 15 people with fatty liver disease out of ev-
ery 100 people screened (Hernaez 2011). It may also yield false-
positive results in 7 out of 100 people without fatty liver disease
(Hernaez 2011).
Description of the intervention
Various interventions have been tried in the treatment of people
withNAFLD.These include lifestylemodifications such as dietary
changes and increased exercise (not included in this review) and
a wide range of agents, such as those that decrease: weight (e.g.
orlistat); insulin resistance (insulin-sensitising agents; such as met-
formin and thiazolidinediones (e.g. pioglitazone, rosiglitazone));
and oxidative stress (e.g. vitamin E, herbal preparations such as
milk thistle (silymarin or Silybum marianum extract) and S-adeno-
sylmethionine); agents such as statins (e.g. simvastatin, atorvas-
tatin); secondary bile acids or analogues such as ursodeoxycholic
acid or obeticholic acid; omega-3 fatty acids that play a role in
fat metabolism; angiotensin-converting enzyme (ACE) inhibitors
such as ramipril or angiotensin II receptor antagonists such as
losartan; and weight reduction surgery (bariatric surgery) (not in-
cluded in this review) in obese peoplewithNAFLD(Adorini 2012;
Anstee 2012; Chalasani 2012; Paschos 2012; Abenavoli 2013a).
How the intervention might work
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Lifestyle modifications such as diet and increased exercise, agents
(e.g. orlistat) and surgeries resulting in weight loss (not included
in this review), and insulin-sensitising agents such as metformin
or thiazolidinediones are aimed at decreasing insulin resistance
(Chalasani 2012; Thoma 2012). Milk thistle, vitamin E, and
S-adenosylmethionine decrease oxidative damage to liver cells
(Anstee 2012; Chalasani 2012; Abenavoli 2013a). Bile acids play
a role in fat metabolism and have anti-inflammatory and anti-fi-
brotic properties (Adorini 2012). Statins and omega-3 fatty acids
decrease circulating cholesterol levels and hencemay decrease fatty
liver (Chalasani 2012). ACE inhibitors and angiotensin II recep-
tor antagonists inhibit the production or action of angiotensin II
and therefore may decrease liver fibrosis, which may be mediated
by the renin-angiotensin-aldosterone axis (Paschos 2012).
Why it is important to do this review
The optimal pharmacological treatment of people with NAFLD
is unknown. Currently, no pharmacological treatment is recom-
mended routinely in the treatment for all people with NAFLD. In
people who do not have diabetes mellitus but who have biopsy-
confirmed NASH, vitamin E has been recommended as the first-
line treatment (Chalasani 2012). Pioglitazone may also be consid-
ered for people with biopsy-confirmed NASH (Chalasani 2012).
Screening for NAFLD is not recommended because of the uncer-
tainties surrounding the effectiveness of diagnostic tests and treat-
ment options (Chalasani 2012).
Network meta-analysis enables direct and indirect evidence to be
combined and to rank different interventions in terms of differ-
ent outcomes (Salanti 2011; Salanti 2012). There has been no
previous Cochrane Review on this topic. This Cochrane Review
and attempted network meta-analysis aimed to provide the best
evidence for the role of different pharmacological interventions in
the treatment of people NAFLD.
O B J E C T I V E S
To assess the comparative benefits and harms of different phar-
macological interventions in the treatment of NAFLD through a
network meta-analysis and to generate rankings of the available
pharmacological interventions according to their safety and effi-
cacy. However, it was not possible to assess whether the potential
effect modifiers were similar across different comparisons. There-
fore, we did not perform the network meta-analysis, and instead,
assessed the comparative benefits and harms of different interven-
tions using standard Cochrane methodology.
When more trials become available with adequate description of
potential effect modifiers, we will attempt to conduct network
meta-analysis to generate rankings of the available interventions
according to their safety and efficacy. This is why we retained the
planned methodology for network meta-analysis in our Appendix
1. Once data appear allowing for the conduct of network meta-
analysis, we will move back Appendix 1 into the Methods section.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Weconsidered only randomised clinical trials for thismeta-analysis
irrespective of language, publication status, or date of publication.
We excluded other designs because of the risk of bias. However,
sSuch exclusions are understood to shift the focusmore to potential
benefits at the risk of not fully assessing the risks of adverse events
and serious adverse events.
Types of participants
We included randomised clinical trials with participants with non-
alcoholic fatty liver disease (NAFLD) irrespective of the method
of diagnosis, diabetic status of participants, or presence of non-al-
coholic steatohepatitis (NASH).We excluded randomised clinical
trials in which participants had undergone liver transplantation
previously.
Types of interventions
We considered any of the following pharmacological interventions
for people withNAFLD, either alone or in combination and could
be compared versus each other or versus placebo or no interven-
tion.
The interventions that we considered a priori were:
• orlistat;
• metformin;
• thiazolidinediones (e.g. pioglitazone, rosiglitazone);
• other anti-diabetes drugs;
• vitamin E or other antioxidants;
• milk thistle (silymarin or Silybum marianum extract);
• S-adenosylmethionine;
• statins (e.g. simvastatin, atorvastatin);
• secondary bile acids or derivatives (ursodeoxycholic acid,
obeticholic acid); and
• angiotensin-converting enzyme (ACE) inhibitors or
angiotensin II receptor antagonists.
This above list of interventions was not an exhaustive list. If we
identified any other pharmacological interventions that we were
not aware of, we considered them as eligible and included them in
the review if they were used primarily for the treatment of people
with NAFLD.
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Types of outcome measures
We planned to assess the comparative benefits and harms of the
available pharmacological interventions aimed at treating people
with NAFLD for the following outcomes.
Primary outcomes
• Mortality at maximal follow-up.
• Mortality:
◦ short-term mortality (up to one year);
◦ medium-term mortality (one to five years).
• Adverse events (within three months after cessation of
treatment). Depending on the availability of data, we attempted
to classify adverse events as serious or non-serious. We defined a
non-serious adverse event as any untoward medical occurrence
not necessarily having a causal relationship with the treatment
but resulting in a dose reduction or discontinuation of treatment
(at any time after commencement of treatment) (ICH-GCP
1997). We defined a serious adverse event as any that could
increase mortality; is life threatening; requires hospitalisation;
results in persistent or significant disability; was a congenital
anomaly or birth defect; or any important medical event that
might have jeopardised the person or required intervention for
its prevention. We used definitions applied by study authors for
non-serious and serious adverse events:
◦ proportion of participants with serious adverse events;
◦ number of serious adverse events;
◦ proportion of participants with any type of adverse
event; and
◦ number of any type of adverse event.
• Health-related quality of life as defined in the included
trials using a validated scale such as EQ-5D or 36-item Short
Form (SF-36) (EuroQol 2014; Ware 2014):
◦ short-term (up to one year);
◦ medium-term (one to five years); and
◦ long-term (beyond five years).
We considered long-term quality of life to be more important
than short- or medium-term quality of life, although short- and
medium-term quality of life are also important primary outcomes.
Secondary outcomes
• Liver transplantation (maximal follow-up):
◦ proportion of participants with liver transplantation;
and
◦ time to liver transplantation.
• Decompensated liver disease (maximal follow-up):
◦ proportion of participants with decompensated liver
disease; and
◦ time to liver decompensation.
• Cirrhosis (maximal follow-up):
◦ proportion of participants with cirrhosis; and
◦ time to cirrhosis.
• Resolution of fatty liver disease (maximal follow-up).
Unvalidated surrogate outcomes
We included two additional histological outcomes as potential sur-
rogate outcomes (fibrosis score and NAFLD activity score) post
hoc (Gluud 2007). This was applied for exploratory purposes be-
cause these outcomes are now accepted by regulatory agencies to
expedite drug approval processes for NAFLD treatment via an ac-
celerated approval pathway (Sanyal 2016). We did not make any
inferences based on observations for these outcomes.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) to August 2016;, MEDLINE (OvidSP) (from Jan-
uary 1947 toAugust 2016), Embase (OvidSP) (from January 1974
to August 2016), and Science Citation Index Expanded (Web of
Knowledge) (Royle 2003) (from January 1945 to August 2016).
Wedidnot apply language restrictions.We also searched theWorld
Health Organization International Clinical Trials Registry Plat-
formSearch Portal (apps.who.int/trialsearch/), which searches var-
ious trial registers, including ISRCTN and ClinicalTrials.gov/ up
to August 2016 (Appendix 2).
Searching other resources
We also searched the references of the included trials andCochrane
reviews on NAFLD.
Data collection and analysis
Selection of studies
Two review authors (SO or RL) independently identified trials for
inclusion by screening the titles and abstracts. We sought full-text
articles for any references that at least one review author identified
for potential inclusion. We selected trials for inclusion based on
full-text articles.
Data extraction and management
Two review authors (SO or RL or KG) independently extracted
the following data.
• Outcome data (for each outcome and for each treatment
arm whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
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◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and number of
participants with events and mean follow-up period for time-to-
event outcomes; and
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex,
comorbidities, and proportion of participants with NASH;
◦ details of the intervention and control (including dose,
frequency, and duration); and
◦ risk of bias (assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria; and
◦ follow-up time points of the outcome.
We planned to obtain data separately for people with NASH and
people without NASH if available. We planned to seek unclear or
missing information by contacting the trial authors. If there was
any doubt about if trials completely or partially reported the same
participant data, (by identifying common authors and centres),
we attempted to contact the trial authors to clarify if data were
duplicated. We resolved any differences in opinion through dis-
cussion.
Assessment of risk of bias in included studies
We followed guidance from the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011) and described in the
Cochrane Hepato-Biliary Group Module (Gluud 2016) to assess
the risk of bias in included studies using the following methods
(Schulz 1995;Moher 1998; Kjaergard 2001;Wood 2008; Savovi
2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random. We planned to only include such studies for assessment
of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We
planned only to include such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judge that the
outcome is not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
is unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome is likely to be influenced
by lack of blinding; or blinding of key study participants and
personnel attempted, but likely that the blinding could have
been broken, and the outcome is likely to be influenced by lack
of blinding.
Blinded outcome assessment
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement is likely to
be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement is likely to be influenced by lack
of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
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• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following pre-defined
outcomes: mortality, decompensated liver disease, requirement
for transplantation, or treatment-related adverse events. If the
original trial protocol was available, the outcomes should be
those called for in that protocol. If the trial protocol was obtained
from a trial registry (e.g. www.clinicaltrials.gov), the outcomes
sought should be those enumerated in the original protocol if the
trial protocol was registered before or at the time that the trial
was begun. If the trial protocol was registered after the trial was
begun, those outcomes will not be considered to be reliable.
• Unclear risk of bias: not all pre-defined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more pre-defined or clinically
relevant and reasonably expected outcomes were not reported,
despite the fact that data on these outcomes should have been
available and even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conduct, or results of the trial.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control, baseline differences, early stopping)
that could put it at risk of bias.
• Unclear risk of bias: the trial may or may not be free of
other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias (e.g. inappropriate control or dose or
administration of control, baseline differences, early stopping).
We considered a trial at low risk of bias if we assessed the trial to
be at low risk of bias across all domains. Otherwise, we considered
trials to be at unclear risk of bias or at high risk of bias regarding
one or more domains as at high risk of bias.
Measures of treatment effect
For dichotomous variables (e.g. short- and medium-term mortal-
ity or liver transplantation, proportion of participants with adverse
events, decompensated liver disease, cirrhosis, or hepatocellular
carcinoma), we calculated the odds ratio (OR) with 95% confi-
dence intervals (CI). For continuous variables (e.g. health-related
quality of life reported on the same scale), we planned to calcu-
late the mean difference with 95% CI. We planned to use stan-
dardised mean difference (SMD) values with 95% CI for health-
related quality of life if included trials used different scales. For
count outcomes (e.g. number of adverse events), we calculated the
rate ratio with 95% CI. For time-to-event data (e.g. mortality at
maximal follow-up or requirement for liver transplantation, time
to liver decompensation, and time to cirrhosis), we planned to use
the hazard ratio (HR) with 95% confidence intervals. We also cal-
culated Trial Sequential Analysis-adjusted CI to control random
errors (Thorlund 2011; Wetterslev 2017).
Unit of analysis issues
The unit of analysis was people with NAFLD according to the
intervention group to which they were randomly assigned.
Cluster randomised clinical trials
We did not anticipate to find cluster randomised clinical trials.
However, if they were found, they were to be included, provided
that the effect estimate adjusted for cluster correlation was avail-
able.
Cross-over randomised clinical trials
We planned to include outcomes after the first treatment pe-
riod only from cross-over randomised clinical trials. NAFLD is a
chronic disease and treatment could potentially have residual ef-
fects.
Trials with multiple treatment groups
We planned to collect data for all trial treatment groups that met
the inclusion criteria.
Dealing with missing data
We performed intention-to-treat analyses where possible (Newell
1992). Otherwise, we used available data (e.g. trials may report
only per-protocol analysis results). As such per-protocol analyses
may be biased, we planned to conduct best-worst case scenario
analysis (good outcome in intervention group and bad outcome in
control group) and worst-best case scenario analysis (bad outcome
in intervention group and good outcome in control group) as
sensitivity analyses whenever possible.
We planned to impute the standard deviation from P values for
continuous outcomes (Higgins 2011). If data were distributed
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normally, we planned to use the median for meta-analysis when
the mean was not available. If it was not possible to calculate the
standard deviation from the P value or the confidence intervals,
we planned to impute this using the largest standard deviation
fromother trials for that outcome. This imputation techniquemay
decrease the weight of the study for calculation of mean differences
and may bias the effect estimate to no effect for calculation of
standardised mean differences (Higgins 2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. We
assessed the presence of clinical heterogeneity by comparing effect
estimates in the presence or absence of symptoms, the presence
or absence of NASH, the diabetes status of participants, and drug
doses. Different trial designs and risk of bias may contribute to
methodological heterogeneity. We used the I² test and Chi² test
for heterogeneity, and overlapping of CIs to assess heterogeneity.
Assessment of reporting biases
We planned to assess visual asymmetry on a funnel plot to explore
reporting bias in the presence of at least 10 trials that could be
included for a direct comparison (Egger 1997; Macaskill 2001).
In the presence of heterogeneity that could be explained by sub-
group analysis, we planned to produce a funnel plot for each eli-
gible subgroup in the presence of an adequate number of trials (at
least 10 trials). We planned to use the linear regression approach
described by Egger 1997 to determine funnel plot asymmetry.
We also considered selective reporting as evidence of reporting
bias.
Data synthesis
We conducted the meta-analyses according to Cochrane meth-
ods and recommendations (Higgins 2011) using ReviewManager
5 (RevMan 2014). We used both random-effects (DerSimonian
1986) and fixed-effect models (DeMets 1987). In the case of a
discrepancy between the models, we reported both results; other-
wise, we reported only the fixed-effect model results.
Calculation of required information size and Trial Sequential
Analysis
Details of the sample size calculation is presented in Appendix 3.
We performed Trial Sequential Analysis to control the risk of ran-
dom errors (Wetterslev 2008; Thorlund 2011; TSA 2011) when
there were at least two trials included in themeta-analysis.We used
an alpha error as per Jakobsen 2014, 90% power (10% beta error),
20% relative risk reduction, control group proportion observed in
the trials, and the diversity observed in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
We planned to assess differences in effect estimates among the
following subgroups.
• Trials with low risk of bias compared to trials at high risk of
bias.
• Participants with NASH compared to participants with
NAFLD but without NASH.
• Participants with diabetes mellitus compared to participants
without diabetes mellitus.
• Different doses of pharmacological interventions.
We planned to use the Chi² test for subgroup differences.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned to
re-analyse the results using the best-worst scenario and worst-best
case scenario as sensitivity analyses whenever possible.
GRADE and ’Summary of findings’ tables
We created ’Summary of findings’ tables using the following out-
comes: mortality, serious adverse events, and health-related quality
of life (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3). We used the five GRADE
considerations (study limitations, consistency of effect, impreci-
sion, indirectness and publication bias) to assess evidence quality
relating to trials that contribute data to the meta-analyses for the
specified outcomes. We used methods and recommendations de-
scribed in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We justified
all decisions to downgrade the quality of evidence in footnotes and
comments to aid understanding of the review where necessary.
R E S U L T S
Description of studies
Results of the search
We identified 2851 references through electronic searches ofCEN-
TRAL (n = 361), MEDLINE (n = 816), Embase (n = 461), Sci-
ence Citation Index Expanded (n = 793), WorldHealthOrganiza-
tion International Clinical Trials Registry Platform (n = 227) and
ClinicalTrials.gov (n = 193). After the removal of 1209 duplicates
we obtained 1642 references. We then excluded 1496 clearly ir-
relevant references from screening titles and reading abstracts. We
retrieved 146 references for further assessment. No references were
identified from scanning reference lists of randomised trials. We
excluded 33 studies (34 reports) (see Characteristics of excluded
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studies). In total, 77 randomised clinical trials (112 reports) met
the inclusion criteria (Figure 1).
Figure 1. Study flow diagram.
Included studies
We included 77 trials that met the inclusion criteria for this re-
view that involved 6287 participants. However, 36 trials did not
contribute any data for this review (Kugelmas 2003; Santos 2003;
Mendez-Sanchez 2004; Sanyal 2004; Uygun 2004; Bugianesi
2005; Morita 2005; Cui 2006; Lewis 2006; Hajaghamohammadi
2008; Copaci 2009; Gastaldelli 2009; Harrison 2009; Hashemi
2009; Yaginuma 2009; Foster 2011; Sofer 2011; Fogari 2012;
Hajiaghamohammadi 2012;Razavizadeh 2012; Askarimoghadam
2013; Basu 2013; Cusi 2013; Kakazu 2013; Taghvaei 2013;
Kedarisetty 2014; Solhi 2014; Song 2014; Stilidi 2014; Baranova
2015; Bonfrate 2015; Klyarytskaya 2015; Shiffman 2015;
Siddique 2015; Sunny 2015; Wang 2015).
We included data from a total of 3829 participants in one or
more analyses in the review. The mean or median age of the
participants ranged from 33 years to 62 years in the trials that
reported this information. The proportion of females ranged
from 6.7% to 85.2% in the trials that reported this information.
Thirty-five trials included participants with non-alcohol related
steatohepatitis (NASH) only (Harrison 2003; Kugelmas 2003;
Merat 2003; Lindor 2004; Uygun 2004; Morita 2005; Belfort
2006; Dufour 2006; Aithal 2008; Ratziu 2008; Copaci 2009;
Gastaldelli 2009; Gomez 2009; Harrison 2009; Hashemi 2009;
Nelson 2009; Shields 2009; Leuschner 2010; Omer 2010; Sanyal
2010; Ratziu 2011; Torres 2011; VanWagner 2011; Sharma2012;
Cusi 2013; Kakazu 2013; Kedarisetty 2014; Ratziu 2014; Chan
2015; Loomba 2015; Neuschwander-Tetri 2015; Sunny 2015;
12Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Alam 2016; Armstrong 2016; Ratziu 2016). The remainder did
not report the proportion of participants with non-alcoholic fatty
liver disease (NAFLD) and NASH or did not report data sepa-
rately for those with and without NASH.
Five trials included only participants with diabetes mellitus
(Morita 2005; Nar 2009; Mudaliar 2013; Song 2014; Wang
2015); and 14 trials included only those who did not have diabetes
mellitus (Uygun 2004; Bugianesi 2005; Athyros 2006; Belfort
2006; Aithal 2008; Hajaghamohammadi 2008; Sanyal 2010;
Fogari 2012; Hajiaghamohammadi 2012; Basu 2013; Gianturco
2013; Basu 2014; Solhi 2014; Aller 2015). The remainder did not
report proportions of people with diabetes mellitus or did not re-
port data separately for those with and without diabetes mellitus.
The interventions, controls, number of participants included in
each trial, and follow-up periods, are reported in Table 1. Overall,
the mean or median follow-up was from 1 month to 18 months.
Sources of funding
We found that 12 trials did not report receiving any additional
funding or were supported by parties without vested interest in
the results (Kugelmas 2003; Merat 2003; Morita 2005; Nelson
2009; Polyzos 2011; Fogari 2012; Hajiaghamohammadi 2012;
Kakazu 2013; Razavizade 2013; Yan 2015; Alam 2016; Parikh
2016). Twenty-six trials were funded by commercial pharmaceu-
tical companies which would benefit from the results of the trial
(Santos 2003; Lindor 2004; Athyros 2006; Belfort 2006; Dufour
2006; Aithal 2008; Ratziu 2008; Gomez 2009; Haukeland 2009;
Leuschner 2010; Sanyal 2010; Ratziu 2011; Torres 2011; Cusi
2013; Magosso 2013; Mudaliar 2013; Basu 2014; Ratziu 2014;
Safadi 2014; Stefan 2014; Loomba 2015; Neuschwander-Tetri
2015; Shiffman 2015; Sunny 2015; Armstrong 2016; Ratziu
2016). The source of funding was not reported in 39 trials.
Excluded studies
We presented the reasons for the 33 excluded studies in
Characteristics of excluded studies.
Risk of bias in included studies
Risk of bias is summarised in Figure 2, Figure 3, and Table 2. Only
one small trial was assessed at low risk of bias in all domains (
Razavizade 2013). All other included trials were assessed at unclear
or high risk of bias for one or more domains.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We assessed 27 trials at low risk of bias due to adequate report-
ing and application of random sequence generation (Harrison
2003; Merat 2003; Mendez-Sanchez 2004; Uygun 2004; Athyros
2006; Belfort 2006; Aithal 2008; Haukeland 2009; Shields 2009;
Sanyal 2010; Polyzos 2011; Torres 2011; Van Wagner 2011;
Sharma 2012; Gianturco 2013; Magosso 2013; Razavizade 2013;
Basu 2014; Song 2014; Stefan 2014; Aller 2015; Loomba 2015;
Neuschwander-Tetri 2015; Yan 2015; Alam 2016; Armstrong
2016; Ratziu 2016). The remainder were assessed at unclear risk
of bias.
We assessed 26 trials at low risk of bias due to allocation con-
cealment (Harrison 2003; Merat 2003; Lindor 2004; Athyros
2006; Belfort 2006; Dufour 2006; Aithal 2008; Haukeland 2009;
Shields 2009; Sanyal 2010; Torres 2011; VanWagner 2011; Fogari
2012; Sharma 2012; Gianturco 2013; Magosso 2013; Mudaliar
2013; Razavizade 2013; Basu 2014; Ratziu 2014; Stefan 2014;
Loomba 2015;Neuschwander-Tetri 2015; Alam2016; Armstrong
2016; Ratziu 2016). The remainder were assessed at unclear risk
of bias.
We found that 21 trials were at low risk of bias due to random
sequence generation and allocation concealment (Harrison 2003;
Merat 2003; Athyros 2006; Belfort 2006; Aithal 2008;Haukeland
2009; Shields 2009; Sanyal 2010; Torres 2011; VanWagner 2011;
Sharma 2012; Gianturco 2013; Magosso 2013; Razavizade 2013;
Basu 2014; Stefan 2014; Loomba 2015; Neuschwander-Tetri
2015; Alam 2016; Armstrong 2016; Ratziu 2016).
Blinding
We assessed 35 trials at low risk of performance bias: both par-
ticipants and healthcare providers were blinded (Santos 2003;
Harrison 2003; Merat 2003; Lindor 2004; Mendez-Sanchez
2004; Belfort 2006; Cui 2006; Dufour 2006; Lewis 2006; Aithal
2008; Ratziu 2008; Gastaldelli 2009; Haukeland 2009; Nelson
2009; Leuschner 2010; Sanyal 2010; Foster 2011; Ratziu 2011;
Sofer 2011; Van Wagner 2011; Fogari 2012; Razavizadeh 2012;
Gianturco 2013; Magosso 2013; Mudaliar 2013; Razavizade
2013; Ratziu 2014; Safadi 2014; Stefan 2014; Chan 2015;
Loomba 2015; Neuschwander-Tetri 2015; Shiffman 2015;
Armstrong 2016; Ratziu 2016). We found that 18 trials were
at high risk of performance bias (Kugelmas 2003; Uygun 2004;
Bugianesi 2005; Ersoz 2005; Athyros 2006; Omer 2010; Torres
2011; Sharma 2012; Askarimoghadam 2013; Basu 2013; Kakazu
2013; Basu 2014; Kedarisetty 2014; Klyarytskaya 2015; Wang
2015; Yan 2015; Alam 2016; Parikh 2016). The remainder were
at unclear risk of bias.
Our assessment found that 39 trials were at low risk of de-
tection bias (Santos 2003; Harrison 2003; Merat 2003; Lindor
2004; Mendez-Sanchez 2004; Belfort 2006; Cui 2006; Dufour
2006; Lewis 2006; Aithal 2008; Ratziu 2008; Gastaldelli 2009;
Gomez 2009; Haukeland 2009; Nar 2009; Nelson 2009; Shields
2009; Garinis 2010; Leuschner 2010; Sanyal 2010; Foster 2011;
Ratziu 2011; Sofer 2011; Van Wagner 2011; Fogari 2012;
Razavizadeh 2012; Gianturco 2013; Magosso 2013; Mudaliar
2013; Razavizade 2013; Ratziu 2014; Safadi 2014; Stefan 2014;
Chan 2015; Loomba 2015; Neuschwander-Tetri 2015; Shiffman
2015; Armstrong 2016;Ratziu 2016).We found that 16 trialswere
at high risk of detection bias (Uygun 2004; Bugianesi 2005; Ersoz
2005; Athyros 2006; Omer 2010; Torres 2011; Sharma 2012;
Askarimoghadam 2013; Basu 2013; Basu 2014; Kedarisetty 2014;
Klyarytskaya 2015; Wang 2015; Yan 2015; Alam 2016; Parikh
2016). The remainder were at unclear risk of bias.
Thirty-five trials were assessed at low risk of performance and de-
tection bias (Santos 2003; Harrison 2003; Merat 2003; Lindor
2004; Mendez-Sanchez 2004; Belfort 2006; Cui 2006; Dufour
2006; Lewis 2006; Aithal 2008; Ratziu 2008; Gastaldelli 2009;
Haukeland 2009; Nelson 2009; Leuschner 2010; Sanyal 2010;
Foster 2011; Ratziu 2011; Sofer 2011; Van Wagner 2011;
Fogari 2012; Razavizadeh 2012; Gianturco 2013; Magosso 2013;
Mudaliar 2013; Razavizade 2013; Ratziu 2014; Safadi 2014;
Stefan 2014; Chan 2015; Loomba 2015; Neuschwander-Tetri
2015; Shiffman 2015; Armstrong 2016; Ratziu 2016). The re-
mainder were at unclear or high risk of performance and detection
bias.
Incomplete outcome data
Eighteen trials were at low risk of bias due to missing outcome
and hence attrition bias (Athyros 2006; Aithal 2008; Gomez
2009; Nelson 2009; Shields 2009; Leuschner 2010; Sanyal 2010;
Ratziu 2011; Sofer 2011; Hajiaghamohammadi 2012; Magosso
2013; Mudaliar 2013; Razavizade 2013; Basu 2014; Kedarisetty
2014; Aller 2015; Neuschwander-Tetri 2015; Armstrong 2016).
We found that 26 trials were at high risk of bias due to miss-
ing outcome data (Harrison 2003; Merat 2003; Lindor 2004;
Mendez-Sanchez 2004; Uygun 2004; Ersoz 2005; Belfort 2006;
Dufour 2006; Ratziu 2008; Harrison 2009; Haukeland 2009;
Garinis 2010;Omer 2010; Torres 2011; VanWagner 2011; Fogari
2012; Sharma 2012; Gianturco 2013; Kakazu 2013; Ratziu 2014;
Safadi 2014; Solhi 2014; Stefan 2014; Alam 2016; Parikh 2016;
Ratziu 2016). The remainder were at unclear risk of bias.
Selective reporting
Published protocols were not available for any of the included tri-
als.We assessed that 11 trialswere at low risk of bias due to selecting
outcome reporting bias (Athyros 2006; Aithal 2008; Leuschner
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2010; Polyzos 2011; Ratziu 2011; Magosso 2013; Mudaliar
2013; Razavizade 2013; Neuschwander-Tetri 2015; Alam 2016;
Armstrong 2016). The remainder were at high risk of selective
outcome reporting bias.
Other potential sources of bias
Twelve trials reported not receiving any additional funding or sup-
port from parties with vested interest in the results and were con-
sidered to be at low risk of for-profit bias (Kugelmas 2003; Merat
2003; Morita 2005; Nelson 2009; Polyzos 2011; Fogari 2012;
Hajiaghamohammadi 2012; Kakazu 2013; Razavizade 2013; Yan
2015; Alam 2016; Parikh 2016). Twenty-six trials were partly-
or fully-funded by pharmaceutical companies that would bene-
fit from trial results (Santos 2003; Lindor 2004; Athyros 2006;
Belfort 2006; Dufour 2006; Aithal 2008; Ratziu 2008; Gomez
2009; Haukeland 2009; Leuschner 2010; Sanyal 2010; Ratziu
2011; Torres 2011; Cusi 2013; Magosso 2013; Mudaliar 2013;
Basu 2014; Ratziu 2014; Safadi 2014; Stefan 2014; Loomba
2015; Neuschwander-Tetri 2015; Shiffman 2015; Sunny 2015;
Armstrong 2016; Ratziu 2016). Sources of funding was not re-
ported in 39 trials.
No trials were at risk of bias due to other factors such as baseline
differences, stopping trials early, or inappropriate controls.
Effects of interventions
See: Summary of findings for the main comparison
Antioxidants versus no intervention for non-alcohol related fatty
liver disease; Summary of findings 2 Bile acids versus no
intervention for non-alcohol related fatty liver disease; Summary
of findings 3 Thiazolidinediones versus no intervention for
non-alcohol related fatty liver disease
Primary outcomes
Mortality at maximal follow up
A total of 11 trials including 1222 participants reported deaths
after follow-up periods from 1 month to 18 months (Athyros
2006; Aithal 2008; Leuschner 2010; Polyzos 2011; Ratziu 2011;
Magosso 2013;Mudaliar 2013; Razavizade 2013; Neuschwander-
Tetri 2015; Alam 2016; Armstrong 2016). There were only two
deaths in participants who received bile acid (2/141 = 1.4%).
These deaths were reported in the trial which followed-up partic-
ipants for about 17 months (Neuschwander-Tetri 2015). There
were no deaths in any other trials or interventions (Analysis 1.1).
Since there were few events, we have not presented the short-term
mortality (up to 1 year) and medium-termmortality (1 to 5 years)
separately.
Proportion of participants with serious adverse events
A total of 19 trials including 1748 participants reported propor-
tions of serious adverse events (Merat 2003; Athyros 2006; Aithal
2008; Hashemi 2009; Nelson 2009; Jin 2010; Polyzos 2011;
Van Wagner 2011; Magosso 2013; Mudaliar 2013; Razavizade
2013; Ratziu 2014; Safadi 2014; Stefan 2014; Aller 2015;
Neuschwander-Tetri 2015; Alam 2016; Armstrong 2016; Ratziu
2016). The proportion of people with serious adverse events
seemed lower in people who received phosphodiesterase type 4 in-
hibitor (1/66 (1.5%)) versus no intervention (4/30 (13.3%)) (OR
0.10, 95% CI 0.01 to 0.94; 96 participants; 1 trial). There was no
evidence of differences in other comparisons (Analysis 1.2).
Number of serious adverse events
A total of 18 trials including 1693 participants reported numbers
of serious adverse events (Merat 2003;Athyros 2006; Aithal 2008;
Hashemi 2009; Nelson 2009; Jin 2010; Sanyal 2010; Polyzos
2011; Magosso 2013; Mudaliar 2013; Razavizade 2013; Ratziu
2014; Safadi 2014; Stefan 2014; Aller 2015; Neuschwander-Tetri
2015; Alam 2016; Armstrong 2016). There was no evidence of
difference in other comparisons (Analysis 1.3).
Proportion of participants with any type of adverse event
A total of 17 trials including 1606 participants reported propor-
tions of adverse events (Merat 2003; Lindor 2004; Ersoz 2005;
Athyros 2006; Aithal 2008; Nelson 2009; Jin 2010; Sharma 2012;
Magosso 2013; Mudaliar 2013; Razavizade 2013; Basu 2014;
Ratziu 2014; Stefan 2014; Aller 2015; Armstrong 2016; Parikh
2016). The proportion of people who experienced adverse events
was higher in the phosphodiesterase type 4 inhibitor group (54/66
(81.8%)) versus no intervention (18/30 (60.0%)) (OR 3.00, 95%
CI 1.15 to 7.85; 96 participants; 1 trial). There was no evidence
of differences in other comparisons (Analysis 1.4).
Number of any type of adverse event
A total of 22 trials including 2319 participants reported num-
bers of adverse events (Merat 2003; Lindor 2004; Ersoz 2005;
Athyros 2006; Aithal 2008; Nelson 2009; Jin 2010; Leuschner
2010; Sanyal 2010;Ratziu 2011;VanWagner 2011; Sharma2012;
Magosso 2013; Mudaliar 2013; Razavizade 2013; Basu 2014;
Stefan 2014; Aller 2015; Loomba 2015; Neuschwander-Tetri
2015; Yan 2015; Armstrong 2016). The rate of adverse events was
higher in participants who received bile acid (rate ratio 1.19, 95%
CI 1.06 to 1.33; 825 participants; 5 trials; I² = 51%) and gluco-
corticosteroid inhibitor (rate ratio 1.56, 95% CI 1.05 to 2.31; 80
participants; 1 trial) versus no intervention. There was no evidence
of differences in any other comparisons (Analysis 1.5).
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Health-related quality of life
No included trial reported on quality of life.
Secondary outcomes
Liver transplantation
A total of nine trials including 639 participants reported pro-
portions of people who underwent liver transplantation (Athyros
2006; Belfort 2006; Aithal 2008; Polyzos 2011; Magosso 2013;
Razavizade 2013; Stefan 2014; Alam 2016; Armstrong 2016). No
trial participants required liver transplantation during the follow-
up period. Therefore, the outcome ’time-to-liver transplantation’
was not applicable in these trials. None of the remaining trials
reported time-to-liver transplantation.
Decompensated liver disease
A total of nine trials including 765 participants reported decom-
pensated liver disease (Athyros 2006; Aithal 2008; Polyzos 2011;
Ratziu 2011;Magosso 2013; Razavizade 2013; Stefan 2014; Alam
2016; Armstrong 2016). No trial participants developed decom-
pensated liver disease during the follow-up period. Therefore, the
outcome ’time-to-decompensated liver disease’ was not applicable
in these trials. None of the remaining trials reported time-to-de-
compensated liver disease.
Cirrhosis
A total of 11 trials including 798 participants reported propor-
tions of people who developed cirrhosis (Athyros 2006; Belfort
2006; Aithal 2008; Haukeland 2009; Polyzos 2011; Magosso
2013; Razavizade 2013; Stefan 2014; Chan 2015; Alam 2016;
Armstrong 2016). Overall 4/236 (1.7%) participants in the no
intervention group developed cirrhosis. There was no evidence of
difference in other comparisons (Analysis 1.6). None of the trials
reported time-to-cirrhosis.
Resolution of fatty liver disease
A total of 16 trials including 1343 participants reported propor-
tions of people whose fatty liver disease resolved (Harrison 2003;
Ersoz 2005; Athyros 2006; Belfort 2006; Aithal 2008; Haukeland
2009; Nar 2009; Garinis 2010; Sanyal 2010; Torres 2011;
Magosso 2013; Chan 2015; Loomba 2015; Neuschwander-Tetri
2015; Alam 2016; Armstrong 2016).
Resolution rates were higher in participants who received antiox-
idants (adjusted proportion: 32.0%) versus no intervention (26/
149 (17.4%)) (OR 2.23, 95%CI 1.28 to 3.87; 299 participants; 3
trials; I² = 0%). Resolution of fatty liver disease also seemed higher
in participants who received other anti-diabetes medications (9/
23 (39.1%)) versus no intervention (2/22 (9.1%)) (OR 6.43, 95%
CI 1.20 to 34.41; 45 participants; 1 trial).
The proportion of people among whom resolution of fatty
liver disease seemed higher in those who received statins (42/
63 (66.7%)) versus other cholesterol-lowering agents (26/62
(41.9%)) (OR 2.77, 95% CI 1.34 to 5.73; 125 participants; 1
trial). This effect also seemed higher in participants who received
statins plus other cholesterol-lowering agents (43/61 (70.5%)) ver-
sus other cholesterol-lowering agents (26/62 (41.9%)) (OR 3.31,
95% CI 1.57 to 6.98; 123 participants; 1 trial).
There was no evidence of differences in any other comparisons.
Unvalidated surrogate outcomes
We could not perform a meta-analysis because many trials that
reported fibrosis scores and NAFLD activity score did not provide
mean or standard deviation or both. A summary of differences
between fibrosis scores and NAFLD Activity Scores (NAS) are
presented (Appendix 4; Appendix 5). None of the interventions
were consistently associated with decreased scores.
Subgroup analyses
Because of the paucity of data, we did not use the tests for subgroup
differences. However, we presented analyses of the subsets for par-
ticipants with non-alcohol related steatohepatitis only, those with
diabetes mellitus only, and those who did not have diabetes mel-
litus only.
Non-alcohol related steatohepatitis
See Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis
2.5; Analysis 2.6.
There was evidence of a difference between participants who re-
ceived phosphodiesterase type 4 inhibitor and those who received
no intervention for proportion of serious adverse events. There
were fewer adverse events in participants who received phospho-
diesterase type 4 inhibitor (rate ratio 0.21, 95% CI 0.05 to 0.95;
239 participants; 2 trials; I² not assessable - only 1 trial contributed
data to the analysis).
There was evidence of a difference between participants who re-
ceived phosphodiesterase type 4 inhibitor group and no interven-
tion for proportion of any adverse events. There were more ad-
verse events in participants who received phosphodiesterase type 4
inhibitor (OR 3.00, 95%CI 1.15 to 7.85; 96 participants; 1 trial).
There was evidence of a difference between those who received bile
acids and no intervention for proportion of any adverse events;
there were more adverse events in participants who received bile
acids (rate ratio 1.20, 95% CI 1.07 to 1.35; 761 participants; 4
trials; I² = 61%).
There was evidence of a difference between participants who re-
ceived antioxidants and no intervention for proportion of people
with resolution of fatty liver disease. Results were in favour of the
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antioxidants (OR 2.14, 95% CI 1.10 to 4.19; 212 participants; 2
trials; I² = 0%). There was also evidence of a difference between
participants who received other anti-diabetes medications and no
intervention favouring other anti-diabetes medications (OR 6.43,
95% CI 1.20 to 34.41; 45 participants; 1 trial). There was no
evidence of differences in other comparisons.
Participants with diabetes mellitus
See Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis 3.4.
There was no evidence of differences in any of the comparisons.
Participants without diabetes mellitus
See Analysis 4.1; Analysis 4.2; Analysis 4.3; Analysis 4.4; Analysis
4.5; Analysis 4.6.
There was evidence of a difference between participants who re-
ceived thiazolidinediones and no intervention for number of seri-
ous adverse events. There were fewer adverse events in those who
received thiazolidinediones (rate ratio 0.21, 95% CI 0.05 to 0.95;
239 participants; 2 trials; I² not assessable - only one trial con-
tributed to the analysis). There was evidence of a difference be-
tween those who received antioxidants and no intervention for
proportion of people with resolution of fatty liver disease favouring
antioxidants (OR 2.16, 95% CI 1.08 to 4.32; 167 participants; 1
trial).
There was evidence of a difference between participants who re-
ceived statins and other cholesterol-lowering agents for propor-
tion of people with resolution of fatty liver disease, which favoured
statins (OR 2.77, 95% CI 1.34 to 5.73; 125 participants; 1 trial).
There was also evidence of a difference between those who received
statins plus other cholesterol-lowering agents and other choles-
terol-lowering agents alone for proportion of people with resolu-
tion of fatty liver disease favouring statins plus other cholesterol-
lowering agents (OR 3.31, 95%CI 1.57 to 6.98; 123 participants;
1 trial).
Sensitivity analysis
We did not perform a sensitivity analysis based on different sce-
narios of imputation because there were too few data to inform
analyses. We did not impute standard deviation; therefore, we did
not perform a sensitivity analysis to assess the impact of imputing
the standard deviation.
Reporting bias
We did not assess reporting bias by creating a funnel plot because
there were too few trials in each comparison.
Fixed-effect versus random-effects models
The interpretation of results was not altered based on the model
used for analysis except for thiazolidinediones versus no interven-
tion; there was no evidence of difference according to the random-
effects model analysis (OR 1.68, 95% CI 0.44 to 6.44; partici-
pants = 272; trials = 3; I² = 66%). However, the proportion of
people with higher rates of resolution of fatty liver disease seemed
higher in people who received thiazolidinediones compared with
no intervention (OR 2.41, 95% CI 1.36 to 4.28; participants =
272; trials = 3; I² = 66%).
Required information size calculations and Trial
Sequential Analysis
The required information size for identifying a 20% relative risk
reduction in the different outcomes based on an alpha error of 5%,
a beta error of 20%, and the control group proportion observed
in trials were as follows.
• Mortality at maximal follow-up (control group proportion:
0%): not estimable.
• Serious adverse events (proportion) (control group
proportion: 6.4%): 10,402 participants.
• Adverse events (proportion) (control group proportion:
38.9%): 1178 participants.
• Liver transplantation (control group proportion: 0%): not
estimable.
• Decompensated liver disease (control group proportion:
0%): not estimable.
• Cirrhosis (control group proportion: 1.7%): 40,922
participants.
• Resolution of fatty liver disease (control group proportion:
12.9%): 4838 participants.
These sample sizes were uncorrected for heterogeneity. In the pres-
ence of heterogeneity, for example, in the presence of a hetero-
geneity of 25%, the required information size for adverse events
(proportion) is 1178/(1-0.25) = 1571 participants.
Very few of the required sample sizes were reached in the com-
parisons in which there was no evidence of difference. Therefore,
beta error could not be excluded in these comparisons.
Two or more trials contributed to the analyses of the following
outcomes.
• Adverse events (proportion): bile acids versus no
intervention.
• Adverse events (proportion): bile acids versus antioxidants.
• Cirrhosis: thiazolidinediones versus no intervention.
• Resolution of fatty liver disease: antioxidants versus no
intervention.
• Resolution of fatty liver disease: sulphonylureas versus no
intervention.
• Resolution of fatty liver disease: thiazolidinediones versus
no intervention.
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The accrued sample size was too small to draw trial sequential
monitoring boundaries (Figure 4; Figure 5). The cumulative Z-
curve did not cross the conventional boundaries, except for res-
olution of fatty liver disease when antioxidants were compared
with no intervention. The Trial Sequential Analysis-adjusted con-
fidence intervals could not be calculated because of the small ac-
crued sample sizes.
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Figure 4. Trial Sequential Analysis (TSA) for adverse events (proportion) and cirrhosis for different
comparisons. TSA was performed using an alpha error of 2.5% for adverse events (proportion) and 2% for
cirrhosis, power of 90% (10% beta error), 20% relative risk reduction (RRR), control group proportion (Pc)
observed in the trials, and the diversity observed in the meta-analysis. The trial sequential monitoring
boundaries were not drawn because the accrued sample sizes (adverse events (proportion): bile acids versus
no intervention = 230 participants; adverse events (proportion): bile acids versus antioxidants = 289
participants; cirrhosis: thiazolidinediones versus no intervention = 121 participants) were only fractions of the
diversity-adjusted required information size (DARIS) (adverse events (proportion): bile acids versus no
intervention = 52,522 participants; adverse events (proportion): bile acids versus no intervention = 6141
participants; cirrhosis: thiazolidinediones versus no intervention = 67,859 participants). The cumulative Z-
curve (blue line) does not cross the conventional P boundary (dotted green lines). There was a high risk of
random error in all comparisons.
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Figure 5. Trial Sequential Analysis (TSA) for adverse events (proportion) and cirrhosis for different
comparisons. TSA was performed using an alpha error of 2%, 90% power (10% beta error), 20% relative risk
reduction (RRR), control group proportion (Pc = 12.9%) observed in the trials, and the diversity-observed in
the meta-analysis. The trial sequential monitoring boundaries were not drawn because the accrued sample
sizes (antioxidants versus no intervention = 299 participants; sulphonylureas versus no intervention = 123
participants; thiazolidinediones versus no intervention = 272 participants) were only fractions of the diversity
adjusted required information size (DARIS) (antioxidants versus no intervention = 8028 participants;
sulphonylureas versus no intervention = 11,394 participants; thiazolidinediones versus no intervention = 39,680
participants). The cumulative Z-curve (blue line) does not cross the conventional P boundary (dotted green
lines). There was a high risk of random error in all comparisons.
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Quality of evidence
The overall quality of evidence was very low for all outcomes
(Summary of findings for the main comparison). The quality of
evidencewas downgradedbecause of high risk of bias (downgraded
by one level), small sample sizes for all outcomes with wide con-
fidence intervals or lack of events (downgraded by two levels for
imprecision), and heterogeneity (downgraded by one level for in-
consistency) for some outcomes.
22Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Bile acids versus no intervention for non-alcohol related fatty liver disease
Patient or population: part icipants with non-alcohol related fatty liver disease (NAFLD)
Settings: secondary or tert iary care
Intervention: bile acids
Control: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Bile acids
M ortality at maximal fol-
low-up
Follow-up: 1 to 18 months
10 per 1000 49 per 1000
(2 to 520)
OR 5.11
(0.24 to 107.34)
659
(4 trials)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
Follow-up: 1 to 17 months
64 per 1000 96 per 1000
(54 to 165)
OR 1.56
(0.84 to 2.88)
404
(3 trials)
⊕©©©
very low1,2,3
Serious adverse events
(number of events)
Follow-up: 1 to 17 months
101 per 1000 102 per 1000
(67 to 156)
Rate ratio 1.01
(0.66 to 1.54)
404
(3 trials)
⊕©©©
very low1,2,3
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group risk across studies, except for mortality at maximal follow-up where there were no deaths; a control group proport ion
of 1% was used for mortality at maximal follow-up. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level for risk of bias because of the high risk of bias in the trial(s).
2 Downgraded one level for imprecision because of sample size.
3 Downgraded one level for imprecision because of wide conf idence intervals.
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Thiazolidinediones versus no intervention for non-alcohol related fatty liver disease
Patient or population: part icipants with non-alcohol related fatty liver disease (NAFLD)
Settings: secondary or tert iary care
Intervention: thiazolidinediones
Control: no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No intervention Thiazolidinediones
M ortality at maximal fol-
low-up
Follow-up: 12 months
There were no events in either group 74
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(proportion)
Follow-up: 6 to 12 months
There were no events in either group 194
(2 trials)
⊕©©©
very low1,2,3
Serious adverse events
(number of events)
Follow-up: 6 to 12 months
101 per 1000 25 per 1000
(6 to 106)
rate ratio 0.25
(0.06 to 1.05)
357
(3 trials)
⊕©©©
very low1,2,4
Health- related quality of
life
None of the trials reported this outcome
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.2
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Very low quality: We are very uncertain about the est imate.
1 Downgraded one level for risk of bias because of the high risk of bias in the trial(s).
2 Downgraded one level for imprecision because of sample size.
3 Downgraded one level for imprecision because of lack of events.
4 Downgraded one level for imprecision because of wide conf idence intervals.
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D I S C U S S I O N
Summary of main results
We included 76 trials (6207 participants); data from 3829 par-
ticipants in 41 trials were included in one or more analyses of
review outcomes. Although we intended to perform a network
meta-analysis, we did not report results because there was only
one closed loop (i.e. comparisons for which there were estimates
from direct comparisons and indirect comparisons) for only one
outcome (number of adverse events) and there was evidence of
inconsistency. Therefore, we reported results of direct pair-wise
comparisons and frequentist meta-analysis.
There was no evidence of any reduction in mortality or any
of the known complications of non-alcoholic fatty liver disease
(NAFLD), that is, cirrhosis, decompensated cirrhosis, or require-
ment for liver transplantation. The follow-up period in trials
ranged from 1 month to 24 months, and most trials had follow-
up periods of less than 12 months, which is not enough time for
NAFLD or non-alcoholic steatohepatitis (NASH) complications
to develop. As a result, the proportion of people who developed
complications was very low, regardless of whether or not they re-
ceived an intervention. Furthermore, the duration of follow-up
was the same as the treatment period in most trials. It is not clear
how long the interventions should continue to provide clinical
improvement.
The Federal Drug Agency (FDA) in the US consented to the use
of the two unvalidated surrogate outcomes ’resolution of steato-
hepatitis without worsening of fibrosis’ or ’improvement in the
fibrosis score without worsening of the steatohepatitis’ or both
at the time of approval of drugs, through an accelerated access
pathway, with sponsor obligation to conduct a post-market trial
to demonstrate that their improvement translated into a clinically
meaningful benefit to patients (Sanyal 2016). However, there is no
evidence that this is a good surrogate outcome (Gluud 2007). We
explored evidence of differences in histological outcomes, but we
did not find any consistent pattern of improvement in histological
outcomes as shown in Appendix 4 and Appendix 5.
Future randomised clinical trials ought to be adequately powered
to measure differences in clinically important outcomes such as
mortality, health-related quality of life, cirrhosis, decompensated
cirrhosis, and liver transplantation.
Overall completeness and applicability of
evidence
The trials included people with andwithoutNASHand those with
and without diabetes mellitus but most excluded people with ad-
vanced liver cirrhosis and thosewith other liver diseases. Therefore,
findings from this review are applicable to people with NAFLD
who do not have advanced liver cirrhosis or those without other
co-existing liver diseases.
Quality of the evidence
The overall quality of evidence was assessed as very low for all out-
comes. Major reasons for downgrading evidence quality were high
risk of bias, especially excluding participants from analyses after
randomisation; small sample sizes, and gross imprecision. Over-
all, there were serious concerns about whether the effect estimates
observed were accurate.
Potential biases in the review process
Weapplied standardCochranemethods to conduct this review and
performed thorough searches of the literature.However, the period
searched included the pre-mandatory trial registration era and it
is possible that some trials on interventions that were not effective
or were harmful were not reported. Publication bias added to the
imprecision of our findings with greater risk of overestimating
benefits and underestimating harms.
We planned to perform a network meta-analysis. However, we
found insufficient information, and it was not possible to assess
if potential effect modifiers were similar across different compar-
isons. There were also differences in potential effect modifiers
when information was available, and we were therefore unable to
conduct a network meta-analysis. There was evidence of incon-
sistency and differences in effect estimates obtained from direct
comparisons and network meta-analysis results. Results from the
network meta-analysis were not reported because they may not be
reliable.
A limitation of the review was the high risk of bias in the included
trials resulting in assessment of low or very low quality of evidence.
The review was further limited by a paucity of data. There were
few trials included in each comparison, many of which included
only one trial. This made assessment of whether effect estimates
were reproducible difficult. and also makes the assessment of in-
consistency underpowered in those comparisons with more than
one trial. Lack of evidence of inconsistency should not be consid-
ered the same as lack of inconsistency. This paucity of data de-
creases the confidence in the results.
We excluded studies that compared variations in the included in-
terventions, and hence, this review does not provide information
on whether particular variations of interventions are better than
others.
Moreover, we only included randomised clinical trials that were
known to focus mostly on benefits and did not collect and report
harms in a detailed manner. Accordingly, we may have missed a
large number of studies that address reporting of harms. As a result,
this review was biased toward reporting and analysing benefits. We
did not search for interventions and trials registered with regula-
tory authorities (e.g. the USA FDA and the European Medicines
Agency, etc). This approachmay havemissed trials (many of which
are likely to be unpublished) to possibly influence making com-
parisons appear more advantageous. However, this is principally
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of academic interest only; we found no evidence of benefit for any
intervention in people with primary biliary cholangitis, that is,
there is no reason to suggest that any interventions should be used
in routine clinical practice regardless of adverse event profiles.
In our results, we give some indication of how heterogeneity may
further drive up the required information size of themeta-analyses
to make them robust to reject or accept plausible null hypothesis (
Jakobsen 2014;Wetterslev 2017). Furthermore, we also totally and
naïvely ignored the increased family-wise error rate by using alpha
of 5% or 2.5% in spite of our primary and secondary outcomes as
well as plans on assessing outcomes at many time points, running
substantial risks for committing type I error risks (Jakobsen 2014;
Wetterslev 2017). In the future, we will consider these risks before
we embark on the update and conduct analyses. However, revising
the alpha level when there are only one or two outcomes that
determine the use of treatment, particularly when they were not
reported is contentious and is of academic interest only since the
imprecision in GRADE and Trial Sequential Analyses using an
alpha error of 5% already indicate high risk of random error.
We planned to perform a network meta-analysis. However, it was
not possible to assess whether the potential effect modifiers were
similar across different comparisons. Performing a network meta-
analysis in this scenario can be misleading. Therefore, we did not
perform the network meta-analysis, and assessed the compara-
tive benefits and harms of different interventions using standard
Cochrane methodology.
Only a fraction of the required sample size was reached for all com-
parisons. There was insufficient information to determine effects
of interventions unequivocally. Some interventions were found to
have better resolution of fatty liver disease. The different studies
reported resolution of fatty liver disease difference. There was also
evidence of heterogeneity in the results in some of the compar-
isons (thiazolidinediones versus control). For the only comparison
in which there was evidence of differences in the proportion of
people with resolution of fatty liver disease and in which more
than one trial was included, there was no evidence of heterogene-
ity despite the differences in the way that resolution of fatty liver
disease was assessed. Although there was evidence of difference in
the resolution of fatty liver disease, the Trial Sequential Analysis
showed that the trial sequential monitoring boundaries were not
crossed (Figure 4), indicating the high risks of random errors, in
addition to the systematic errors in the trials included in the anal-
ysis. Therefore, there is a lot of uncertainty over these findings.
In addition, there was no consistent evidence that one of the in-
terventions improved the unvalidated surrogate outcomes such as
fibrosis scores or NAFLD activity scores in histology, adding more
uncertainty to the effectiveness of the interventions.
Agreements and disagreements with other
studies or reviews
We identified two network meta-analyses on this topic (Singh
2015; Sawangjit 2016) and several systematic reviews on the inter-
ventions included in this Cochrane Review (Lirussi 2007;Orlando
2007; Li 2011; Mahady 2011; Li 2013; Xiang 2013; Ji 2014). We
agree with the finding reported by the authors of many of these
reviews that further well-designed randomised clinical trials are
needed on this topic. We disagree with Singh 2015 which con-
cluded that future trials of combination therapies targeting distinct
histological features are warranted. There is no evidence that any
of the histological features are valid surrogate outcomes (Gluud
2007).
We also disagree with Dongiovanni 2015 who suggested that
statins may have a protective effect for people with NAFLD and
Zhou 2016 who suggested that statins may prevent hepatocellu-
lar carcinoma in people who are at high risk of developing this
disease. However, these suggestions are based on observational ev-
idence and Dongiovanni 2015 used unvalidated surrogate histo-
logical markers to arrive at their conclusion.
Bile acids have not been shown to be harmful to treat other con-
ditions (Gurung 2013; Saffioti 2017a; Saffioti 2017b) apart from
alcoholic hepatitis (Buzetti 2017). We found that bile acids can
increase rates of adverse events. The differences observed among
reviews may be due to random error; observations were made in
only a few participants. It is also possible that the harms of bile
acids may differ among groups of patients. This is only of aca-
demic interest because there was no evidence that bile acids are
beneficial for people with NAFLD.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the very low quality evidence, we are very uncertain about
the effectiveness of pharmacological interventions for non-alcohol
related fatty liver disease including participants with steatohepati-
tis.
Implications for research
Randomised clinical trials need to be conducted and reported ac-
cording to the SPIRIT (Standard Protocol Items: Recommenda-
tions for Interventional Trials) statement (Chan 2013) and re-
ported according to the CONSORT (Consolidated Standards for
Reporting of Trials) statement (Schulz 2010). Future randomised
clinical trials should be adequately powered, involve people who
are generally seen in clinics rather than in highly selected partic-
ipants, employ blinding, avoid post-randomisation drop-outs or
planned cross-overs. Future trials should be planned to investi-
gate clinically important outcomes such as mortality, health-re-
lated quality of life, cirrhosis, decompensated cirrhosis, and liver
transplantation. NAFLD is a slowly progressing disease and ex-
pected liver-related outcomes may be identified only on long-term
28Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis (Review)
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follow-up or in very large cohorts. It may be difficult to design tri-
als with sufficiently long follow-up periods to identify the effects
of pharmacological interventions on NAFLD.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aithal 2008
Methods Randomised clinical trial
Participants Country: United Kingdom.
Number randomised: 74.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 74.
Average age: 54 years.
Females: 29 (39,2%).
NASH: 74 (100%).
Diabetics: 0 (0%).
Average follow-up period in months: 12.
Inclusion criteria
1. Age 18 to 70 years of age.
2. Biopsy proven NASH.
3. If under lipid lowering treatment, stable dosage in the previous 3 months before the
run-in period.
Exclusion criteria
1. History of alcohol excess more than 210 g per week for men and more than 140 g per
week for women.
2. Liver diseases other than NAFLD.
3. Treatment with drugs associated with fatty liver.
4. Diabetes.
5. Only simple steatosis at biopsy.
6. Treatment with weight-reduction medications.
7. Pregnancy or lactation.
8. Current or previous heart failure.
9. Renal impairment.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = 37).
Further details: pioglitazone (30 mg/day).
Group 2: control (N = 37).
Further details: control: placebo.
Duration of treatment: 12 months. All people also underwent diet and lifestyle modifi-
cation
Outcomes Outcomes reported: 1. Deaths 2. Adverse events 3. Decompensated liver disease 4. Liver
transplantation 5. Cirrhosis
Notes Authors provided additional information in February 2016.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Aithal 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed via the arand com-
puter program (Pharmacy department, University Hospitals
NHS Trust, Nottingham, UK) in blocks of 4 ”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was done in research pharmacy and
study nurse provided tablets to the patients. ”
Comment: Replies by authors.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, double-blind, placebo controlled
trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized, double-blind, placebo controlled
trial”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “Takeda Pharmaceuticals UK provided the pioglita-
zone and placebo tablets for this investigator-initiated study”
Other bias Low risk Comment: no other risk of bias.
Alam 2016
Methods Randomised clinical trial
Participants Country: Bangladesh.
Number randomised: 50.
Post-randomisation drop-outs: 20 (40%).
Revised sample size: 30.
Average age: 42 years.
Females: 23 (76,7%).
NASH: 30 (100%).
Diabetics: 8 (26,7%).
Average follow-up period in months: 12.
Inclusion criteria
1. Patients aged 18 to 65 years in whom NAFLD activity score ≥ 5 in liver histology.
Exclusion criteria
1. Alcohol intake > 20 g/day.
2. Presence of comorbid conditions such as chronic hepatitis of other causes, chronic
obstructive pulmonary disease, chronic kidney disease, congestive cardiac failure, history
of recent myocardial infarction, hypothyroidism.
3. Decompensated cirrhosis of liver.
4. Alanine aminotransferase (ALT) > five times upper normal limit.
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Alam 2016 (Continued)
5. History of taking angiotensin receptor blocker or angiotensin converting enzyme
inhibitors
Interventions Participants were randomly assigned to two groups.
Group 1: telmisartan (N = 20).
Further details: telmisartan 40 mg OD.
Group 2: control (N = 10).
Further details: control: no intervention.
Duration of treatment: 12 months. All people also underwent lifestyle modification
Outcomes Outcomes reported: 1. Mortality 2. Adverse events 3. Decompensated liver disease 4.
Liver transplantation 5. Cirrhosis 6. Change in fibrosis score 7. Change in NAS score 8.
Resolution of fatty liver disease
Notes Authors provided additional information in September 2016
Reasons for post-randomisation drop-outs: lack of interest in undergoing liver biopsy
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random sequence was generated by lottery. Each
subject was requested to pick up one among folded papers
on which their destined group name was inscribed”.
Comment: author replies.
Allocation concealment (selection bias) Low risk Quote: “Random sequence was generated by lottery. Each
subject was requested to pick up one among folded papers
on which their destined group name was inscribed”.
Comment: author replies.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This was an open-label RCT”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This was an open-label RCT”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias Low risk Quote: “Alam S, Kabir J, Mustafa G, Gupa UD, Hasan
SKMN and Alam KAK declare that there is no financial
relation with any person or organization for this study”
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Alam 2016 (Continued)
Other bias Low risk Comment: no other risk of bias.
Aller 2015
Methods Randomised clinical trial
Participants Country: Spain.
Number randomised: 36.
Post-randomisation drop-outs: not stated.
Revised sample size: 36.
Average age: 47 years.
Females: 14 (38,9%).
NASH: 15 (41.7%).
Diabetics: 0 (0%).
Average follow-up period in months: 3.
Inclusion criteria
1. Patients with biopsy proven NAFLD.
Exclusion criteria
1. Hepatitis B or C, Cytomegalovirus, Epstein Barr infections.
2. Non organ-specific autoantibodies.
3. Alcohol consumption.
4. Diabetes mellitus.
5. Impaired glucose tolerance.
6. Medication (blood-pressure lowering medication and statins).
7.Hereditary defects (iron and copper storage diseases and alpha 1-antitrypsin deficiency)
Interventions Participants were randomly assigned to two groups.
Group 1: silymarin plus antioxidants (N = 18).
Further details: silymarin 2 tablets per day plus antioxidants: vitamin E 36 mg per day.
Group 2: control (N = 18).
Further details: control: no intervention.
Duration of treatment: 3months. All people also underwent lifestylemodification which
included hypocalorific diet and exercise program
Outcomes Outcomes reported: 1. Adverse events.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “All patients were randomized (table of numbers)”.
Allocation concealment (selection bias) Unclear risk Quote: “All patients were randomized (table of numbers)”.
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Aller 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Armstrong 2016
Methods Randomised clinical trial
Participants Country: UK.
Number randomised: 52.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 52.
Average age: 51 years.
Females: 21 (40.4%).
NASH: 52 (100%).
Diabetics: 17 (32.7%).
Average follow-up period in months: 17.
Inclusion criteria
1. Patients with biopsy confirmed NASH (within 6 months prior to recruitment).
2. 18 to 70 years of age.
3. Body-mass index (BMI) of 25 kg/m² at screening.
Exclusion criteria
1. Substantial alcohol consumption.
2. Poor glycaemic control.
3. Child-Pugh B/C cirrhosis.
4. Other causes of liver disease.
5. Confounding concomitant drug use (including insulin, incretin mimetics, thiazo-
lidinediones, vitamin E).
6. Disorders such as amedical history of pancreatitis and pancreatic or thyroid carcinoma
Interventions Participants were randomly assigned to two groups.
Group 1: liraglutide (N = 26).
Further details: liraglutide started at 0.6 mg/day to reach a maximum dose of 1.8 mg/
day.
45Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Armstrong 2016 (Continued)
Group 2: control (N = 26).
Further details: control: placebo.
Duration of treatment: 11 months. All patients received advice on lifestyle modification
Outcomes Outcomes reported: 1. Mortality. 2. Adverse events 3. Decompensated liver disease 4.
Liver transplantation 5. Cirrhosis 6. Change in fibrosis score. 7. Change in NAS score.
8. Resolution of fatty liver
Notes Authors provided additional information in September 2016
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Centre-delegated staff telephoned randomisation
officers at the Cancer Research UK Clinical Trials Unit
(Birmingham, UK), who used a computer-generated, cen-
trally administered procedure to randomly assign eligible
patients ”
Allocation concealment (selection bias) Low risk Quote: “Centre-delegated staff telephoned randomisation
officers at the Cancer Research UK Clinical Trials Unit
(Birmingham, UK), who used a computer-generated, cen-
trally administered procedure to randomly assign eligible
patients ”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, randomised, placebo-controlled
phase 2 study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, randomised, placebo-controlled
phase 2 study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: this was low for adverse events but high for
change in fibrosis score, NAS score, and resolution of
NAFLD as 7 patients were excluded from these analysis
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “Wellcome Trust, National Institute of Health Re-
search, and Novo Nordisk”
Other bias Low risk Comment: no other risk of bias.
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Askarimoghadam 2013
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 93.
Post-randomisation drop-outs: not stated.
Revised sample size: 93.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Diagnosis of NAFLD based on ultrasound.
2. Age 18 to 65 years.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin plus antioxidants (N = 40).
Further details: metformin 1500 mg/day plus antioxidants: vitamin E 400 IU/day.
Group 2: metformin (N = 53).
Further details: metformin 1500 mg/day.
Duration of treatment: 6 months. Overweight people in both groups received weight
loss advice
Outcomes None of the outcomes of interest for this review were reported
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A randomized clinical trial”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open label”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open label”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
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Askarimoghadam 2013 (Continued)
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Athyros 2006
Methods Randomised clinical trial
Participants Country: Greece.
Number randomised: 186.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 186.
Average age: 60 years.
Females: 66 (35.5%).
NASH: not stated
Diabetics: 0 (0%).
Average follow-up period in months: 12.
Inclusion criteria
1. Metabolic syndrome.
2. Low density lipoprotein cholesterol (LDL) > 3.4 mmol/L (130 mg/dL)
3. Ultrasonographic evidence of fatty liver.
4. Elevated AST or ALT activity.
Exclusion criteria
1. Diabetes.
2. Cardiovascular disease.
3. History of excessive alcohol ingestion (> 20 g/day).
4. Other liver diseases.
5. Impaired renal function (serum creatinine > 115 µmol/L; 1.5 mg/dL).
6. Aminotransferase > 3 times the upper limit of normality.
7. Creatine kinase activity > 5 times the upper limit of normal (ULN)
Interventions Participants were randomly assigned to three groups.
Group 1: atorvastatin (N = 63).
Further details: atorvastatin (20 mg/day).
Group 2: fenofibrate (N = 62).
Further details: fenofibrate (200 mg/day).
Group 3: atorvastatin plus fenofibrate (N = 61).
Further details: atorvastatin (20 mg/day) plus fenofibrate (200 mg/day).
Duration of treatment: 12 months. All people also underwent diet and lifestyle modifi-
cation
Outcomes Outcomes reported: 1. Mortality 2. Adverse events 3. Liver cirrhosis 4. Decompensated
liver disease 5. Liver transplantation
Notes Authors provided additional information in February 2016.
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random Number Generation Computer Pro-
gram”.
Allocation concealment (selection bias) Low risk Quote: “The randomisation sequencewas generated byAAP,
the enrolment was performed by OIG, OIK and KG and
the random allocation was performed by VGA, who was
blinded to hypolipidaemic drug treatment”.
Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “prospective, open-label, randomized”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “prospective, open-label, randomized”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “ Some of the authors have given talks, attended
conferences and participated in trials and advisory boards
sponsored by various pharmaceutical companies”
Other bias Low risk Comment: no other risk of bias.
Baranova 2015
Methods Randomised clinical trial
Participants Country: Russia.
Number randomised: 20.
Post-randomisation drop-outs: not stated.
Revised sample size: 20.
Average age: 52 years.
Females: 12 (60%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Patients with metabolic syndrome (high blood pressure, dyslipidaemia, and NAFLD)
Exclusion criteria
1. Patients with severe chronic diseases, heart disease, chronic heart failure, atrial fibril-
lation, myocardial infarction, stroke, unstable angina
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2. Inability to accept ACE inhibitors.
Interventions Participants were randomly assigned to two groups.
Group 1: rosuvastatin (N = not stated).
Further details: rosuvastatin (dose not stated).
Group 2: control (N = not stated).
Further details: control: no intervention.
Duration of treatment: 6 months. Number of participants in each group was not stated.
All received advice on lifestyle changes
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “6 months randomised study”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Basu 2013
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 80.
Post-randomisation drop-outs: not stated.
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Revised sample size: 80.
Average age: not stated
Females: not stated
NASH: not stated
Diabetics: 0 (0%).
Average follow-up period in months: 12.
Inclusion criteria
1. Diagnosis of NAFLD.
Exclusion criteria
1. Alcohol consumption > 30 g/day.
2. HIV.
3. Steatosis inducing medications like herbal supplementations.
4. Lipodystrophy.
5. Overt diabetes.
6. Pregnancy.
7. Hypersensitivity to study medications.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = not stated).
Further details: pioglitazone 15 mg (frequency not stated).
Group 2: antioxidants (N = not stated).
Further details: antioxidants: vitamin E (dose and frequency not stated).
Duration of treatment: 12 months. In both groups, half of patients received curcumin
which was chosen at random
Outcomes None of the outcomes of interest for this review were reported
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “a randomized open label placebo controlled clinical
prospective trial ”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open label”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open label”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
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Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Basu 2014
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 155.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 155.
Average age: 36 years.
Females: 102 (65.8%).
NASH: not stated
Diabetes: 0 (0%).
Average follow-up period in months: 6.
Inclusion criteria
1. BMI > 28.
2. Diagnosis of NAFLD/NASH.
Exclusion criteria
1. Diabetes.
2. BMI > 33.
3. Alcohol intake > 30 g/day.
4. Hepatitis B or C.
5. Hypothyroidism.
6. Medications including herbs and supplements.
Interventions Participants were randomly assigned to two groups.
Group 1: antioxidants (N = 120).
Further details: antioxidants: vitamin E (700 IU/day) and/or alfa lipoic acid (300 mg/
day).
Group 2: control (N = 35).
Further details: control: placebo.
Duration of treatment: 6 months.
Outcomes Outcomes reported: 1. Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “The envelopes were used for concealment but the
randomization was based on random numbers generated by
a computer”
Allocation concealment (selection bias) Low risk Quote: “The envelopes were used for concealment but the
randomization was based on random numbers generated by
a computer. People uninvolved with the study were tasked
with the randomization process”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open label”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open label”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias High risk Quote: “Editorial assistance was provided under the direc-
tion of the authors by Med Think SciCom with support
from Salix Pharmaceuticals, Inc”
Other bias Low risk Comment: no other risk of bias.
Belfort 2006
Methods Randomised clinical trial
Participants Country: USA, Italy.
Number randomised: 55.
Post-randomisation drop-outs: 8 (14,5%).
Revised sample size: 47.
Average age: 51 years.
Females: 26 (55.3%).
NASH: 47 (100%).
Diabetics: 0 (0%).
Average follow-up period in months: 6.
Inclusion criteria
1. Biopsy-proven NASH.
2. Impaired glucose tolerance or type 2 diabetes mellitus (DM).
Exclusion criteria
1. AST and ALT elevated≥ to 2.5 times the upper limit of normal.
2. History of alcohol use (> 1 drink per day).
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3. Fasting glucose more or equal to 240 mg/dL.
4. Type 1 diabetes.
5. Heart disease.
6. Hepatic (other than NASH) disease.
7. Renal disease.
8. Metformin, thiazolidinediones or insulin use.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = 26).
Further details: pioglitazone (30 mg/day increased to 45 mg/day after 2 months).
Group 2: control (N = 21).
Further details: control: placebo.
Duration of treatment: 6 months. All people also underwent dietary advice
Outcomes Outcomes reported: 1. Cirrhosis 2. Resolution of fatty liver disease 3. Change in fibrosis
score
Notes Reasons for post-randomisation drop-outs: discontinued treatment, withdrew from
study, developed medical complications
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was computer-generated by the re-
search pharmacy”
Allocation concealment (selection bias) Low risk Quote: “Randomization was computer-generated by the re-
search pharmacy, and the investigators were unaware of the
treatment assignments”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, double-blind, placebo controlled
trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized, double-blind, placebo controlled
trial”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “Supported by grants from the National Center for
Research Resources (MO1-RR-01346, to the Frederic C.
Bartter General Clinical Research Center and its Imaging
Core), Takeda Pharmaceuticals, and the Veterans Affairs
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Medical Research Fund”
Other bias Low risk Comment: no other risk of bias.
Bonfrate 2015
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 40.
Post-randomisation drop-outs: not stated.
Revised sample size: 40.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Patients with NAFLD and metabolic disorders.
Interventions Participants were randomly assigned to two groups.
Group 1: silymarin plus antioxidants (N = not stated).
Further details: silymarin plus antioxidants: vitamin E (Eurosil).
Group 2: control (N = not stated).
Further details: control: no intervention.
Duration of treatment: 6 months. Number of participants in each group was not stated
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomized 1:1 into Eurosil 85-vit.
E complex or placebo for six months”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Bugianesi 2005
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 57.
Post-randomisation drop-outs: not stated.
Revised sample size: 57.
Average age: 41 years.
Females: 7 (12.3%).
NASH: not stated.
Diabetics: 0 (0%).
Average follow-up period in months: 12.
Inclusion criteria
1. Increased ALT values: > 1.5 times the upper limit of normal.
2. NAFLD.
Exclusion criteria
1. Alcohol consumption > 20 g/day.
2. Positive screening for B or C viral hepatitis.
3. Autoimmune hepatitis or coeliac disease.
4. Gene markers of familiar haemochromatosis.
5. Diabetes.
6. BMI more or equal than 35 kg/m².
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 29).
Further details: metformin 2 g/day.
Group 2: antioxidants (N = 28).
Further details: antioxidants: vitamin E 400 mg twice daily.
Duration of treatment: 12months. All people also underwent exercise and dietary advice.
Another group which involved prescriptive low calorie diet as the other groups did not
receive this intervention
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The randomization procedure was centralized in
Bologna, and based on a random sequence”.
Comment: Further details were not available.
Allocation concealment (selection bias) Unclear risk Quote: “Sealed envelopes”.
Comment: Further information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open label, randomized trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open label, randomized trial”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Authors used an intention-to-treat analysis based
on last observation carried forward technique”
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Chan 2015
Methods Randomised clinical trial
Participants Country: Malaysia.
Number randomised: 64.
Post-randomisation drop-outs: not stated.
Revised sample size: 64.
Average age: 50 years.
Females: 36 (56.3%).
NASH: 64 (100%).
Diabetics: not stated.
Average follow-up period in months: 11.
Inclusion criteria
1. Patients with NASH.
Interventions Participants were randomly assigned to two groups.
Group 1: silymarin (N = 30).
Further details: silymarin 700 mg thrice daily.
Group 2: control (N = 34).
Further details: control: placebo.
Duration of treatment: 11 months.
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Outcomes Outcomes reported: 1. Cirrhosis. 2. Change in fibrosis score. 3. Change in NAS score.
4. Resolution of NASH
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This is a randomized, double-blind, placebo-con-
trolled study of silymarin”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Copaci 2009
Methods Randomised clinical trial
Participants Country: Romania.
Number randomised: 94.
Post-randomisation drop-outs: not stated.
Revised sample size: 94.
Average age: 49 years.
Females: 44 (46.8%).
NASH: 94 (100%).
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Biopsy proven NASH.
Exclusion criteria
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1. Liver diseases other than NAFLD.
2. Insulin treatment.
3. Renal failure.
Interventions Participants were randomly assigned to three groups.
Group 1: pentoxifylline (N = 32).
Further details: pentoxifylline 1200 mg/day.
Group 2: UDCA (N = 30).
Further details: UDCA 13 mg/kg/day.
Group 3: pentoxifylline plus UDCA (N = 32).
Further details: pentoxifylline 1200 mg/day and UDCA 13 mg/kg/day.
Duration of treatment: 12months. All people also underwent lifestylemodification (diet
and regular exercise)
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned to three groups:”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: China.
Number randomised: 124.
Post-randomisation drop-outs: not stated.
Revised sample size: 124.
Average age: 45 years.
Females: 60 (48.4%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Alcohol consumption less than 40 g/week.
2. Elevated transaminases.
3. US proven NAFLD.
4. Histologically proven steatosis.
Exclusion criteria
1. Viral hepatitis.
2. Total parenteral nutrition.
3. Other causes of fatty liver disease.
4. Lipid lowering drug.
5. Cirrhosis.
Interventions Participants were randomly assigned to two groups.
Group 1: rosiglitazone (N = 63).
Further details: rosiglitazone 4 mg twice daily.
Group 2: control (N = 60).
Further details: control: placebo.
Duration of treatment: 6 months. Both groups received dietary and exercise advice
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized, double-blind treatment group”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, double-blind treatment group”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized, double-blind treatment group”.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Cusi 2013
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 101.
Post-randomisation drop-outs: not stated.
Revised sample size: 101.
Average age: 51 years.
Females: not stated.
NASH: 101 (100%).
Diabetics: 52 (51.5%).
Average follow-up period in months: 18.
Inclusion criteria
1. Biopsy proven NASH.
2. Prediabetes or type 2 diabetes.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = not stated).
Further details: pioglitazone (dose and duration not stated).
Group 2: control (N = not stated).
Further details: control: placebo.
Duration of treatment: 18 months.
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “We randomized 101 patients with biopsy-proven
NASH ”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neithermortality nor
adverse events were reported
For-profit bias High risk Quote: “Grant/Research Support: Takeda, Novartis,
Mannkind”.
Other bias Low risk Comment: no other risk of bias.
Dufour 2006
Methods Randomised clinical trial
Participants Country: Switzerland.
Number randomised: 48.
Post-randomisation drop-outs: 8 (16.7%).
Revised sample size: 40.
Average age: not stated.
Females: not stated.
NASH: 40 (100%).
Diabetics: not stated.
Average follow-up period in months: 24.
Inclusion criteria
1. Aged between 18 and 75 years.
2. Biopsy proven NASH performed within 6 months from inclusion.
3. Persistent elevation of ALT levels of at least 1.5 times the upper limit of normal.
4. Weekly alcohol consumption < 40 g.
Exclusion criteria
1. Positive screening for B or C viral hepatitis.
2. Abnormal transferrin saturation.
3. ANA title more than 1:80.
4. Histologic findings suggestive of other liver diseases.
5. Decompensated cirrhosis.
6. Serious diseases limiting life expectancy.
7. Pregnancy or lactation.
8. Treatment with NASH-inducing drugs (amiodarone, calcium channel blockers, ta-
moxifen) or oral anticoagulant
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Interventions Participants were randomly assigned to three groups.
Group 1: UDCA plus antioxidants (N = 12).
Further details: UDCA 12 - 15 mg/kg/day plus antioxidants: vitamin E 400 IU twice
daily.
Group 2: UDCA (N = 15).
Further details: UDCA 12 to 15 mg/kg/day.
Group 3: control (N = 13).
Further details: control: placebo.
Duration of treatment: 6 months. All people also underwent dietary advice
Outcomes Outcomes reported: 1. Change in fibrosis scores.
Notes Reasons for post-randomisation drop-outs: did not have paired biopsy
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The pharmacy established before the start of the
study a list randomly assigning each patient to 1 of the 3
arms of the study”.
Comment: Further details were not available.
Allocation concealment (selection bias) Low risk Quote: “The pharmacy established before the start of the
study a list randomly assigning each patient to 1 of the 3
arms of the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients as well as their physicians were blinded
to the treatment until completion of the whole study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patients as well as their physicians were blinded
to the treatment until completion of the whole study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “Capsules containing UDCA 250 mg and placebo
capsules were provided by Falk Pharma GmH (Freiburg,
Germany). Tablets containing vitamin E (natural d-toco-
pherol) 400 IU and placebo tablets were provided by Anti-
stress AG (Rapperswil, Switzerland)”
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: Turkey.
Number randomised: 57.
Post-randomisation drop-outs: 1 (1.8%).
Revised sample size: 56.
Average age: 47 years.
Females: 23 (41.1%).
NASH: 6 (10.7%).
Diabetics: 14 (25%).
Average follow-up period in months: 6.
Inclusion criteria
1. ALT levels at least 1.2 times the upper limit of normal despite a three-month weight
reducing diet.
2. Biopsy proven NAFLD.
Exclusion criteria
1. Alcohol intake > 20 g/day.
2. Viral hepatitis B and C.
3.Other hepatic diseases including auto-immune hepatitis,Wilson’s disease, haemochro-
matosis and alpha-1 antitrypsin deficiency.
4. Severe cardiac, pulmonary, renal or psychological problems
Interventions Participants were randomly assigned to two groups.
Group 1: UDCA (N = 29).
Further details: UDCA 10 mg/kg/day.
Group 2: antioxidants (N = 27).
Further details: antioxidants: vitamin E 600 IU/day and vitamin C 500 mg/day.
Duration of treatment: 6 months.
Outcomes Outcomes reported: 1. Adverse events 2. Resolution of fatty liver disease
Notes Reasons for post-randomisation drop-outs: discontinued participation
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “prospective, open-label, randomized”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “prospective, open-label, randomized”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “prospective, open-label, randomized”.
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Fogari 2012
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 150.
Post-randomisation drop-outs: 9 (6%).
Revised sample size: 141.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: 0 (0%).
Average follow-up period in months: 12.
Inclusion criteria
1. Mild-moderate hypertension (> 140/90 mmHg).
2. Normal cholesterol (LDL < 160 mg/dL).
3. Overweight or obesity (BMI between 25 and 34.9 kg/m²).
4. US proven hepatic steatosis.
Exclusion criteria
1. Malignant or secondary hypertension.
2. Impaired kidney function.
3. Muscle toxicity.
4. CPK > 2 times upper limit of normal.
5. Hb less than 8 g/dL.
6. Diabetes mellitus.
7. Valvular heart disease.
8. Hypertensive retinopathy of III-IV grade.
9. Unstable cardiovascular condition in the previous 6 months (congestive heart failure
NYHA class 1 to 4 or history of myocardial infarction or stroke).
10. Pregancy or lactation.
11. Contra-indication or intolerance to angiotensin 1 receptor blockers, calcium channel
blockers or HMG-CoA inhibitors
Interventions Participants were randomly assigned to two groups.
Group 1: losartan (N = 71).
Further details: losartan 50 mg/day increased to 100 mg/day after one month.
Group 2: amlodipine (N = 70).
Further details: amlodipine 5 mg/day increased to 10 mg/day after one month.
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Fogari 2012 (Continued)
Duration of treatment: 6 months. After this simvastatin was added to both groups for
another 6 months
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: lost-to-follow up, side effects
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was done using a drawing of en-
velopes containing randomization codes prepared by a statis-
tician”.
Comment: Further details were not available.
Allocation concealment (selection bias) Low risk Quote: “Randomization was done using a drawing of en-
velopes containing randomization codes prepared by a statis-
tician”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, double-blind, parallel study”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized, double-blind, parallel study”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Low risk Quote: “The authors have no relevant affiliations or financial
involvement with any organization or entity with a financial
interest in or financial conflict with the subjectmatter orma-
terials discussed in the manuscript. This includes employ-
ment, consultancies, honoraria, stock ownership or options,
expert testimony, grants or patents received or pending, or
royalties”
Other bias Low risk Comment: no other risk of bias.
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Foster 2011
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 80.
Post-randomisation drop-outs: not stated.
Revised sample size: 80.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: not stated.
Inclusion criteria
1. CT proven hepatic steatosis.
Exclusion criteria
1. Coronary artery disease.
2. Insulin-dependent diabetes.
3. Bleeding diathesis.
4. Severe anaemia.
5. Cancer within past 5 years.
Interventions Participants were randomly assigned to two groups.
Group 1: atorvastatin plus antioxidants (N = 44).
Further details: atorvastatin 20 mg/day plus vitamin C 1 g/day plus vitamin E 1,000 U/
day.
Group 2: control (N = 36).
Further details: control: placebo.
Duration of treatment: not reported.
Outcomes None of the outcomes of interest were reported in this trial
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Garinis 2010
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 50.
Post-randomisation drop-outs: 5 (10%).
Revised sample size: 45.
Average age: 44 years.
Females: 38 (84.4%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Ultrasound proven NAFLD.
2. BMI more than 25 kg/m².
Exclusion criteria
1. Heart disease.
2. Renal failure.
3. Smoking habits.
4. Alcohol intake > 20 g/day.
5. Viral, autoimmune, metabolic or genetic liver diseases.
6. Drugs known for inducing liver steatosis.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 20).
Further details: metformin 1 g per day.
Group 2: control (N = 25).
Further details: control: no intervention.
Duration of treatment: 6 months. Both groups received hypocaloric diet
Outcomes Outcomes reported: Resolution of fatty liver.
Notes Reasons for post-randomisation drop-outs: non-compliance to treatment
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized into two groups”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All patients underwent US liver evaluation by a
single experienced operator (M.D.S.), blinded to the clinical
data”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Gastaldelli 2009
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 48.
Post-randomisation drop-outs: not stated.
Revised sample size: 48.
Average age: not stated.
Females: not stated.
NASH: 48 (100%).
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Biopsy proven NASH.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = not stated).
Further details: pioglitazone 45 mg/day.
Group 2: control (N = not stated).
Further details: control: placebo.
Duration of treatment: 6 months. Both groups received hypocaloric diet
Outcomes None of the outcomes of interest were reported.
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Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients received a hypocaloric diet and were ran-
domized (double-blind) to PIO (45 mg/d) or placebo
(Placebo) for 6 months”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Gianturco 2013
Methods Randomised clinical trial
Participants Country: Italy.
Number randomised: 200.
Post-randomisation drop-outs: 4 (2%).
Revised sample size: 196.
Average age: 62 years.
Females: 92 (46.9%).
NASH: not stated.
Diabetics: 0 (0%).
Average follow-up period in months: 12.
Inclusion criteria
1. Biopsy proven NAFLD.
Exclusion criteria
1. History of HBV or HCV infection.
2. Gallstones.
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3. Alcohol consumption.
4. Renal failure.
5. Diabetes.
Interventions Participants were randomly assigned to four groups.
Group 1: UDCA plus antioxidants (N = 52).
Further details: UDCA (300 mg/day) plus antioxidants: alpha lipoic acid (400 mg/ day)
.
Group 2: antioxidants (N = 52).
Further details: antioxidants: alpha lipoic acid (400 mg/ day).
Group 3: UDCA (N = 46).
Further details: UDCA (300 mg/day).
Group 4: control (N = 46).
Further details: control: no intervention.
Duration of treatment: 12 months. All four groups received hypocaloric diet
Outcomes Outcomes reported: 1. NAFLD activity score.
Notes Reasons for post-randomisation drop-outs: onset of diabetes.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computerized random numbers”.
Allocation concealment (selection bias) Low risk Quote: “The ALA and UDCA were in capsule forms and
were identical in appearance. They were prepared in bottles
and consecutively numbered for each patient, according to
the randomization schedule”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, randomized clinical trial ”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, randomized clinical trial ”.
Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
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Gomez 2009
Methods Randomised clinical trial
Participants Country: Cuba.
Number randomised: 60.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 60.
Average age: 47 years.
Females: 26 (43.3%).
NASH: 60 (100%).
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Biopsy proven NASH.
2. Age between 18 and 70 year old.
3. Weekly alcohol consumption < 20 g.
Exclusion criteria
1. Any other liver disease.
2. HBV or HCV positivity.
3. Pregnancy or lactation.
4. Decompensated cirrhosis.
5. Drug related NAFLD gastrointestinal by-pass.
6. Treatment with UDCA, vitamin E, pioglitazone, betaine, rosiglitazone, metformin,
pentoxyphilline or gemfibrozil.
7. Use of statin within the 6 month period before enrolment.
8. Fasting glucose level less than 250 mg/dL.
9. Contraindication to liver biopsy.
10. BMI more or equal to 35 kg/m².
11. Concomitant disease with reduced life expectancy.
12. Severe psychiatric conditions and drug dependence.
Interventions Participants were randomly assigned to two groups.
Group 1: antioxidants (N = 22).
Further details: antioxidants: visuid 50 g/day (antioxidant).
Group 2: control (N = 20).
Further details: control: no intervention.
Duration of treatment: 6 months. Both groups received hypocaloric diet and exercise
advice
Outcomes Outcomes reported: 1. Change in fibrosis score. 2. Change in NAFLD activity score
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was conducted by blocks of 4”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Biopsy specimenswere examined by a single pathol-
ogist who was unaware of the patients’ clinical and biochem-
ical data, treatment assignment and liver biopsy sequence”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs..
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “Supported in part by a grant from Catalysis Labo-
ratories, Spain”
Other bias Low risk Comment: no other risk of bias.
Hajaghamohammadi 2008
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 50.
Post-randomisation drop-outs: not stated.
Revised sample size: 50.
Average age: 40 years.
Females: 18 (36%).
NASH: not stated.
Diabetics: 0 (0%).
Average follow-up period in months: 2.
Inclusion criteria
1. Ultrasound proven NAFLD.
2. Elevated AST and ALT.
Exclusion criteria
1. Diabetes.
2. Alcohol abuse.
3. Positive markers for autoimmune or viral hepatitis.
Interventions Participants were randomly assigned to two groups.
Group 1: silymarin (N = 25).
Further details: silymarin 140 mg/day.
Group 2: control (N = 25).
Further details: control: placebo.
Duration of treatment: 2 months.
Outcomes None of the outcomes of interest were reported in this trial
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Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned to each group”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Placebo was completely similar to the active drug
respecting the shape, color andpackage and all its ingredients
were identical to the main drug except for silymarin active
extract which did not exist in the placebo ”.
Comment: an identical placebo was used; however, there
was no mention about blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Placebo was completely similar to the active drug
respecting the shape, color andpackage and all its ingredients
were identical to the main drug except for silymarin active
extract which did not exist in the placebo ”.
Comment: an identical placebo was used; however, there
was no mention about blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Hajiaghamohammadi 2012
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 66.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 66.
Average age: 33 years.
Females: 24 (36.4%).
NASH: not stated.
Diabetics: 0 (0%).
Average follow-up period in months: 2.
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Inclusion criteria
1. Ultrasound proven NAFLD.
2. Elevated AST and ALT.
Exclusion criteria
1. Diabetes.
2. Alcohol consumption.
3. Positive markers for autoimmune or viral hepatitis.
4. Use of drugs like statins, NSAID and fibrate.
5. Chronic liver disease.
Interventions Participants were randomly assigned to three groups.
Group 1: pioglitazone (N = 22).
Further details: pioglitazone 15 mg once daily.
Group 2: metformin (N = 22).
Further details: metformin 500 mg/day.
Group 3: silymarin 140 mg/day (N = 22).
Further details: silymarin 140 mg/day.
Duration of treatment: 2 months.
Outcomes None of the outcomes of interest were reported in this trial
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated patients into three intervention
groups”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Low risk Quote: “Funding/Support: None declared”.
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: U.S.A.
Number randomised: 49.
Post-randomisation drop-outs: 4 (8.2%).
Revised sample size: 45.
Average age: 51 years.
Females: 25 (55.6%).
NASH: 45 (100%).
Diabetics: 19 (42.2%).
Average follow-up period in months: 6.
Inclusion criteria
1. Biopsy proven NASH performed within 6 months before the study.
2. Age more than 18 years old.
3. Elevation of transaminases.
Exclusion criteria
1. Other causes for chronic liver disease like hepatitis B and C, hereditary haemochro-
matosis, alpha1 antitrypsin deficiency, Wilson’s disease, or autoimmune liver disease.
2. Use of drugs associated with steatohepatitis, such as tamoxifen, steroids, chloroquine,
or amiodarone.
3. Prior surgical procedures, such as gastroplasty, jejunoileal or jejunocolic bypass.
4. Evidence of decompensated liver disease, such as a history of or the presence of ascites,
bleeding varices, or hepatic encephalopathy
5. Pregnancy.
6. Total parenteral nutrition within the past 6 months.
7. History of organ transplant.
8. Other conditions that have been known to cause NASH or worsen the disease.
9. History of alcohol consumption > 10 g per day.
Interventions Participants were randomly assigned to two groups.
Group 1: antioxidants (N = 23).
Further details: antioxidants: vitamin E 1000 IU/day and vitamin C 1000 mg/day.
Group 2: control (N = 22).
Further details: control: placebo.
Duration of treatment: 6 months.
Outcomes Outcomes reported: 1. Change in fibrosis score. 2. Resolution of NAFLD
Notes Reasons for post-randomisation drop-outs: Did not complete the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated randomization table”.
Allocation concealment (selection bias) Low risk Quote: “This randomization table was kept by the pharmacy
where the vitamins or placebo were to be obtained by the pa-
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tient. The patients were assigned to either the vitamin group
or the placebo group, based on the coded randomization
table, so that only the pharmacist knew which intervention
the patient was receiving”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “so that only the pharmacist knew which interven-
tion the patient was receiving…..Both the principal investi-
gator and pathologist were blinded as to the patient’s inter-
vention”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “so that only the pharmacist knew which interven-
tion the patient was receiving…..Both the principal investi-
gator and pathologist were blinded as to the patient’s inter-
vention”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Harrison 2009
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 50.
Post-randomisation drop-outs: 9 (18%).
Revised sample size: 41.
Average age: 47 years.
Females: 28 (68.3%).
NASH: 41 (100%).
Diabetics: 4 (9.8%).
Average follow-up period in months: 9.
Inclusion criteria
1. Biopsy proven NASH within 24 months before enrolment.
2. Ages > 18 years.
Exclusion criteria
1. Other liver disease than NASH.
2. Decompensated liver disease.
3. History of alcohol consumption > 20 g/day in the past 2 years.
3. Prior surgical weight loss procedures within the past 6 months.
4. Use of UDCA, rosiglitazone, pioglitazone, metformin in the previous 6 months
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Interventions Participants were randomly assigned to two groups.
Group 1: orlistat plus antioxidants (N = 23).
Further details: orlistat 120 mg thrice daily plus antioxidants: vitamin E 800 IU once
daily.
Group 2: antioxidants (N = 18).
Further details: antioxidants: vitamin E 800 IU once daily.
Duration of treatment: 9 months. Both groups received hypocaloric diet and exercise
advice
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: Withdrew consent, lost-to follow-up, unable
to obtain pre-treatment trichrome value
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “prospective, parallel, randomized treatment trial”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Liver histology (H&E stain andMasson’s trichrome
stain) was evaluated in a blinded fashion at study completion
by an expert hepatopathologist (E.B.)”.
Comment: It was not clear whether the remaining outcomes
were assessed by blinded assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
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Hashemi 2009
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 100.
Post-randomisation drop-outs: not stated.
Revised sample size: 100.
Average age: 39 years.
Females: 43 (43%).
NASH: 100 (100%).
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Sonographic evidence of fatty liver.
2. Elevated ALT > 1.2 times of the normal.
3. Suggestive histological evidence of NASH.
4. Presence of strong risk factors such as type 2 diabetes or obesity (BMI > 30 kg/m²).
Exclusion criteria
1. Intake of ethanol > 20 g per day.
2. Use of drugs known to produce fatty liver disease (steroids, oestrogens, amiodarone,
tamoxifen, or other chemotherapeutic agents ) in the previous 6 months.
3. Viral hepatitis B and C, auto-immune hepatitis, Wilson’s disease, haemochromatosis,
and alpha-1 antitrypsin deficiency.
4. Severe comorbid medical conditions (cardiac, pulmonary, renal, or psychological
problems)
Interventions Participants were randomly assigned to two groups.
Group 1: silymarin (N = 50).
Further details: silymarin 280 mg/day.
Group 2: control (N = 50).
Further details: control: placebo.
Duration of treatment: 6 months.
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized controlled trial”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although an identical placebo was used, there
was no mention of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although an identical placebo was used, there
was no mention of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Haukeland 2009
Methods Randomised clinical trial
Participants Country: Norway.
Number randomised: 48.
Post-randomisation drop-outs: 4 (8.3%).
Revised sample size: 44.
Average age: 47 years.
Females: 12 (27.3%).
NASH: not stated.
Diabetics: 12 (27.3%).
Average follow-up period in months: 6.
Inclusion criteria
1. Histologically proven NAFLD by biopsy performed within 18 months prior to en-
rolment.
2. ALT and AST elevated (> upper limit of normal)
3. Impaired glucose tolerance or type 2 diabetes.
Exclusion criteria
1. Loss > 5 kg since the time of biopsy.
2. Previous or ongoing treatment with insulin, metformin, thiazolinediones.
3. Kidney failure, pharmacologically-treated heart failure, significant coronary heart
disease (NYHA 3 or 4), moderate to severe chronic obstructive lung disease.
4. Liver cirrhosis.
5. Liver disease other than NAFLD.
6. Alcohol consumption > 24 g per day.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 20).
Further details: metformin 2500 mg to 3000 mg/day (escalating dose from 500 mg/day)
.
Group 2: control (N = 24).
Further details: control: placebo.
Duration of treatment: 6 months. Both groups received lifestyle modification advice
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(dietary and physical activity)
Outcomes Outcomes reported: 1. NAFLD activity score 2. Cirrhosis. 3. Resolution of fatty liver
disease
Notes Reasons for post-randomisation drop-outs: Did not complete the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-assisted process of minimalization”.
Allocation concealment (selection bias) Low risk Quote: “The allocation code was blinded to patients and
investigators until all patients had completed the trial”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The allocation code was blinded to patients and
investigators until all patients had completed the trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The allocation code was blinded to patients and
investigators until all patients had completed the trial”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “This work was supported by Eastern Norway Re-
gional Health Authority (grant) andMerck Sante´ (delivery
of study medication) ”
Other bias Low risk Comment: no other risk of bias.
Jin 2010
Methods Randomised clinical trial
Participants Country: China.
Number randomised: 120.
Post-randomisation drop-outs: not stated.
Revised sample size: 120.
Average age: 52 years.
Females: 55 (45.8%).
NASH: not stated.
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Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. NASH.
Exclusion criteria
1. ALT and AST > 100 IU/L.
2. Hepatitis B or C antigen or antibody.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = 60).
Further details: pioglitazone 30 mg once daily.
Group 2: control (N = 60).
Further details: control: no intervention.
Duration of treatment: 6 months.
Outcomes Outcomes reported: 1. Adverse events.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly divided”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
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Kakazu 2013
Methods Randomised clinical trial
Participants Country: Japan.
Number randomised: 25.
Post-randomisation drop-outs: 1 (4%).
Revised sample size: 24.
Average age: 57 years.
Females: 18 (75%).
NASH: 24 (100%).
Diabetics: not stated.
Average follow-up period in months: 24.
Inclusion criteria
1. Biopsy proven NASH.
2. Impaired glucose tolerance or diabetes.
Exclusion criteria
1. Liver disease other than NAFLD.
2. Decompensated liver disease.
3. Alcohol consumption > 20 g per day.
4. Use of drugs associated with fatty liver.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = 12).
Further details: pioglitazone 15 mg/day.
Group 2: control (N = 12).
Further details: control: no intervention.
Duration of treatment: 24 months. Both groups received dietary and physical activity
advice
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: lost to follow-up.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The subjects were randomly assigned to either a
diet only group or diet plus pioglitazone”
Allocation concealment (selection bias) Unclear risk Quote: “a sealed envelope technique”.
Comment: Further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “No placebo was given to patients not given piogli-
tazone supplementation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although an identical placebo was used, there
was no mention of blinding
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Low risk Quote: “This work was supported by Grant-in-Aid for
Young Scientists (B), no. 23790762, from the Ministry
of Education, Culture, Sports, Science and Technology of
Japan, and grants fromMinistry of Health, Labor, and Wel-
fare of Japan”
Other bias Low risk Comment: no other risk of bias.
Kedarisetty 2014
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 116.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 116.
Average age: not stated.
Females: not stated.
NASH: 116 (100%).
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Biopsy-proven NASH.
Interventions Participants were randomly assigned to two groups.
Group 1: pentoxifylline and Antioxidants (N = 58).
Further details: pentoxifylline 400 mg thrice daily plus antioxidants: vitamin E 400 IU
twice daily.
Group 2: antioxidants (N = 58).
Further details: antioxidants: vitamin E 400 IU twice daily.
Duration of treatment: 12 months. All people also underwent diet and lifestyle modifi-
cation
Outcomes None of the outcomes of interest were reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “Consecutive histologically proven patients with
NASH were randomized to either”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This is the first randomized open label trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This is the first randomized open label trial”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Klyarytskaya 2015
Methods Randomised clinical trial
Participants Country: Russia.
Number randomised: 51.
Post-randomisation drop-outs: not stated.
Revised sample size: 51.
Average age: 45 years.
Females: 31 (60.8%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Patients with NASH.
2. Adult patients (aged ≥18 years).
3. Increased ALT and/or alkaline phosphatase (AP) > 2 times compared to the normal.
4. No hereditary liver diseases (Wilson’s disease, haemochromatosis, and antitrypsin
deficiency).
5. A negative result of enzyme immunoassay (ELISA) for bloodmarkers of viral Hepatitis
B, C and D.
6. A negative result ELISA blood for markers of auto-immune hepatitis.
7. Avoidance of use of hepatotoxic drugs.
Exclusion criteria
1. Alcohol consumption > 30 g/day for men, > 20 g/day for women.
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2. History of acute viral hepatitis over the past 12 months.
3. The presence of concomitant decompensated diseases.
4. Pregnancy, lactation period.
Interventions Participants were randomly assigned to two groups.
Group 1: losartan plus atorvastatin plus antioxidants (N = 26).
Further details: losartan 50 mg/day and atorvastatin 20 mg/day plus antioxidants: vita-
min E 800 IU/day.
Group 2: atorvastatin plus antioxidants (N = 25).
Further details: atorvastatin 20 mg/day plus antioxidants: vitamin E 800 IU/day.
Duration of treatment: 12 months. All people also underwent lifestyle modification
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “An open randomised prospective comparative
study”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “An open randomised prospective comparative
study”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “An open randomised prospective comparative
study”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 16.
Post-randomisation drop-outs: not stated.
Revised sample size: 16.
Average age: 47 years.
Females: 9 (56.3%).
NASH: 16 (100%).
Diabetics: not stated.
Average follow-up period in months: 3.
Inclusion criteria
1. Aged 18 to 65 years.
2. Biopsy proven NASH.
3. Negative serologic markers for known chronic liver diseases.
Exclusion criteria
1. Decompensated liver disease.
2. Other chronic liver diseases.
3. Ongoing total parenteral nutrition.
4. Jejunal ileal bypass.
5. HIV infection.
6. Vitamin E replacement within 3 months before enrolment.
7. History of alcohol abuse or consumption of an average > 1 drink per week in the past
6 months
Interventions Participants were randomly assigned to two groups.
Group 1: antioxidants (N = 9).
Further details: antioxidants: vitamin E 800 IU/day.
Group 2: control (N = 7).
Further details: control: no intervention.
Duration of treatment: 3 months. Both groups received dietary and physical activity
advice
Outcomes No outcomes of interest were reported in this trial.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “In a single-blinded fashion (principal investigator
was blinded), patients were randomized to receive 800 IU
of vitamin E daily”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
High risk Quote: “In a single-blinded fashion (principal investigator
was blinded), patients were randomized to receive 800 IU
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All outcomes of vitamin E daily”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “In a single-blinded fashion (principal investigator
was blinded), patients were randomized to receive 800 IU
of vitamin E daily”.
Comment: It was not clear whether all the assessments were
made by the principal investigator
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Low risk Quote: “Supported by National Institutes of Health grants
MO1 RR02602, AA00297 (to D.B.H.), AA014185 (D.B.
H.), AA01762 (to C.J.M.), and AA10496 (to C.J.M.); Ken-
tucky Science and Engineering Foundation grant; and the
Department of Veterans Affairs”
Other bias Low risk Comment: no other risk of bias.
Leuschner 2010
Methods Randomised clinical trial
Participants Country: Multicentre, international.
Number randomised: 186.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 186.
Average age: 43 years.
Females: 60 (32.3%).
NASH: 186 (100%).
Diabetics: 21 (11.3%).
Average follow-up period in months: 18.
Inclusion criteria
1. Aged > 18 years.
2. Biopsy proven NASH within 1 month prior or after the first visit (NAS score > 6).
3. ALT level at least 1.5 times the upper limit of normal.
4. Metabolic syndrome.
5. Type II diabetes or hypertriglyceridemia or BMI more than 25 kg/m².
8. Alcohol consumption < 70 g/week.
Exclusion criteria
1. Liver cirrhosis.
2. Hepatitis B or C markers.
3. Antinuclear antibody/smooth muscle antibody titers > 1:160.
4. Cholestatic liver diseases.
5. Wilson disease.
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6. Haemochromatosis.
7. Alpha1-antitripsin deficiency.
8. History of HIV.
9. Recent intake of potential liver-toxic drugs or drug interacting with ursodeoxycholic
acid (UDCA).
10. Treatment with UDCA, metformin, glitazones, vitamin E, angiotensin receptor
antagonists in the last 3 months prior to the study entry.
11 Alcohol consumption > 70 g/week.
12. Mean corpuscolar volume more than 101 fl.
13. Pregnancy or lactation or insufficient contraception in fertile women.
14. Patients unreliable or not compliant.
Interventions Participants were randomly assigned to two groups.
Group 1: UDCA (N = 95).
Further details: UDCA 23 to 28 mg/kg/day.
Group 2: control (N = 91).
Further details: control: placebo.
Duration of treatment: 18 months.
Outcomes Outcomes reported: 1. Mortality 2. Adverse events 3. Change in fibrosis score 4. Change
in NAFLD activity score
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Double-Blind, Randomized, Placebo-Controlled
Trial”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double-Blind, Randomized, Placebo-Controlled
Trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Double-Blind, Randomized, Placebo-Controlled
Trial”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all patients were included for adverse events; pa-
tients were excluded for histological analysis
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “This study was supported by Dr. Falk Pharma
GmbH (Freiburg, Germany)”
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Other bias Low risk Comment: no other risk of bias.
Lewis 2006
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 175.
Post-randomisation drop-outs: not stated.
Revised sample size: 175.
Average age: 50 years.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 9.
Inclusion criteria
1. Diagnosis of NAFLD.
2. Total cholesterol > 160 mg/dL.
3. LDL > 100 mg/dL.
4. Triglycerides < 400 mg/dL.
Interventions Participants were randomly assigned to two groups.
Group 1: pravastatin (N = 90).
Further details: pravastatin 80 mg/day.
Group 2: control (N = 85).
Further details: control: placebo.
Duration of treatment: 9 months.
Outcomes No outcomes of interest for this review were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “with 90 randomized to Prava and 85 to PBO”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Lindor 2004
Methods Randomised clinical trial
Participants Country: Multicentre, international.
Number randomised: 174.
Post-randomisation drop-outs: 8 (4.6%).
Revised sample size: 166.
Average age: 47 years.
Females: 93 (56%).
NASH: 166 (100%).
Diabetics: not stated.
Average follow-up period in months: 24.
Inclusion criteria
1. Aged 18 to 75 years.
2. Biopsy proven NASH (at least 10% steatosis ) within 6 months before the enrolment.
3. Persistent elevation of serum alanine aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) at least 1.5 times the upper limit of normal for at least 3 months.
4. Weekly ethanol consumption < 40 g.
Exclusion criteria
1. Treatment with ursodeoxycholic acid or chenodeoxycholic acid in the 3 months prior
to the study.
2. Anticipated need for liver transplantation within 1 year or recurrent variceal bleeding,
spontaneous portosystemic encephalopathy, diuretic resistant ascites, or bacterial peri-
tonitis.
3. Pregnancy or lactation.
4. Treatment with any drugs associated with steatohepatitis (e.g. corticosteroids, high-
dose estrogens, methotrexate, amiodarone, calcium channel blockers, spironolactone,
sulfasalazine, naproxen, or oxacillin) in the 6 months prior to the study.
5. Laboratory or histologic findings highly suggestive of liver disease of another etiology,
such as chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, biliary
obstruction, or genetic liver diseases such as haemochromatosis, alpha-1-antitrypsin de-
ficiency, or Wilson’s disease
Interventions Participants were randomly assigned to two groups.
Group 1: UDCA (N = 80).
Further details: UDCA 13 to 15 mg/kg/day.
Group 2: control (N = 86).
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Further details: control: placebo.
Duration of treatment: 24 months.
Outcomes Outcomes reported: 1. Adverse events 2. Change in fibrosis score
Notes Reasons for post-randomisation drop-outs: protocol violations
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “prospective, randomized, double-blind, placebo
controlled trial”
Allocation concealment (selection bias) Low risk Quote: “The patients brought their entry forms to the phar-
macy. Each patient’s name and clinic ormedical record num-
ber was recorded, and each patient was assigned a study
number. Patients were then given their study drug based on
the previously randomized list”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The investigators, study coordinators, and patients
were blinded as to the treatment administered”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The investigators, study coordinators, and patients
were blinded as to the treatment administered”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants re-
ceived.
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias High risk Quote: “Supported, in part, byAxcanPharma, Inc.,Quebec,
Canada”
Other bias Low risk Comment: no other risk of bias.
Loomba 2015
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 50.
Post-randomisation drop-outs: not stated.
Revised sample size: 50.
Average age: 49 years.
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Females: 31 (62%).
NASH: 50 (100%).
Diabetics: 14 (28%).
Average follow-up period in months: 6.
Inclusion criteria
1. Patients with biopsy proven NASH.
2. Aged ≥ 18 years.
3. ALT > upper limit of normal (19 U/L for women and 30 U/L for men).
4. Presence of hepatic steatosis as defined by ≥ 5% on MRI.
Exclusion criteria
1. Evidence of other forms of liver disease shown by the presence of serum hepatitis
B surface antigen, hepatitis C viral RNA, positive auto-immune serologies with biopsy
consistent with autoimmune hepatitis, haemochromatosis by 3+ or 4+ stainable iron on
biopsy and homozygosity/heterozygosity on genetic analysis, low ceruloplasmin levels
with biopsy suggestive of Wilson’s disease, or low alpha-1-antitrypsin levels with biopsy
suggestive of alpha-1-antitrypsin disease.
2. Alcohol intake > 30 g/day in the previous 10 years or > 10 g/day in the previous year.
3. Decompensated cirrhosis with Child-Pugh score > 7 points.
4. Active substance abuse.
5. Significant systemic illnesses.
6. Renal insufficiency.
7. Positive human immunodeficiency virus test.
8. Pregnancy.
9. Evidence of hepatocellular carcinoma.
10. Ingestion of drugs known to cause hepatic steatosis.
11. Ingestion of drugs known to improve NASH such as vitamin E or pioglitazone.
12. Contraindications to liver biopsy or inability to undergo MRI
Interventions Participants were randomly assigned to two groups.
Group 1: ezetimibe (N = 25).
Further details: ezetimibe 10 mg once daily.
Group 2: control (N = 25).
Further details: control: placebo.
Duration of treatment: 6 months.
Outcomes Outcomes reported: 1. Adverse events 2. Fibrosis score 3.NAS score 4. Resolution of
fatty liver disease
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated numbers”.
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Allocation concealment (selection bias) Low risk Quote: “Independent investigational drug services pharma-
cists dispensed either active or placebo treatment pills, which
were identical in appearance”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 4 patients did not compelete the treatment. It
was not clear whether these patients were included in the
results for adverse events. For histological assessment only
17 patients and 18 patients were included in the analysis
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias High risk Quote: “Supported by an investigator-initiated study grant
to R.L. by Merck.”
Other bias Low risk Comment: no other risk of bias.
Magosso 2013
Methods Randomised clinical trial
Participants Country: Malaysia.
Number randomised: 87.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 87.
Average age: 50 years.
Females: 53 (60.9%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Aged ≥ 35 years.
2. Mild untreated hypercholesterolaemia (total cholesterol 200 to 240 mg/dL or LDL
100-161 mg/dL).
3. Ultrasound proven NAFLD.
4. AST, ALT and GGT < 3 times the respective upper limit value of 53 IU/l, 40 IU/l
and 49 IU/l for males or 32 IU/l for females.
Exclusion criteria
1. Anti-hyperlipidaemic treatment or vitamin E within 3 months before enrolment.
2. Alcohol consumption > 20 g/day.
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3. Previous cardiovascular event.
4. Previous hepatitis.
Interventions Participants were randomly assigned to two groups.
Group 1: antioxidants (N = 43).
Further details: antioxidants: tocotrienols 200 mg twice daily.
Group 2: control (N = 44).
Further details: control: placebo.
Duration of treatment: 12 months.
Outcomes Outcomes reported: 1. Mortality 2. Adverse events 3. Liver cirrhosis 4. Decompensated
liver disease 5. Liver transplantation 6. Resolution of fatty liver disease
Notes Authors provided additional information in February 2016.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were randomised using a computer
generated random allocation sequence”
Allocation concealment (selection bias) Low risk Quote: “The researcher (WJW) who generated the random
allocation sequence and assigned participants was blinded to
subjects’ clinical data and was independent from the persons
who enrolled participants”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Researchers and volunteers were blinded to the as-
signed treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Researchers and volunteers were blinded to the as-
signed treatment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “The authors acknowledge the Malaysian Palm Oil
Board (MPOB) for providing the supporting research grant”
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: Mexico.
Number randomised: 27.
Post-randomisation drop-outs: 4 (14.8%).
Revised sample size: 23.
Average age: 39 years.
Females: 23 (100%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 1.
Inclusion criteria
1. BMI more than 30.
2. Ages 20 to 60 years.
3. Willing to join a diet plan for 6 weeks.
4. Normal serum potassium and calcium levels.
5. Abnormal serum transaminases not related to other causes of liver disease (viral or
auto-immune hepatitis, haemochromatosis, alcohol).
6. Ultrasound evidence of hepatic steatosis.
7. Negative pregnancy test.
Exclusion criteria
1. History of hypothyroidism or Cushing syndrome.
2. Eating disorder or psychological problems.
3. Use of oral bile acid preparations, aluminium-based antacids of lithium.
4. Long-term use of nonsteroidal anti-inflammatory agents (including aspirin) or anti-
hyperlipidemic agents within 2 weeks of entering the trial
Interventions Participants were randomly assigned to two groups.
Group 1: UDCA (N = 12).
Further details: UDCA 1200 mg/day.
Group 2: control (N = 11).
Further details: control: placebo.
Duration of treatment: 1 month. Both groups received hypocaloric diet
Outcomes No outcomes of interest were reported in this trial.
Notes Reasons for post-randomisation drop-outs: withdrew prematurely, became pregnant
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “according to a table of random numbers”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
Low risk Quote: “A double-blind placebo-controlled trial”.
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All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A double-blind placebo-controlled trial”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Quote: “This work was partly supported by Medica Sur
Clinic & Foundation”.
Comment: the source of remaining funds was not reported.
Other bias Low risk Comment: no other risk of bias.
Merat 2003
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 30.
Post-randomisation drop-outs: 3 (10%).
Revised sample size: 27.
Average age: 36 years.
Females: 6 (22.2%).
NASH: 27 (100%).
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Biopsy proven NASH.
2. Aged 15 to 60 years.
3. Liver function test alteration lasted for at least three months (AST and ALT > 1.2
times upper limit of normal).
Exclusion criteria
1. Alcohol consumption.
2. Viral hepatitis B or C.
3. Auto-immune hepatitis.
4. Wilson’s disease.
5. Haemochromatosis.
6. Alpha1-antitrypsin deficiency.
7. Pregnancy, lactation or women who wished to have children in the following years.
8. Severe comorbidities (cardiac, pulmonary, renal or psychological)
Interventions Participants were randomly assigned to two groups.
Group 1: probucol (N = 18).
Further details: probucol 500 mg once daily.
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Group 2: control (N = 9).
Further details: control: placebo.
Duration of treatment: 6 months.
Outcomes Outcomes reported: 1. Adverse events.
Notes Reasons for post-randomisation drop-outs: withdrew from study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by a computer gen-
erated random list of the containers’ numbers”
Allocation concealment (selection bias) Low risk Quote: “Patients found eligible for the study in any of the
three study centers were referred to a single investigator who
assigned new cases sequentially to the next available con-
tainer on the list”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “a double-blind randomized controlled study”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a double-blind randomized controlled study”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants re-
ceived.
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias Low risk Quote: “This work was funded by the Digestive Disease
Research Center of Tehran University of Medical Sciences”
Other bias Low risk Comment: no other risk of bias.
Morita 2005
Methods Randomised clinical trial
Participants Country: Japan.
Number randomised: 10.
Post-randomisation drop-outs: not stated.
Revised sample size: 10.
Average age: 50 years.
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Females: 7 (70%).
NASH: 10 (100%).
Diabetics: 10 (100%).
Average follow-up period in months: 5.
Inclusion criteria
1. Biopsy proven NASH.
2. ALT > 30 UI/l.
3. Diabetes.
4. Ultrasound or CT proven liver steatosis.
Exclusion criteria
1. Alcohol intake > 20 g/day.
2. Hepatitis B or C.
3. ANA or AMA positivity.
Interventions Participants were randomly assigned to two groups.
Group 1: nateglinide (N = 5).
Further details: nateglinide 270 mg/day.
Group 2: control (N = 5).
Further details: control: no intervention.
Duration of treatment: 5 months. Both groups received dietary and physical activity
advice
Outcomes No outcomes of interest were reported in this trial.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The subjects were randomly divided into two
groups”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
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For-profit bias Low risk Quote: “This study was supported by the grant 16590150
from the Ministry of Education, Science, Sports, and Cul-
ture of Japan and part of a project for establishing new high
technology research center supported by theMinistry of Ed-
ucation, Science, Sports, and Culture of Japan”
Other bias Low risk Comment: no other risk of bias.
Mudaliar 2013
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 64.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 64.
Average age: 52 years.
Females: 31 (48.4%).
NASH: not stated.
Diabetics: 64 (100%).
Average follow-up period in months: 1.
Inclusion criteria
1. Type 2 diabetes.
2. NAFLD defined by one or more of the following criteria: ALT ≥ 47 IU/l for females
and 56 for males; AST ≥ 47 IU/l for females and 60 IU/l for males; enlarged liver (on
ultrasound or other imaging technique) and diagnostic histologic findings shown on
prior biopsy (in the prior 5 years).
Exclusion criteria
1. Viral hepatitis B or C.
2. Primary biliary cirrhosis.
3. Primary sclerosing cirrhosis.
4. AST > 155 IU/l for females and 200 for males and ALT > 155 IU/l for females and
185 IU/l for males.
5. Bilirubin level > 2 times upper limit of normal.
6. Use of anti-diabetes drugs except for metformin and sulphonylureas.
7. Alcohol consumption > 210 mL/week or other substance abuse in the previous 2
years.
8. Significant heart or renal disease.
Interventions Participants were randomly assigned to two groups.
Group 1: obeticholic acid (N = 41).
Further details: obeticholic acid 25 mg or 50 mg once daily (dose decided by randomi-
sation).
Group 2: control (N = 23).
Further details: control: placebo.
Duration of treatment: 1 month.
Outcomes Outcomes reported: 1. Mortality 2. Adverse events.
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Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This number was preprinted on the patient drug
kit according to the master randomization schedule”.
Comment: Details on how this randomization schedule was
drawn were not available
Allocation concealment (selection bias) Low risk Quote: “Eligible patients were assigned a 3-digit patient ran-
domization number. This number was preprinted on the pa-
tient drug kit according to the master randomization sched-
ule. The drug kit was dispensed by the site pharmacists”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo controlled”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo controlled”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “Supported by a research grant from Intercept Phar-
maceuticals, Inc.”
Other bias Low risk Comment: no other risk of bias.
Nar 2009
Methods Randomised clinical trial
Participants Country: Turkey.
Number randomised: 34.
Post-randomisation drop-outs: not stated.
Revised sample size: 34.
Average age: 47 years.
Females: 25 (73.5%).
NASH: not stated.
Diabetics: 34 (100%).
Average follow-up period in months: 6.
Inclusion criteria
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1. Type 2 diabetes.
2. Ultrasound proven NAFLD.
Exclusion criteria
1. Anti-diabetes medication.
2. Acute or chronic viral hepatitis.
3. Autoimmune hepatitis.
4. Excessive alcohol consumption.
5. History of malignancy, renal impairment, haemodynamic instability, diseases of pitu-
itary adrenal glands and pancreas.
6. Prolonged use of corticosteroids or sexual hormones.
7. Use of antihyperlipidaemic agents and anti-obesity medications
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 19).
Further details: metformin 1700 mg/day.
Group 2: control (N = 15).
Further details: control: no intervention.
Duration of treatment: 6 months. Both groups received dietary and physical activity
advice
Outcomes Outcomes reported: 1. Resolution of fatty liver disease.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned into two study
groups”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Same operator performed all US procedures and
was blind to the randomization of the patients”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other risk of bias.
Nelson 2009
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 16.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 16.
Average age: 53 years.
Females: 5 (31.3%).
NASH: 16 (100%).
Diabetics: 7 (43.8%).
Average follow-up period in months: 12.
Inclusion criteria
1. Aged ≥ 18 years.
2. Biopsy proven NASH within 6 months before enrolment.
3. Compensated liver disease.
4. Serum creatinine < 1.4 mg/dL.
5. Total cholesterol > 200 mg/dL or triglycerides > 200 mg/dL or LDL > 130 mg/dL.
Exclusion criteria
1. Any other cause of liver disease.
2. Alcohol consumption > 1 drink/day.
3. Prior gastroplasty, jejuno-ileal or jejuno-colic bypass.
4. Prior exposure to organic solvent.
5. Total parenteral nutrition in the previous 6 months.
6. Prior organ transplantation.
7. Use of statin in the previous 12 months.
8. Use of tamoxifen, prednisone, chloroquine, methotrexate, highly active antiretroviral
therapy, amiodarone, or any other hepatotoxic medications.
9. Serum transaminases level > 3 times the upper limit of normal
Interventions Participants were randomly assigned to two groups.
Group 1: Simvastatin (N = 10).
Further details: Simvastatin 40 mg/day.
Group 2: control (N = 6).
Further details: control: placebo.
Duration of treatment: 12 months.
Outcomes Outcomes reported: 1. Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
103Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nelson 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized to receive either simvas-
tatin 40 mg or placebo once daily for 12 months”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind randomized placebo-controlled trial
”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind randomized placebo-controlled trial
”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs..
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias Low risk Quote: “Funding: None”.
Other bias Low risk Comment: no other risk of bias.
Neuschwander-Tetri 2015
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 283.
Post-randomisation drop-outs: not stated.
Revised sample size: 283.
Average age: 51 years.
Females: 187 (66.1%).
NASH: 283 (100%).
Diabetics: 149 (52.7%).
Average follow-up period in months: 17.
Inclusion criteria
1. Aged ≥ 18 years at the time of screening.
2. Histological evidence of definite or borderline non-alcoholic steatohepatitis based
upon a liver biopsy obtained 90 days or less before randomisation.
3. NAS score ≥ 4 with a score ≥ 1 in each component of the score.
Exclusion criteria
1. Presence of cirrhosis.
2. Other causes of liver disease.
3. Substantial alcohol consumption (> 20 g/day for women or > 30 g/day for men).
4. Other confounding conditions.
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Interventions Participants were randomly assigned to two groups.
Group 1: obeticholic acid (N = 141).
Further details: obeticholic acid 25 mg OD.
Group 2: control (N = 142).
Further details: control: placebo.
Duration of treatment: 17 months.
Outcomes Outcomes reported: 1. Mortality 2. Adverse events 3. Change in fibrosis score 4. Change
in NAS score. 5. Resolution of fatty liver disease
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated, centrally administered proce-
dure”
Allocation concealment (selection bias) Low risk Quote: “computer-generated, centrally administered proce-
dure.Treatment was assigned centrally using a web-based ap-
plication”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients, investigators, clinical site staff, and pathol-
ogists were masked to treatment assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients, investigators, clinical site staff, and pathol-
ogists were masked to treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants were included for safety issues
and non-histological outcomes but 64 participants were ex-
cluded for histological outcomes
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “National Institute of Diabetes and Digestive and
Kidney Diseases, Intercept Pharmaceuticals”
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: Turkey.
Number randomised: 64.
Post-randomisation drop-outs: not stated.
Revised sample size: 64.
Average age: 49 years.
Females: 29 (45.3%).
NASH: 64 (100%).
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Impaired glucose metabolism (type 2 diabetes or impaired glucose tolerance).
2. Elevated ALT for at least 6 months before enrolment.
3. NAFLD activity score at least of 5 in liver biopsy performed within 6 months before
enrolment.
4. Diet and exercise program for at least 12 weeks before enrolment.
Exclusion criteria
1. Alcohol consumption > 20 g/day.
2. Use of oral anti-diabetes, insulin or a chemotherapeutic agent.
3. Presence of other chronic liver diseases, such as metabolic liver diseases, auto-immune
liver diseases, and chronic viral hepatitis B or C.
4. HIV infection.
5. Pregnancy or lactation.
6. Candidate for organ transplantation.
7. Malignancy.
8. Renal function impairment (serum creatinine more than 1.5 mg/dL in men and 1.4
mg/dL in women).
9. Clinically significant systemic illness.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 22).
Further details: metformin 1700 mg/day.
Group 2: rosiglitazone (N = 20).
Further details: rosiglitazone 4 mg/day.
Duration of treatment: 12 months. Both groups received dietary and physical activity
advice
Outcomes Outcomes reported: 1. NAFLD activity score.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “open-label, randomized, preliminary and single-
center study”
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Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label, randomized, preliminary and single-
center study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label, randomized, preliminary and single-
center study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Biopsy was performed and reported in only a
proportion of the randomised population
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Parikh 2016
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 250.
Post-randomisation drop-outs: 17 (6.8%).
Revised sample size: 233.
Average age: 42 years.
Females: not stated.
NASH: 35 (15%).
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Patients with NAFLD with abnormal ALT or AST.
2. Aged 18 to 80 years.
Exclusion criteria
1. History of alcohol intake > 20 g per day (during previous 5 years).
2. Hepatitis B antigen (HBsAg) reactive.
3. Presence of antibody against hepatitis C (anti-HCV) human immunodeficiency virus
(HIV) reactive.
4. Active hepatitis.
5. Biliary obstruction on ultrasound.
6. Diagnosed as cirrhosis at any time in the past.
7. Tuberculosis.
8. Malabsorption.
9. Chronic drug use.
10. Pregnancy.
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11. Any cardiorespiratory comorbid conditions.
Interventions Participants were randomly assigned to two groups.
Group 1: antioxidants (N = 95).
Further details: antioxidants: vitamin E 400 IU twice daily.
Group 2: UDCA (N = 138).
Further details: UDCA 300 mg twice daily.
Duration of treatment: 12months. All people also underwent lifestylemodification (diet
and regular exercise)
Outcomes Outcomes reported: 1. Adverse events.
Notes Reasons for post-randomisation drop-outs: lost-to-follow up.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “prospective, single center, open-labeled, RCT”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “prospective, single center, open-labeled, RCT”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “prospective, single center, open-labeled, RCT”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Low risk Quote: “Financial support and sponsorship: Nil”.
Other bias Low risk Comment: no other risk of bias.
Polyzos 2011
Methods Randomised clinical trial
Participants Country: Greece.
Number randomised: 31.
Post-randomisation drop-outs: not stated.
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Revised sample size: 31.
Average age: not stated.
Females: not stated.
NASH: 16 (51.6%).
Diabetics: 5 (16.1%).
Average follow-up period in months: 2.
Inclusion criteria
1. Aged ≥ 18 years.
2. Ultrasound liver brightness and increased liver function tests for at least 6 months
before liver biopsy.
3. Biopsy proven NAFLD.
Exclusion criteria
1. Known intolerance to spironolactone.
2. Ethanol consumption > 20 g/day.
3. History of liver disease (chronic viral hepatitis, auto-immune hepatitis, drug-induced
liver disease, primary biliary cirrhosis, haemochromatosis, Wilson’s disease, a1-antit-
rypsin deficiency).
4. Exposure to hepatotoxic drugs or evidence of liver cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1: spironolactone plus antioxidants (N = 14).
Further details: spironolactone 25 mg/day plus antioxidants: vitamin E 400 IU/day.
Group 2: antioxidants (N = 17).
Further details: antioxidants: vitamin E 400 IU/day.
Duration of treatment: planned 12 months. The report includes only 2 months of
treatment
Outcomes Outcomes reported: 1. Mortality. 2. Adverse events. 3. Cirrhosis. 4. Decompensated
liver disease. 5. Liver transplantation
Notes Authors provided additional information in February 2016
Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was accomplished by a computer
program before the screening of the first patient”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias Low risk Quote: “This research received no specific grant from any
funding agency in the public, commercial, or not-for-profit
sectors”
Other bias Low risk Comment: no other risk of bias.
Ratziu 2008
Methods Randomised clinical trial
Participants Country: France.
Number randomised: 64.
Post-randomisation drop-outs: 1 (1,6%).
Revised sample size: 63.
Average age: 54 years.
Females: 26 (41.3%).
NASH: 63 (100%).
Diabetics: 20 (31.7%).
Average follow-up period in months: 16.
Inclusion criteria
1. Aged 18 to 75 years.
2. Biopsy proven NASH (and steatosis > 20%).
3. Elevated ALT (> 28 UI/L for women and > 35 UI/L for men at baseline and at least
2 abnormal values in the last 6 months).
Exclusion criteria
1 .Presence of bland steatosis on liver biopsy or steatosis with no specific inflammation.
2. Daily alcohol consumption > 30 g in men and 20 g in women whether current or in
the past.
3. Any cause of liver disease other thanNASH, including suspicion of drug-induced liver
injury (introduction of a new drug in the past 6 months without prior documentation
of elevated ALT level).
4. Treatment with insulin for diabetes or with ursodeoxycholic acid.
5. Cardiac insufficiency (NYHA class I).
6. Current or past treatment with drugs that can induce steatohepatitis.
7. Neoplastic disease.
8. Child B or C cirrhosis.
9. Pregnancy.
10. Organ transplantation.
11. Haemoglobin level < 10 g/dL.
12. Polymorphonuclear count < 750/mm³.
13. Platelet count < 50,000/mm³
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Interventions Participants were randomly assigned to two groups.
Group 1: rosiglitazone (N = 32).
Further details: rosiglitazone 4 mg/day for 1 month increased to 8 mg/day thereafter.
Group 2: control (N = 31).
Further details: control: placebo.
Duration of treatment: 12 months. Both groups received dietary and physical activity
advice
Outcomes Outcomes reported: 1. Change in fibrosis score 2. Change in NAFLD activity score
Notes Reasons for post-randomisation drop-outs: withdrew consent.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization (presealed envelopes) was con-
ducted by blocks of 4 and stratified on metformin use”
Allocation concealment (selection bias) Unclear risk Quote: “Randomization (presealed envelopes) was con-
ducted by blocks of 4 and stratified on metformin use”.
Comment: Further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, double-blind, placebo controlled trial
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized, double-blind, placebo controlled trial
”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “GlaxoSmithKline provided rosiglitazone and
placebo for this trial and partly funded the trial”
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: France.
Number randomised: 126.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 126.
Average age: 50 years.
Females: 31 (24.6%).
NASH: 126 (100%).
Diabetics: 40 (31.7%).
Average follow-up period in months: 12.
Inclusion criteria
1. Aged > 18 years.
2. Increased ALT (≥ 50UI/L) in at least three determinations within the past 12 months.
3. Biopsy proven NASH.
Exclusion criteria
1. > one normal ALT level within the 12 months before screening.
2. No inflammation on liver biopsy which excluded the diagnosis of NASH.
3. Alcohol consumption > 30 g/day for men and 20 g/day for women.
4. Liver diseases other than NAFLD.
5. Child B or C cirrhosis.
6. Secondary NASH.
7. Treatment with UDCA in the previous 12 months, with vitamin E in the previous 6
months or with glitazone in the previous 3 months.
8. Newly instituted antihyperglycaemic therapy in the previous 4 months.
9. Loss ≥ 15% body weight since liver biopsy.
10. Hepatocellular carcinoma.
11. Pregnancy or breastfeeding.
Interventions Participants were randomly assigned to two groups.
Group 1: UDCA (N = 62).
Further details: UDCA 28 to 35 mg/kg/day.
Group 2: control (N = 64).
Further details: control: placebo.
Duration of treatment: 12 months. Both groups received dietary and physical activity
advice
Outcomes Outcomes reported: 1. Mortality. 2. Adverse events. 3. Decompensated cirrhosis
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This multicenter, randomized, double-blind, par-
allel arm, placebo-controlled phase II study of HD-UDCA
was conducted in 15 centers in France”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “This multicenter, randomized, double-blind, par-
allel arm, placebo-controlled phase II study of HD-UDCA
was conducted in 15 centers in France”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “This multicenter, randomized, double-blind, par-
allel arm, placebo-controlled phase II study of HD-UDCA
was conducted in 15 centers in France”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias High risk Quote: “This trial was sponsored and funded by Axcan
Pharma S.A. V. Ratziu is a consultant to Astellas Pharma,
Axcan Pharma, Gilead Sciences, Genentech, Intercept Phar-
maceuticals, and Sanofi-Aventis”
Other bias Low risk Comment: no other risk of bias.
Ratziu 2014
Methods Randomised clinical trial
Participants Country: Multicentre, international.
Number randomised: 99.
Post-randomisation drop-outs: 3 (3%).
Revised sample size: 96.
Average age: 45 years.
Females: 26 (27.1%).
NASH: 96 (100%).
Diabetics: not stated.
Average follow-up period in months: 3.
Inclusion criteria
1. Patients with NASH without cirrhosis.
2. Aged ≥ 18 years.
3. ALT > 1.5 times normal limit or > 60 U/L on more than 1 occasion.
Exclusion criteria
1. Uncontrolled diabetes.
2. Hepatic cirrhosis.
3. Liver disease other than NASH.
4. Excessive alcohol use (20 g/day for women and 30 g/day for men).
5. Weight change > 5% in the prior 6 months.
Interventions Participants were randomly assigned to two groups.
Group 1: ASP9832 (N = 66).
Further details: ASP9832 50 mg and 100 mg (random).
Group 2: control (N = 30).
Further details: control: placebo.
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Duration of treatment: 3 months.
Outcomes Outcomes reported: 1. Adverse events.
Notes Reasons for post-randomisation drop-outs: discontinued treatment
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The randomization codes were created by an exter-
nal organization”
Allocation concealment (selection bias) Low risk Quote: “The randomization codes were created by an exter-
nal organization and had been concealed until the end of
the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The participants were blinded to the received treat-
ment; in addition, neither the investigator nor the pharma-
cist, nor the sponsor was aware of the treatment group”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The participants were blinded to the received treat-
ment; in addition, neither the investigator nor the pharma-
cist, nor the sponsor was aware of the treatment group”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias High risk Quote: “All clinical trials were sponsored by Astellas Pharma
Europe BV”
Other bias Low risk Comment: no other risk of bias.
Ratziu 2016
Methods Randomised clinical trial
Participants Country: Multicentre, international.
Number randomised: 276.
Post-randomisation drop-outs: 2 (0.7%).
Revised sample size: 274.
Average age: 53 years.
Females: 123 (44.9%).
NASH: 274 (100%).
Diabetics: 107 (39.1%).
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Average follow-up period in months: 12.
Inclusion criteria
1. Patients with NASH without cirrhosis.
2. Aged 18 to 75 years.
Exclusion criteria
1. Daily alcohol consumption > 2 drink units/d (equivalent to 20 g) in women and 3
drink units/d (30 g) in men.
2. Steatohepatitis was due to secondary causes.
3. Any other chronic liver disease was identified.
Interventions Participants were randomly assigned to two groups.
Group 1: elafibranor (N = 182).
Further details: elafibranor (80 mg or 120 mg: trial started initally at 80 mg but the dose
was changed to 120 mg later).
Group 2: control (N = 92).
Further details: control: placebo.
Duration of treatment: 12 months.
Outcomes Outcomes reported: 1. Adverse events.
Notes Reasons for post-randomisation drop-outs: not treated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated coding list”.
Allocation concealment (selection bias) Low risk Quote: “allocation was performed centrally for all sites
through a web system”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “ Patients, investigators, clinical site staff, and the
pathologist were masked to treatment assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “ Patients, investigators, clinical site staff, and the
pathologist were masked to treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: since there was no significant difference between
the groups in the primary outcome, the definition was re-
vised and according to the new definition, there was statis-
tically significant difference
For-profit bias High risk Quote: “The study was funded by Genfit SA.”.
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Other bias Low risk Comment: no other risk of bias.
Razavizade 2013
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 80.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 80.
Average age: 35 years.
Females: 12 (15%).
NASH: not stated.
Diabetics: 6 (7.5%).
Average follow-up period in months: 4.
Inclusion criteria
1. Aged ≥ 18 years.
2. Ultrasound proven NAFLD.
3. Persistently elevated transaminases (≥ 40 UI/L).
4. NAFLD liver fat score > -0.64.
Exclusion criteria
1. Alcohol consumption > 20 g/day for men and 10 g/day for women.
2. Type 1 diabetes.
3. Heart disease.
4. Liver diseases (viral hepatitis, auto-immune hepatitis, Wilson disease, haemochro-
matosis, liver mass lesion).
5. Renal disease (creatinine > 1.5 mg/dL).
6. Severe systemic comorbidities.
7. Neoplasm.
8. Any medication in the previous 3 months.
9. Previous treatment with thiazolinediones, biguanides or insulin.
10. Pregnancy or breastfeeding.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 40).
Further details: metformin 1 g per day.
Group 2: pioglitazone (N = 40).
Further details: pioglitazone 30 mg/day.
Duration of treatment: 4 months. Both groups received hypocaloric diet
Outcomes Outcomes reported: 1. Mortality. 2. Adverse events. 3. Cirrhosis. 4. Decompensated
liver disease. 5. Liver transplantation
Notes Authors provided additional information in February 2016.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “predefined computer-generated block randomiza-
tion table”
Allocation concealment (selection bias) Low risk Quote: “An investigator whowas not involved in data collec-
tion and treatment, performed the enrolment patients and
their assignments into treatment groups”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized double blind clinical trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized double blind clinical trial”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For-profit bias Low risk Quote: “This study was supported by the research funds of
Kashan University of Medical Sciences (No: 29-5-1-2851)”
Other bias Low risk Comment: no other risk of bias.
Razavizadeh 2012
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 100.
Post-randomisation drop-outs: not stated.
Revised sample size: 100.
Average age: 38 years.
Females: 24 (24%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 2.
Inclusion criteria
1. US fatty liver.
2. Persistently elevated ALT.
Exclusion criteria
1. Causes of liver disease other than NAFLD.
Interventions Participants were randomly assigned to two groups.
Group 1: antioxidants (N = not stated).
Further details: antioxidants: vitamin E 400 IU/day.
Group 2: silymarin (N = not stated).
Further details: silymarin 140 mg/day.
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Duration of treatment: 2 months.
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “They were randomly assigned to take…”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Safadi 2014
Methods Randomised clinical trial
Participants Country: Israel.
Number randomised: 60.
Post-randomisation drop-outs: 3 (5%).
Revised sample size: 57.
Average age: 40 years.
Females: 16 (28.1%).
NASH: 6 (10.5%).
Diabetics: not stated.
Average follow-up period in months: 4.
Inclusion criteria
1. Histologically proven NAFLD or NASH by biopsy performed within 18 months
prior to enrolment.
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2. Aged 18 to 75 years.
Interventions Participants were randomly assigned to two groups.
Group 1: aramchol (N = 38).
Further details: aramchol (100 mg once daily or 300 mg once daily: randomly allocated
to the two doses).
Group 2: control (N = 19).
Further details: control: placebo.
Duration of treatment: 3 months.
Outcomes Outcomes reported: 1. Adverse events.
Notes Reasons for post-randomisation drop-outs: withdrew consent; major protocol violation
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized, double-blind, placebo-controlled
trial”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias High risk Quote: “Supported by Galmed Medical Research, Ltd.”.
Other bias Low risk Comment: no other risk of bias.
Santos 2003
Methods Randomised clinical trial
Participants Country: Brasil.
Number randomised: 30.
Post-randomisation drop-outs: not stated.
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Revised sample size: 30.
Average age: 38 years.
Females: 2 (6.7%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 3.
Inclusion criteria
1. BMI ≥ 25.
2. ALT, AST or GGT ≥ 1.5 times the upper limit of normal for more than six months.
3. Ultrasound proven liver steatosis.
Exclusion criteria
1. Alcohol consumption > 40 g/week.
2. Decompensated diabetes.
3. Total cholesterol or triglycerides more than 300 mg/dL.
4. Intake of hepatotoxic medications.
5. HBV or HCV infection.
6. Other concomitant hepatic or systemic diseases.
Interventions Participants were randomly assigned to two groups.
Group 1: UDCA (N = 15).
Further details: UDCA 10 mg/kg/day.
Group 2: control (N = 15).
Further details: control: placebo.
Duration of treatment: 3 months.
Outcomes No outcomes of interest were reported in this trial.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized double-blind study”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized double-blind study”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized double-blind study”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
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Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “Ursodeoxycholic acid was kindly provided by Zam-
bon Laboratories, São Paulo, SP, Brazil”
Other bias Low risk Comment: no other risk of bias.
Sanyal 2004
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 20.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 20.
Average age: 47 years.
Females: 10 (50%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Patients with biopsy proven NASH.
Exclusion criteria
1. Age < 18 years.
2. Diabetes mellitus.
3. Cirrhosis.
4. Weight gain or loss > 5 pounds in the month preceding entry.
5. Severe comorbid conditions limiting life expectancy to < 1 year.
6. Pregnancy.
7. Symptomatic gallstone disease.
8. Those being considered for or who had bariatric surgery.
9. Iatrogenic NASH.
10. Concomitant presence of other causes of liver disease (eg. hepatitis C).
11. Refusal to give informed consent or have a liver biopsy examination performed
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone plus antioxidants (N = 10).
Further details: pioglitazone 30 mg once daily plus antioxidants: vitamin E 400 IU once
daily.
Group 2: antioxidants (N = 10).
Further details: antioxidants: vitamin E 400 IU once daily.
Duration of treatment: 6 months. All people also had low-calorie diet
Outcomes None of the outcomes of interest were reported.
Notes
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A randomized prospective trial”.
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed by an independent
statistician in the General Clinical Research Center ”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Sanyal 2010
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 247.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 247.
Average age: 46 years.
Females: 147 (59.5%).
NASH: 247 (100%).
Diabetics: 0 (0%).
Average follow-up period in months: 22.
Inclusion criteria
1. Biopsy proven NASH (definite or possible) with NAFLD activity score of at least 4
and ballooning score of at least 1, performed within 6 months before randomization.
Exclusion criteria
1. Diabetes.
2. Alcohol consumption > 20 g/day for women and 30 g/day for men for at least 3
consecutive months in the previous 5 years.
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3. Cirrhosis.
4. Hepatitis C or other liver diseases.
5. Heart failure NYHA (New York Heart Association) II-IV.
6. Drugs known for inducing steatohepatitis.
Interventions Participants were randomly assigned to three groups.
Group 1: pioglitazone (N = 80).
Further details: pioglitazone 30 mg once daily.
Group 2: antioxidants (N = 84).
Further details: antioxidants: vitamin E 800 IU once daily.
Group 3: control (N = 83).
Further details: control: placebo.
Duration of treatment: 22 months.
Outcomes Outcomes reported: 1. Adverse events. 3. Resolution of fatty liver disease. 4. Change in
fibrosis score. 5. Change in NAFLD activity score
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization plan was prepared and admin-
istered centrally by the Data Coordinating Center (DCC).
Requests for randomizations were made by the clinical staff
using a web-based application”
Allocation concealment (selection bias) Low risk Quote: “The randomization plan was prepared and admin-
istered centrally by the Data Coordinating Center (DCC).
Requests for randomizations were made by the clinical staff
using a web-based application”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, multicenter, double-masked, placebo-
controlled trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized, multicenter, double-masked, placebo-
controlled trial”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs for
main clinical outcomes but high for histological outcomes
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
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For-profit bias High risk Quote: “Additional funding was provided by Takeda Phar-
maceuticals North America through a Cooperative Research
and Development Agreement with the NIH”
Other bias Low risk Comment: no other risk of bias.
Sharma 2012
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 60.
Post-randomisation drop-outs: 1 (1.7%).
Revised sample size: 59.
Average age: 39 years.
Females: 24 (40.7%).
NASH: 59 (100%).
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Aged 18 to 70 years.
2. ALT > 1.2 time the upper limit of normal on three occasions at least 1 month apart
in the last 6 months.
3. Ultrasound proven fatty liver.
4. Liver biopsy showing steatosis, necro-inflammation activity, ballooning and/or fibrosis.
Exclusion criteria
1. Alcohol intake > 20 g/day.
2. Viral or auto-immune hepatitis.
3. Primary biliary cirrhosis.
4. Wilson’s disease.
5. Haemochromatosis.
6. Biliary obstruction.
7. Decompensated cirrhosis.
8. Drugs ingestion for > 4 weeks during past 6 months (amiodarone, methotrexate,
perhexiline, glucocorticoids, estrogens, tamoxifen, nifedipine, diltiazem).
9. Pregnancy.
10. Insulin treated diabetes.
Interventions Participants were randomly assigned to two groups.
Group 1: pentoxifylline (N = 30).
Further details: pentoxifylline 400 mg thrice daily.
Group 2: pioglitazone (N = 29).
Further details: pioglitazone 30 mg once daily.
Duration of treatment: 6 months. Both groups received hypocaloric diet and exercise
advice
Outcomes Outcomes reported: 1. Adverse events. 2. Fibrosis score.
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Notes Reasons for post-randomisation drop-outs: lost to follow-up.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by computer pro-
gram”.
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed by computer pro-
gram”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open label randomized controlled trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open label randomized controlled trial”.
Comment: Low for histological assessment as the histologist
was blind to the treatment groups
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants re-
ceived.
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Shields 2009
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 19.
Post-randomisation drop-outs: not stated.
Revised sample size: 19.
Average age: 47 years.
Females: 6 (31.6%).
NASH: 19 (100%).
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Biopsy proven NASH within 18 months of enrolment.
2. BMI > 27.
3. Fasting blood sugar between 110 and 125 mg/dL.
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4. Diagnosis of polycystic ovarian syndrome or the metabolic syndrome.
5. Aged > 17 years.
6. Geographical stability for 1 year from study inclusion.
7. Unremarkable serology for other chronic liver diseases.
Exclusion criteria
1. Known diabetes mellitus type 1 or 2.
2. Fasting blood sugar > 125 mg/dL.
3. Prior history of alcoholic liver disease.
4. Any other known chronic liver disease.
5. Renal insufficiency defined as a serum creatinine > 1.2 mg/dL.
6. Known allergic reaction to metformin.
7. Prior use of an insulin-sensitisers agents such as metformin or thiazolidinedione.
8. Gastric bypass within 2 years.
9. Untreated thyroid disease.
10. Coagulopathy.
11.Chronic thrombocytopenia.
12. Significant alcohol use defined as a consumption > 20 g/day or 80 g/week during
the 2 years prior to study enrolment
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 9).
Further details: metformin 500 mg/day increased to 1000 mg/day after 3 months if there
was no improvement of serum transaminases.
Group 2: control (N = 10).
Further details: control: placebo.
Duration of treatment: 12 months. Both groups received dietary and exercise advice
Outcomes Outcomes reported: 1. Fibrosis score. 2. NAFLD activity score
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects whomet eligibility requirements were ran-
domized to group A or B by the pharmacy using a computer-
generated program”
Allocation concealment (selection bias) Low risk Quote: “Subjects whomet eligibility requirements were ran-
domized to group A or B by the pharmacy using a computer-
generated program”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All biopsies were evaluated separately in a blinded
fashion by two study pathologists who scored the histology
using the scoring system proposed by Brunt et al”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The analysis was carried out on an intention-to-
treat basis”
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Shiffman 2015
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 38.
Post-randomisation drop-outs: not stated.
Revised sample size: 38.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 1.
Inclusion criteria
1. Patients with provenNAFLD or NASHwith elevated AST at least 1.5 times > normal
limits on 2 occasions.
2. Stable dose of statins, fibrates, sulphonylureas, metformin
Interventions Participants were randomly assigned to two groups.
Group 1: emricasan (N = not stated).
Further details: emricasan 25 mg twice daily.
Group 2: control (N = not stated).
Further details: control: placebo.
Duration of treatment: 1 month.
Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned to receive”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “Conatus Pharmaceuticals”.
Other bias Low risk Comment: no other risk of bias.
Siddique 2015
Methods Randomised clinical trial
Participants Country: India.
Number randomised: 67.
Post-randomisation drop-outs: not stated.
Revised sample size: 67.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Patients with NAFLD.
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = 34).
Further details: pioglitazone (dose not stated).
Group 2: rosuvastatin (N = 33).
Further details: rosuvastatin (dose not stated).
Durationof treatment: 6months. All people also underwent dietary lifestylemodification
Outcomes None of the outcomes of interest were reported in this trial
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Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “a randomized trial with nested control study”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Sofer 2011
Methods Randomised clinical trial
Participants Country: Israel.
Number randomised: 63.
Post-randomisation drop-outs: not stated.
Revised sample size: 63.
Average age: 54 years.
Females: 32 (50.8%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 4.
Inclusion criteria
1. Ultrasound proven NAFLD.
2. Exclusion of viral, auto-immune or drug induced liver diseases.
3. Exclusion of alcohol intake > 20 g/day.
Exclusion criteria
1. History of unstable angina.
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2. Myocardial infarction.
3. Cerebrovascular accident.
4. Major surgery within the 6 months preceding the entrance to the study.
5. Creatinine > 1.5 mg/dL.
6. Electrolyte abnormalities.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 32).
Further details: metformin 850 mg to 1700 mg/day.
Group 2: control (N = 31).
Further details: control: placebo.
Duration of treatment: 4 months.
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned to 1 of 2 groups”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “This was a randomized, placebo-controlled, dou-
ble-blinded study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “This was a randomized, placebo-controlled, dou-
ble-blinded study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “An intention-to-treat analysis”.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 80.
Post-randomisation drop-outs: 16 (20%).
Revised sample size: 64.
Average age: 42 years.
Females: 29 (45.3%).
NASH: not stated.
Diabetics: 0 (0%).
Average follow-up period in months: 2.
Inclusion criteria
1. Ultrasound proven NASH.
2. Increase in the ALT and AST levels > 1.2 times the upper limit of normal.
Exclusion criteria
1. Autoimmune hepatitis.
2. Wilson’s disease.
3. Haemochromatosis.
4. Alpha-1 antitrypsin.
5. Chronic hepatitis B and C.
6. Diabetes.
7. Severe cardiac, pulmonary, renal, or psychological problems.
8. Positive pregnancy test.
9. Daily ethanol consumption > 20 g.
10. Substance abuse.
11. Use of drugs, such as statins, fibrates, NSAIDs, acetaminophen, warfarin, metron-
idazol, anticonvulsivants, antidepressants, antipsychotics and antihistamines
Interventions Participants were randomly assigned to two groups.
Group 1: silymarin (N = 33).
Further details: silymarin 210 mg/day.
Group 2: control (N = 31).
Further details: control: placebo.
Duration of treatment: 2 months. Both groups received dietary and exercise advice
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: lost to follow-up.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomly divided into case and
control group with random block design method”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebowas used, there is nomention
about blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebowas used, there is nomention
about blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Quote: “The project has been performed under financial
support of research department of Arak’s university of med-
ical sciences, Arak, Iran”.
Comment: the pharmaceutical company manufactured the
placebo - it was not clear whether it was supplied free for
the study
Other bias Low risk Comment: no other risk of bias.
Song 2014
Methods Randomised clinical trial
Participants Country: China.
Number randomised: 70.
Post-randomisation drop-outs: 3 (4,3%).
Revised sample size: 67.
Average age: 57 years.
Females: 28 (41.8%).
NASH: not stated.
Diabetics: 67 (100%).
Average follow-up period in months: 4.
Inclusion criteria
1. Aged 18 to 77 years.
2. NAFLD.
3. Newly diagnosed type 2 diabetes.
Exclusion criteria
1. Auto-immune hepatitis.
2. Genetic disorders, such as hepatolenticular degeneration, haemochromatosis.
3. Alcohol consumption > 40 g/week.
4. Infectious diseases.
5. Severe liver and kidney dysfunction.
6. Anaemia.
7. Severe thyroid dysfunction.
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8. Acute complications of diabetes.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin plus sitagliptin (N = 34).
Further details: metformin 500 mg thrice daily plus sitagliptin 100 mg once daily.
Group 2: metformin plus glipizide (N = 33).
Further details: metformin 500 mg thrice daily plus glipizide 2.5 mg to 5 mg once daily.
Duration of treatment: 4 months. Both groups received dietary and exercise advice
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: Did not complete the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random numbers method”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Stefan 2014
Methods Randomised clinical trial
Participants Country: Multicentre, international.
Number randomised: 82.
Post-randomisation drop-outs: 2 (2.4%).
Revised sample size: 80.
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Average age: 53 years.
Females: 23 (28.8%).
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 3.
Inclusion criteria
1. Hepatic steatosis by magnetic resonance spectroscopy.
2. BMI < 27.
3. Aged 35 to 65 years.
4. Insulin resistance.
5. Negative alcohol test and drug screening.
6. Agreement to maintain previous diet and exercise habits.
Exclusion criteria
1. History of diabetes.
2. Other liver disease, including chronic viral hepatitis (B or C), alcohol abuse,
haemochromatosis, a1-antitrypsin deficiency, auto-immune hepatitis, Wilson’s disease,
primary sclerosing cholangitis or primary biliary cirrhosis, or liver cirrhosis of any cause.
3. Known auto-immune disease or chronic inflammatory disorder.
4. Myocardial infarction or stroke within 6 months before screening.
5. Use of drugs potentially associated with NAFLD for more than 2 consecutive weeks
in the 2 years before screening.
6. Use of anti-NASH drugs (thiazolidinediones, vitamin E, metformin, ursodeoxycholic
acid, S-adenosylmethionine, betaine, milk thistle, gemfibrozil, anti-TNF therapies, pro-
biotics) in the 3 months before randomisation.
7. AST or ALT > 2.5 times the upper limit of normal.
Interventions Participants were randomly assigned to two groups.
Group 1: R05093151 (N = 40).
Further details: R05093151 (glucocorticosteroid blocker) 200 mg twice daily.
Group 2: control (N = 40).
Further details: control: placebo.
Duration of treatment: 3 months.
Outcomes Outcomes reported: 1. Adverse events. 2. Cirrhosis. 3. Decompensated liver disease. 4.
Liver transplantation
Notes Authors provided additional information in March 2016
Reasons for post-randomisation drop-outs: withdrew or non-compliant
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was done via the interactive voice-
response system”
Allocation concealment (selection bias) Low risk Quote: “randomisation was done via the interactive voice-
response system”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Randomised, double-blind, placebo-controlled
trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Randomised, double-blind, placebo-controlled
trial”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias High risk Quote: “Funding F Hoffman-La Roche”.
Other bias Low risk Comment: no other risk of bias.
Stilidi 2014
Methods Randomised clinical trial
Participants Country: Ukraine.
Number randomised: 58.
Post-randomisation drop-outs: not stated.
Revised sample size: 58.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. NASH.
Interventions Participants were randomly assigned to two groups.
Group 1: losartan and UDCA (N = 30).
Further details: losartan 50 mg/day and UDCA 30 mg/kg/day.
Group 2: UDCA (N = 28).
Further details: UDCA 30 mg/kg/day.
Duration of treatment: 6 months.
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “58 NASH patients were randomly assigned ”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Sunny 2015
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 50.
Post-randomisation drop-outs: not stated.
Revised sample size: 50.
Average age: 54 years.
Females: not stated.
NASH: 50 (100%).
Diabetics: not stated.
Average follow-up period in months: 18.
Inclusion criteria
1. Patients with biopsy proven NASH and prediabetes or type 2 diabetes
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = 27).
Further details: pioglitazone (dose not stated).
Group 2: control (N = 23).
Further details: control: placebo.
Duration of treatment: 18 months
Outcomes None of the outcomes of interest were reported in this trial
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Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were then randomized to pioglitazone (n=
27) or placebo (n=23)”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “American Diabetes Association (1-08-CR-08 to K.
C.); Burroughs Wellcome Fund”
Other bias Low risk Comment: no other risk of bias.
Taghvaei 2013
Methods Randomised clinical trial
Participants Country: Iran.
Number randomised: 41.
Post-randomisation drop-outs: not stated.
Revised sample size: 41.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 6.
Inclusion criteria
1. Patients with NAFLD.
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Interventions Participants were randomly assigned to two groups.
Group 1: silymarin (N = 21).
Further details: silymarin 140 mg twice daily.
Group 2: control (N = 20).
Further details: control: no intervention.
Duration of treatment: 6 months.
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomly divided into case and
control groups”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Torres 2011
Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 135.
Post-randomisation drop-outs: 46 (34.1%).
Revised sample size: 89.
Average age: not stated.
Females: not stated.
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NASH: 89 (100%).
Diabetics: 18 (20.2%).
Average follow-up period in months: 11.
Inclusion criteria
1. Aged 18 to 70 years.
2. Biopsy proven NASH within 6 months before enrolment.
Exclusion criteria
1. NYHA class III or IV for heart failure.
2. Insulin-requiring diabetes.
3. History of thiazolidinediones, metformin, angiotensin receptor blockers use in the 3
months before enrolment.
4. Alcohol consumption > 20 g/day in females and 30/day in males.
5. Serum creatinine on initial screening > 1.4 mg/dL.
6. Known hypersensitivity to a study drug.
7. Known history of diabetic ketoacidosis.
8. Pregnancy or lactation.
9. Evidence of co-existent chronic liver disease to include viral hepatitis, Wilson’s dis-
ease, auto-immune hepatitis, haemochromatosis, primary biliary cirrhosis, or primary
sclerosing cholangitis
Interventions Participants were randomly assigned to three groups.
Group 1: rosiglitazone plus losartan (N = 35).
Further details: rosiglitazone 4 mg twice daily plus losartan 50 mg once daily.
Group 2: rosiglitazone plus metformin (N = 28).
Further details: rosiglitazone 4 mg twice daily plus metformin 500 mg twice daily.
Group 3: rosiglitazone 4 mg BD (N = 26).
Further details: rosiglitazone 4 mg twice daily.
Duration of treatment: 11 months.
Outcomes Outcomes reported: 1. Change in fibrosis. 2. Change in NAFLD activity score. 3. Res-
olution of NASH
Notes Reasons for post-randomisation drop-outs: stopped treatment before end of treatment
period (including loss to follow-up, withdrawal by physician), did not have paired biopsy
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients were randomly assigned using a
computer-generated, random-sequence grid maintained by
the principal investigator to one of three treatment arms”
Allocation concealment (selection bias) Low risk Quote: “Eligible patients were randomly assigned using a
computer-generated, random-sequence grid maintained by
the principal investigator to one of three treatment arms”
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Randomized, Prospective, Open Label Trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Randomized, Prospective, Open Label Trial”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias High risk Quote: “Dr. Harrison advises Amylin. He received grants
from Mochida and Rottapharm. Dr. Williams is on the
speakers’ bureau of Vertex and Kadman”
Other bias Low risk Comment: no other risk of bias.
Uygun 2004
Methods Randomised clinical trial
Participants Country: Turkey.
Number randomised: 36.
Post-randomisation drop-outs: 2 (5.6%).
Revised sample size: 34.
Average age: 41 years.
Females: 13 (38.2%).
NASH: 34 (100%).
Diabetics: 0 (0%).
Average follow-up period in months: 6.
Inclusion criteria
1. Biopsy proven NASH.
Exclusion criteria
1. Suspected acute or chronic viral hepatitis, auto-immune hepatitis or any other liver
disease.
2. Relative or absolute contra-indication for metformin.
3. Possible liver disease other than NASH.
4. History of malignant liver disease.
5. Impaired renal function (serum creatinine > 1.5 mg/dL).
6. Heart failure.
7. History of lactic acidosis.
8. Severe infection.
9. Hypoxic status.
10. Serious acute and chronic illnesses.
11. Haemodynamic instability.
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12. Aged > 70 years.
13. Diabetes mellitus.
14. Current use of any drugs that may affect the results.
15. GGT levels > 75 IU/l.
Interventions Participants were randomly assigned to two groups.
Group 1: metformin (N = 17).
Further details: metformin 850 mg twice daily.
Group 2: control (N = 17).
Further details: control: no intervention.
Duration of treatment: 6 months. Both groups received hypocaloric and low lipid diet
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: lost to follow-up; development of autoim-
mune disease
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After the selection procedure, patients were ran-
domly assigned into two study groups using random sam-
pling numbers”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The small number of patients, the unblind nature
of the study and the lack of a placebo group were major
drawbacks of this investigation”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The small number of patients, the unblind nature
of the study and the lack of a placebo group were major
drawbacks of this investigation”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: protocol was not available; neither mortality nor
adverse events were reported
Other bias Low risk Comment: no other risk of bias.
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Methods Randomised clinical trial
Participants Country: USA.
Number randomised: 30.
Post-randomisation drop-outs: 4 (13.3%).
Revised sample size: 26.
Average age: not stated.
Females: not stated.
NASH: 26 (100%).
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. Aged 18 to 65 years.
2. Biopsy proven NASH within 6 months from enrolment.
Exclusion criteria
1. HIV positivity.
2. Ongoing alcohol consumption > 20 g (males) and 10 g (females) daily.
3. Current or past use (in the previous 6 months) of drugs known to cause steatohepatitis
(tamoxifen, valproic acid, amiodarone, methotrexate).
4. Current or past history of decompensated liver disease.
5. Renal failure.
6. Evidence of active bleeding.
7. Cerebral or retinal haemorrhage.
8. Concomitant use of thiazolidinediones, weight loss medications, metformin, vitamin
E, anti TNF alpha therapy or theophylline.
9. Insulin secretagogues.
Interventions Participants were randomly assigned to two groups.
Group 1: pentoxifylline (N = 19).
Further details: pentoxifylline 400 mg thrice daily.
Group 2: control (N = 7).
Further details: control: placebo.
Duration of treatment: 12 months. Both groups received dietary and exercise advice
Outcomes Outcomes reported: 1. Adverse events. 2. Change in fibrosis score. 3. Change in NAS
score
Notes Reasons for post-randomisation drop-outs: lost to follow-up, brain tumour, uncovered
alcohol abuse
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A randomization table was generated to distribute
groups in a 2:1 ratio”
Allocation concealment (selection bias) Low risk Quote: “On the morning of the initial visit, subjects were
randomized by the Northwestern pharmacy and supplied
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with corresponding pills PTX or placebo”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Investigators and subjects were blinded to the treat-
ment group”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Investigators and subjects were blinded to the treat-
ment group”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs, which
may be related to the treatment that the participants received
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
For-profit bias Unclear risk Quote: “This research was supported by investigator initi-
ated funds”.
Comment: Further information on the source of funding
was not available
Other bias Low risk Comment: no other risk of bias.
Wang 2015
Methods Randomised clinical trial
Participants Country: China.
Number randomised: 68.
Post-randomisation drop-outs: not stated.
Revised sample size: 68.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: 68 (100%).
Average follow-up period in months: 6.
Inclusion criteria
1. Patients with NAFLD and type 2 diabetes.
Interventions Participants were randomly assigned to four groups.
Group 1: sitagliptin (N = 17).
Further details: sitagliptin 100 mg/day.
Group 2: metformin (N = 17).
Further details: metformin 500 mg thrice daily.
Group 3: metformin and sitagliptin (N = 20).
Further details: metformin 500 mg thrice daily and sitagliptin 100 mg/day.
Group 4: control (N = 14).
Further details: control: no intervention.
Duration of treatment: 6 months.
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Outcomes None of the outcomes of interest were reported in this trial
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomly divided into 4 groups”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Yaginuma 2009
Methods Randomised clinical trial
Participants Country: Japan.
Number randomised: 20.
Post-randomisation drop-outs: not stated.
Revised sample size: 20.
Average age: not stated.
Females: not stated.
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 12.
Inclusion criteria
1. NAFLD.
2. Insulin resistance.
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Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = not stated).
Further details: pioglitazone 7.5 mg once daily.
Group 2: control (N = not stated).
Further details: control: no intervention.
Duration of treatment: 12 months.
Outcomes None of the outcomes of interest were reported.
Notes Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “ randomly assigned for treatmentwith/without low-
dose pioglitazone”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: protocol was not available; neither mortality nor
adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Yan 2015
Methods Randomised clinical trial
Participants Country: China.
Number randomised: 122.
Post-randomisation drop-outs: not stated.
Revised sample size: 122.
Average age: 52 years.
Females: 62 (50.8%).
145Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yan 2015 (Continued)
NASH: not stated.
Diabetics: not stated.
Average follow-up period in months: 4.
Inclusion criteria
1. Patients with NAFLD and impaired glucose tolerance or diabetes.
Exclusion criteria
1. Alcohol consumption ≥ 10 g/day for women and 20 g/day for men.
2. Hepatitis B or C, or other liver diseases.
3. Treatment with the following drugs within 4 weeks before enrolment: hypoglycaemic
or lipid-regulating (statins, fibrates) drugs, silybin, ursodeoxycholic acid, bicyclol, phos-
phatidylcholine and vitamin E and Chinese herbs.
4. Patients with severe metabolic abnormalities and organ dysfunction
Interventions Participants were randomly assigned to two groups.
Group 1: pioglitazone (N = 60).
Further details: pioglitazone 15 mg once daily.
Group 2: control (N = 62).
Further details: control: no intervention.
Duration of treatment: 4 months. All people also underwent lifestyle modification (diet
and regular exercise)
Outcomes Outcomes reported: 1. Adverse events.
Notes Another group which received a Chinese herb and Pioglitazone was excluded.
Reasons for post-randomisation drop-outs: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated random allocation sequence”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label clinical trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label clinical trial”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: It was not clear whether all participants were
included in the analysis of adverse events
Selective reporting (reporting bias) High risk Comment: protocol was not available; mortality was not
reported
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For-profit bias Low risk Quote: “Funding was by several Government agencies in
China”
Other bias Low risk Comment: no other risk of bias.
AST = aspartate transaminase
ALT = alanine transaminase
BMI = Body Mass Index
GGT = gamma glutamyl transferase
HBV = hepatitis B virus
HCV = hepatitis C virus
LDL = low density lipoprotein
MRI = magnetic resonance imaging
NAFLD = non-alcohol related fatty liver disease
NASH = non-alcohol related steatohepatitis
NYHA = New York Heart Association
TNF = Tumour Necrosis Factor
UDCA = ursodeoxycholic acid
US = ultrasound
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abenavoli 2013 Not a pharmacological intervention.
Abenavoli 2015 Not a randomised clinical trial.
Acquati 2007 Comparison of different regimens of same drug class.
Athyros 2011 Comparison of different regimens of same drug class.
Carnelutti 2012 Comparison of pharmacological intervention versus non pharmacological intervention
Corey 2015a study excluded because on children.
Dajani 2015 Not a pharmacological intervention.
Faghihzadeh 2014 Not a pharmacological intervention
Fan 2010 Not a randomised clinical trial.
Fan 2013 Not a randomised clinical trial.
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Gastaldelli 2015 Study on patients without NAFLD.
Han 2012 Comparison of same class of drugs.
Han 2014a Not a pharmacological intervention
Idilman 2008 Not a randomised clinical trial.
Jaafari 2012 Not a randomised clinical trial.
Kowdley 2015 Not a primary study.
Kowdley 2015a Not a primary study.
Li 2015 Not a pharmacological intervention.
Lo 2016 Study on patients without NAFLD.
McCormick 2015 Not a pharmacological intervention.
Merat 2015 Study on patients without NAFLD.
Oh 2016 Study on patients fatigued patients with and without NAFLD. Separate data on people with NAFLD was not
reported
Scorletti 2014 Not a pharmacological intervention.
Scorletti 2015 Not a pharmacological intervention.
Shiasi 2014 Study on children.
Sultana 2012 Not a randomised clinical trial.
Talebi 2015 Not a pharmacological intervention.
Tan 2011 Not a pharmacological intervention.
Taniai 2009 Not a randomised clinical trial.
Tsuchiya 2011 Comparison of two ’other’ anti-diabetes drugs.
Vos 2016 Wrong population. Study on children.
Wang 2013 Not a pharmacological intervention.
Zelber-Sagi 2006 Not a randomised clinical trial (quasi-randomised study).
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D A T A A N D A N A L Y S E S
Comparison 1. All studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 11 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Antioxidants versus no
intervention
1 87 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Bile acids versus no
intervention
4 659 Odds Ratio (M-H, Fixed, 95% CI) 5.11 [0.24, 107.34]
1.4 Other anti-diabetes drug
versus no intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Thiazolidinediones versus
no intervention
1 74 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Antioxidants versus renin-
angiotensin-aldosterone system
inhibitor plus antioxidants
1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Thiazolidinediones
versus sulphonylureas
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events
(proportion)
19 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Anti-fibrotic versus no
intervention
1 274 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [0.66, 2.94]
2.3 Antioxidants versus no
intervention
1 87 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Bile acids versus no
intervention
3 404 Odds Ratio (M-H, Fixed, 95% CI) 1.56 [0.84, 2.88]
2.5 Other cholesterol-
lowering agents versus no
intervention
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Other anti-diabetes drug
versus no intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.69]
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2.7 Phosphodiesterase type 4
inhibitor versus no intervention
1 96 Odds Ratio (M-H, Fixed, 95% CI) 0.1 [0.01, 0.94]
2.8 Glucocorticosteroid
inhibitor versus no intervention
1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.16 [0.31, 31.78]
2.9 Silymarin versus no
intervention
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.10 Silymarin plus
antioxidants versus no
intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.11 Statins versus no
intervention
1 16 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.12 Pentoxifylline versus no
intervention
1 26 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.13 Thiazolidinediones
versus no intervention
2 194 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.14 Antioxidants versus
renin-angiotensin-aldosterone
system inhibitor plus
antioxidants
1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.15 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.16 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.17 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.18 Thiazolidinediones
versus sulphonylureas
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events (number
of events)
18 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Antioxidants versus no
intervention
2 254 Rate Ratio (Fixed, 95% CI) 0.89 [0.36, 2.19]
3.3 Bile acids versus no
intervention
3 404 Rate Ratio (Fixed, 95% CI) 1.01 [0.66, 1.54]
3.4 Other cholesterol-
lowering agents versus no
intervention
1 27 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Other anti-diabetes drug
versus no intervention
1 52 Rate Ratio (Fixed, 95% CI) 0.67 [0.11, 3.99]
3.6 Phosphodiesterase type 4
inhibitor versus no intervention
1 96 Rate Ratio (Fixed, 95% CI) 0.15 [0.02, 1.46]
3.7 Silymarin versus no
intervention
1 100 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Silymarin plus
antioxidants versus no
intervention
1 36 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
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3.9 Statins versus no
intervention
1 16 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Glucocorticosteroid
inhibitor versus no intervention
1 80 Rate Ratio (Fixed, 95% CI) 5.00 [0.58, 42.80]
3.11 Thiazolidinediones
versus no intervention
3 358 Rate Ratio (Fixed, 95% CI) 0.21 [0.05, 0.95]
3.12 Antioxidants versus
renin-angiotensin-aldosterone
system inhibitor plus
antioxidants
1 31 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.13 Thiazolidinediones
versus antioxidants
1 164 Rate Ratio (Fixed, 95% CI) 0.23 [0.05, 1.08]
3.14 Statins versus other
cholesterol-lowering agents
1 125 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.15 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.16 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.17 Thiazolidinediones
versus sulphonylureas
1 80 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events (proportion) 17 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Antioxidants versus no
intervention
2 242 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Bile acids versus no
intervention
2 230 Odds Ratio (M-H, Fixed, 95% CI) 1.72 [0.72, 4.10]
4.3 Other cholesterol-
lowering agents versus no
intervention
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Other anti-diabetes drug
versus no intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.10, 4.18]
4.5 Phosphodiesterase type 4
inhibitor versus no intervention
1 96 Odds Ratio (M-H, Fixed, 95% CI) 3.0 [1.15, 7.85]
4.6 Silymarin plus
antioxidants versus no
intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Statins versus no
intervention
1 16 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Glucocorticosteroid
inhibitor versus no intervention
1 80 Odds Ratio (M-H, Fixed, 95% CI) 1.68 [0.68, 4.13]
4.9 Thiazolidinediones versus
no intervention
2 194 Odds Ratio (M-H, Fixed, 95% CI) 3.07 [0.96, 9.87]
4.10 Bile acids versus
antioxidants
2 289 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.50, 1.81]
4.11 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Fixed, 95% CI) 5.08 [0.24, 108.01]
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4.12 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Fixed, 95% CI) 3.10 [0.12, 77.57]
4.13 Thiazolidinediones
versus pentoxifylline
1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.5 [0.04, 5.83]
4.14 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.04, 5.76]
4.15 Thiazolidinediones
versus sulphonylureas
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events (number of
events)
22 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Antioxidants versus no
intervention
3 409 Rate Ratio (Fixed, 95% CI) 1.03 [0.70, 1.52]
5.2 Bile acids versus no
intervention
5 825 Rate Ratio (Fixed, 95% CI) 1.19 [1.06, 1.33]
5.3 Other cholesterol-
lowering agents versus no
intervention
2 77 Rate Ratio (Fixed, 95% CI) 2.50 [0.49, 12.89]
5.4 Other anti-diabetes drug
versus no intervention
1 52 Rate Ratio (Fixed, 95% CI) 0.94 [0.78, 1.14]
5.5 Pentoxifylline versus no
intervention
1 26 Rate Ratio (Fixed, 95% CI) 1.11 [0.44, 2.78]
5.6 Silymarin plus
antioxidants versus no
intervention
1 36 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.7 Statins versus no
intervention
1 16 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.8 Glucocorticosteroid
inhibitor versus no intervention
1 80 Rate Ratio (Fixed, 95% CI) 1.56 [1.05, 2.31]
5.9 Thiazolidinediones versus
no intervention
4 481 Rate Ratio (Fixed, 95% CI) 1.14 [0.82, 1.58]
5.10 Bile acids versus
antioxidants
1 58 Rate Ratio (Fixed, 95% CI) 6.53 [0.34, 126.48]
5.11 Thiazolidinediones
versus antioxidants
1 164 Rate Ratio (Fixed, 95% CI) 0.87 [0.58, 1.30]
5.12 Statins versus other
cholesterol-lowering agents
1 127 Rate Ratio (Fixed, 95% CI) 4.92 [0.24, 102.52]
5.13 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 125 Rate Ratio (Fixed, 95% CI) 3.05 [0.12, 74.83]
5.14 Thiazolidinediones
versus pentoxifylline
1 59 Rate Ratio (Fixed, 95% CI) 0.52 [0.05, 5.70]
5.15 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Rate Ratio (Fixed, 95% CI) 0.52 [0.05, 5.69]
5.16 Thiazolidinediones
versus sulphonylureas
1 80 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Cirrhosis 11 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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6.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Antioxidants versus no
intervention
1 87 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Other anti-diabetes drug
versus no intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Silymarin versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.15]
6.5 Glucocorticosteroid
inhibitor versus no intervention
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.6 Sulphonylureas versus no
intervention
1 44 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.7 Thiazolidinediones versus
no intervention
2 121 Odds Ratio (M-H, Fixed, 95% CI) 5.99 [0.71, 50.28]
6.8 Antioxidants versus renin-
angiotensin-aldosterone system
inhibitor plus antioxidants
1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.9 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.10 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.11 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.12 Thiazolidinediones
versus sulphonylureas
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Resolution of fatty liver disease 16 Odds Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Antioxidants versus no
intervention
3 299 Odds Ratio (M-H, Random, 95% CI) 2.23 [1.28, 3.87]
7.3 Bile acids versus no
intervention
1 219 Odds Ratio (M-H, Random, 95% CI) 1.85 [0.88, 3.89]
7.4 Other cholesterol-
lowering agents versus no
intervention
1 35 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.25, 4.70]
7.5 Other anti-diabetes drug
versus no intervention
1 45 Odds Ratio (M-H, Random, 95% CI) 6.43 [1.20, 34.41]
7.6 Silymarin versus no
intervention
1 64 Odds Ratio (M-H, Random, 95% CI) 11.72 [0.60, 227.31]
7.7 Sulphonylureas versus no
intervention
3 123 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.23, 4.41]
7.8 Thiazolidinediones versus
no intervention
3 272 Odds Ratio (M-H, Random, 95% CI) 1.68 [0.44, 6.44]
7.9 Bile acids versus
antioxidants
1 56 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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7.10 Thiazolidinediones
versus antioxidants
1 164 Odds Ratio (M-H, Random, 95% CI) 1.63 [0.87, 3.05]
7.11 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Random, 95% CI) 2.77 [1.34, 5.73]
7.12 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Random, 95% CI) 3.31 [1.57, 6.98]
7.13 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.56, 2.55]
7.14 Thiazolidinediones plus
renin-angiotensin-aldosterone
system inhibitor versus
thiazolidinediones
1 61 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.16, 1.35]
7.15 Thiazolidinediones
plus sulphonylureas versus
thiazolidinediones
1 54 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.22, 1.93]
7.16 Thiazolidinediones
plus sulphonylureas versus
thiazolidinediones plus renin-
angiotensin-aldosterone system
inhibitor
1 63 Odds Ratio (M-H, Random, 95% CI) 1.39 [0.48, 4.03]
Comparison 2. Non-alcohol related steatohepatitis only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events
(proportion)
10 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Anti-fibrotic versus no
intervention
1 274 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [0.66, 2.94]
1.3 Bile acids versus no
intervention
1 283 Odds Ratio (M-H, Fixed, 95% CI) 1.56 [0.84, 2.88]
1.4 Other cholesterol-
lowering agents versus no
intervention
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Other anti-diabetes drug
versus no intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.69]
1.6 Phosphodiesterase type 4
inhibitor versus no intervention
1 96 Odds Ratio (M-H, Fixed, 95% CI) 0.1 [0.01, 0.94]
1.7 Pentoxifylline versus no
intervention
1 26 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Silymarin versus no
intervention
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.9 Statins versus no
intervention
1 16 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Thiazolidinediones
versus no intervention
1 74 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events (number
of events)
9 Rate Ratio (Fixed, 95% CI) Subtotals only
2.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Antioxidants versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.89 [0.36, 2.19]
2.3 Bile acids versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.01 [0.66, 1.54]
2.4 Other cholesterol-
lowering agents versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Other anti-diabetes drug
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 0.67 [0.11, 3.99]
2.6 Phosphodiesterase type 4
inhibitor versus no intervention
1 Rate Ratio (Fixed, 95% CI) 0.15 [0.02, 1.46]
2.7 Silymarin versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.0 [0.02, 50.40]
2.8 Statins versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Thiazolidinediones versus
no intervention
2 Rate Ratio (Fixed, 95% CI) 0.21 [0.05, 0.95]
2.10 Thiazolidinediones
versus antioxidants
1 Rate Ratio (Fixed, 95% CI) 0.23 [0.05, 1.08]
3 Adverse events (proportion) 8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bile acids versus no
intervention
1 166 Odds Ratio (M-H, Fixed, 95% CI) 7.0 [0.84, 58.22]
3.2 Other cholesterol-
lowering agents versus no
intervention
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Other anti-diabetes drug
versus no intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.10, 4.18]
3.4 Phosphodiesterase type 4
inhibitor versus no intervention
1 96 Odds Ratio (M-H, Fixed, 95% CI) 3.0 [1.15, 7.85]
3.5 Statins versus no
intervention
1 16 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Thiazolidinediones versus
no intervention
1 74 Odds Ratio (M-H, Fixed, 95% CI) 3.07 [0.96, 9.87]
3.7 Bile acids versus
antioxidants
1 56 Odds Ratio (M-H, Fixed, 95% CI) 7.26 [0.36, 147.49]
3.8 Thiazolidinediones versus
pentoxifylline
1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.5 [0.04, 5.83]
4 Adverse events (number of
events)
12 Rate Ratio (Fixed, 95% CI) Subtotals only
4.1 Antioxidants versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.03 [0.70, 1.52]
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4.2 Bile acids versus no
intervention
4 Rate Ratio (Fixed, 95% CI) 1.20 [1.07, 1.35]
4.3 Other cholesterol-
lowering agents versus no
intervention
2 Rate Ratio (Fixed, 95% CI) 2.50 [0.49, 12.89]
4.4 Other anti-diabetes drug
versus no intervention
1 Rate Ratio (Fixed, 95% CI) 0.94 [0.78, 1.14]
4.5 Pentoxifylline versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.11 [0.44, 2.78]
4.6 Statins versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Thiazolidinediones versus
no intervention
2 Rate Ratio (Fixed, 95% CI) 1.08 [0.77, 1.51]
4.8 Thiazolidinediones versus
antioxidants
1 Rate Ratio (Fixed, 95% CI) 0.87 [0.58, 1.30]
4.9 Thiazolidinediones versus
pentoxifylline
1 Rate Ratio (Fixed, 95% CI) 0.52 [0.05, 5.70]
5 Cirrhosis 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Other anti-diabetes drug
versus no intervention
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Silymarin versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.15]
5.4 Thiazolidinediones versus
no intervention
2 121 Odds Ratio (M-H, Fixed, 95% CI) 5.99 [0.71, 50.28]
6 Resolution of fatty liver disease 10 Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Renin-angiotensin-
aldosterone system inhibitor
versus no intervention
1 30 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Antioxidants versus no
intervention
2 212 Odds Ratio (M-H, Random, 95% CI) 2.14 [1.10, 4.19]
6.3 Bile acids versus no
intervention
1 219 Odds Ratio (M-H, Random, 95% CI) 1.85 [0.88, 3.89]
6.4 Other cholesterol-
lowering agents versus no
intervention
1 35 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.25, 4.70]
6.5 Other anti-diabetes drug
versus no intervention
1 45 Odds Ratio (M-H, Random, 95% CI) 6.43 [1.20, 34.41]
6.6 Silymarin versus no
intervention
1 64 Odds Ratio (M-H, Random, 95% CI) 11.72 [0.60, 227.31]
6.7 Thiazolidinediones versus
no intervention
3 272 Odds Ratio (M-H, Random, 95% CI) 1.68 [0.44, 6.44]
6.8 Thiazolidinediones versus
antioxidants
1 164 Odds Ratio (M-H, Random, 95% CI) 1.63 [0.87, 3.05]
6.9 Thiazolidinediones plus
renin-angiotensin-aldosterone
system inhibitor versus
thiazolidinediones
1 61 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.16, 1.35]
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6.10 Thiazolidinediones
plus sulphonylureas versus
thiazolidinediones
1 54 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.22, 1.93]
6.11 Thiazolidinediones
plus sulphonylureas versus
thiazolidinediones plus renin-
angiotensin-aldosterone system
inhibitor
1 63 Odds Ratio (M-H, Random, 95% CI) 1.39 [0.48, 4.03]
Comparison 3. People with diabetes mellitus only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events
(proportion)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Bile acids versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events (number
of events)
1 Rate Ratio (Fixed, 95% CI) Subtotals only
2.1 Bile acids versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events (proportion) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bile acids versus no
intervention
1 64 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.35, 2.86]
4 Adverse events (number of
events)
1 Rate Ratio (Fixed, 95% CI) Subtotals only
4.1 Bile acids versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 1.01 [0.64, 1.58]
Comparison 4. People without diabetes mellitus only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events
(proportion)
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Silymarin plus
antioxidants versus no
intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Thiazolidinediones versus
no intervention
1 74 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.4 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events (number
of events)
4 Rate Ratio (Fixed, 95% CI) Subtotals only
2.1 Antioxidants versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.89 [0.36, 2.19]
2.2 Silymarin plus
antioxidants versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Thiazolidinediones versus
no intervention
2 Rate Ratio (Fixed, 95% CI) 0.21 [0.05, 0.95]
2.4 Thiazolidinediones versus
antioxidants
1 Rate Ratio (Fixed, 95% CI) 0.23 [0.05, 1.08]
2.5 Statins versus other
cholesterol-lowering agents
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Statins plus other
cholesterol-lowering agents
versus statins
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events (proportion) 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Antioxidants versus no
intervention
1 155 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Silymarin plus
antioxidants versus no
intervention
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Thiazolidinediones versus
no intervention
1 74 Odds Ratio (M-H, Fixed, 95% CI) 3.07 [0.96, 9.87]
3.4 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Fixed, 95% CI) 5.08 [0.24, 108.01]
3.5 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Fixed, 95% CI) 3.10 [0.12, 77.57]
3.6 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.04, 5.76]
4 Adverse events (number of
events)
6 Rate Ratio (Fixed, 95% CI) Subtotals only
4.1 Antioxidants versus
control
2 Rate Ratio (Fixed, 95% CI) 1.03 [0.70, 1.52]
4.2 Other cholesterol-
lowering agents versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 2.50 [0.49, 12.89]
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4.3 Silymarin plus
antioxidants versus no
intervention
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Thiazolidinediones versus
no intervention
2 Rate Ratio (Fixed, 95% CI) 1.08 [0.77, 1.51]
4.5 Thiazolidinediones versus
antioxidants
1 Rate Ratio (Fixed, 95% CI) 0.87 [0.58, 1.30]
4.6 Statins versus other
cholesterol-lowering agents
1 Rate Ratio (Fixed, 95% CI) 4.92 [0.24, 102.52]
4.7 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 Rate Ratio (Fixed, 95% CI) 3.05 [0.12, 74.83]
4.8 Statins plus other
cholesterol-lowering agents
versus statins
1 Rate Ratio (Fixed, 95% CI) 0.52 [0.05, 5.69]
5 Cirrhosis 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Sulphonylureas versus no
intervention
1 44 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Thiazolidinediones versus
no intervention
2 121 Odds Ratio (M-H, Fixed, 95% CI) 5.99 [0.71, 50.28]
5.3 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Resolution of fatty liver disease 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Antioxidants versus no
intervention
1 167 Odds Ratio (M-H, Random, 95% CI) 2.16 [1.08, 4.32]
6.2 Thiazolidinediones versus
no intervention
3 272 Odds Ratio (M-H, Random, 95% CI) 1.68 [0.44, 6.44]
6.3 Thiazolidinediones versus
antioxidants
1 164 Odds Ratio (M-H, Random, 95% CI) 1.63 [0.87, 3.05]
6.4 Statins versus other
cholesterol-lowering agents
1 125 Odds Ratio (M-H, Random, 95% CI) 2.77 [1.34, 5.73]
6.5 Statins plus other
cholesterol-lowering agents
versus other cholesterol-
lowering agents
1 123 Odds Ratio (M-H, Random, 95% CI) 3.31 [1.57, 6.98]
6.6 Statins plus other
cholesterol-lowering agents
versus statins
1 124 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.56, 2.55]
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A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies (by comparison)
Study
name
(to-
tal partici-
pants ran-
domised)
Interven-
tion(s)
Control Total after
post-ran-
domisa-
tion drop-
outs
(number
who
dropped
out)
NASH NASH
only
Diabetes
mellitus
People
with dia-
betes only
Peo-
ple with-
out dia-
betes mel-
litus only
Average
follow-
up period
(months)
Fogari
2012
(150)
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
Antihyper-
tensives
141 (9) Not stated Not stated 0/141 (0.
0%)
No Yes 12
Ersoz 2005
(57)
Bile acids Antioxi-
dants
56 (1) 6/56 (10.
7%)
No 14/56 (25.
0%)
No No 6
Harrison
2009
(50)
Orlis-
tat plus an-
tioxidants
Antioxi-
dants
41 (9) 41/41
(100.0%)
Yes 4/41 (9.
8%)
No No 9
Kedarisetty
2014
(116)
Pentoxi-
fylline plus
antioxi-
dants
Antioxi-
dants
116 (0) 116/116
(100.0%)
Yes Not stated Not stated Not stated 12
Polyzos
2011
(31)
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
plus an-
tioxidants
Antioxi-
dants
31 (not
stated)
16/31 (51.
6%)
No 5/31 (16.
1%)
No No 2
Bugianesi
2005
(57)
Sulphony-
lureas
Antioxi-
dants
57 (not
stated)
Not stated Not stated 0/57 (0.
0%)
No Yes 12
Sanyal
2010
(247)
Thiazo-
lidine-
diones
Antioxi-
dants
247 (0) 247/247
(100.0%)
Yes 0/247 (0.
0%)
No Yes 22
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Table 1. Characteristics of included studies (by comparison) (Continued)
Basu 2013
(80)
Thiazo-
lidine-
diones
Antioxi-
dants
80 (not
stated)
Not stated Not stated 0/80 (0.
0%)
No Yes 12
Sanyal
2004
(20)
Thiazo-
lidine-
diones plus
antioxi-
dants
Antioxi-
dants
20 (0) Not stated Not stated Not stated Not stated Not stated 6
Parikh
2016
(250)
Antioxi-
dants
Bile acids 233 (17) 35/233
(15.0%)
No Not stated Not stated Not stated 12
Copaci
2009
(94)
Interven-
tion
1: Pentoxi-
fylline
Interven-
tion
2: Pentoxi-
fylline plus
bile acids
Bile acids 94 (not
stated)
94/94
(100.0%)
Yes Not stated Not stated Not stated 12
Stilidi
2014
(58)
Renin-an-
giotensin-
aldos-
teronesys-
tem
inhibitor
plus bile
acids
Bile acids 58 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Shiffman
2015
(38)
Anti-
caspase
No inter-
vention
38 (not
stated)
Not stated Not stated Not stated Not stated Not stated 1
Ratziu
2016
(276)
Anti-
fibrotic
No inter-
vention
274 (2) 274/274
(100.0%)
Yes 107/274
(39.1%)
No No 12
Harrison
2003
(49)
Antioxi-
dants
No inter-
vention
45 (4) 45/45
(100.0%)
Yes 19/45 (42.
2%)
No No 6
Kugelmas
2003
(16)
Antioxi-
dants
No inter-
vention
16 (not
stated)
16/16
(100.0%)
Yes Not stated Not stated Not stated 3
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Table 1. Characteristics of included studies (by comparison) (Continued)
Gomez
2009
(60)
Antioxi-
dants
No inter-
vention
60 (0) 60/60
(100.0%)
Yes Not stated Not stated Not stated 6
Magosso
2013
(87)
Antioxi-
dants
No inter-
vention
87 (0) Not stated Not stated Not stated Not stated Not stated 12
Basu 2014
(155)
Antioxi-
dants
No inter-
vention
155 (0) Not stated Not stated 0/155 (0.
0%)
No Yes 6
Santos
2003
(30)
Bile acids No inter-
vention
30 (not
stated)
Not stated Not stated Not stated Not stated Not stated 3
Lindor
2004
(174)
Bile acids No inter-
vention
166 (8) 166/166
(100.0%)
Yes Not stated Not stated Not stated 24
Mendez-
Sanchez
2004
(27)
Bile acids No inter-
vention
23 (4) Not stated Not stated Not stated Not stated Not stated 1
Leuschner
2010
(186)
Bile acids No inter-
vention
186 (0) 186/186
(100.0%)
Yes 21/186
(11.3%)
No No 18
Ratziu
2011
(126)
Bile acids No inter-
vention
126 (0) 126/126
(100.0%)
Yes 40/126
(31.7%)
No No 12
Mudaliar
2013
(64)
Bile acids No inter-
vention
64 (0) Not stated Not stated 64/64
(100.0%)
Yes No 1
Safadi
2014
(60)
Bile acids No inter-
vention
57 (3) 6/57 (10.
5%)
No Not stated Not stated Not stated 4
Neuschwan-
der-
Tetri 2015
(283)
Bile acids No inter-
vention
283 (not
stated)
283/283
(100.0%)
Yes 149/283
(52.7%)
No No 17
Gianturco
2013
(200)
Interven-
tion 1: Bile
acids plus
No inter-
vention
196 (4) Not stated Not stated 0/196 (0.
0%)
No Yes 12
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Table 1. Characteristics of included studies (by comparison) (Continued)
antioxi-
dants
Interven-
tion 2: An-
tioxidants
Interven-
tion 3: Bile
acids
Dufour
2006
(48)
Interven-
tion 1: Bile
acids plus
antioxi-
dants
Interven-
tion 2: Bile
acids
No inter-
vention
40 (8) 40/40
(100.0%)
Yes Not stated Not stated Not stated 24
Stefan
2014
(82)
Glucocor-
ticosteroid
inhibitor
No inter-
vention
80 (2) Not stated Not stated Not stated Not stated Not stated 3
Morita
2005
(10)
Other
anti-dia-
betes med-
ication
No inter-
vention
10 (not
stated)
10/10
(100.0%)
Yes 10/10
(100.0%)
Yes No 5
Armstrong
2016
(52)
Other
anti-dia-
betes med-
ication
No inter-
vention
52 (0) 52/52
(100.0%)
Yes 17/52 (32.
7%)
No No 17
Wang
2015
(68)
Inter-
vention 1:
Other
anti-dia-
betes med-
ication
Inter-
vention 1:
Sulphony-
lureas plus
other anti-
dia-
betes med-
ication
Sulphony-
lureas
No inter-
vention
68 (not
stated)
Not stated Not stated 68/68
(100.0%)
Yes No 6
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Table 1. Characteristics of included studies (by comparison) (Continued)
Merat
2003
(30)
Other
choles-
terol-
lowering
agents
No inter-
vention
27 (3) 27/27
(100.0%)
Yes Not stated Not stated Not stated 6
Loomba
2015
(50)
Other
choles-
terol-
lowering
agents
No inter-
vention
50 (not
stated)
50/50
(100.0%)
Yes 14/50 (28.
0%)
No No 6
Van
Wagner
2011
(30)
Pentoxi-
fylline
No inter-
vention
26 (4) 26/26
(100.0%)
Yes Not stated Not stated Not stated 12
Ratziu
2014
(99)
Phospho-
diesterase
type 4 in-
hibitor
No inter-
vention
96 (3) 96/96
(100.0%)
Yes Not stated Not stated Not stated 3
Alam 2016
(50)
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
No inter-
vention
30 (20) 30/30
(100.0%)
Yes 8/30 (26.
7%)
No No 12
Ha-
jaghamo-
hammadi
2008
(50)
Silymarin No inter-
vention
50 (not
stated)
Not stated Not stated 0/50 (0.
0%)
No Yes 2
Hashemi
2009
(100)
Silymarin No inter-
vention
100 (not
stated)
100/100
(100.0%)
Yes Not stated Not stated Not stated 6
Taghvaei
2013
(41)
Silymarin No inter-
vention
41 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Solhi 2014
(80)
Silymarin No inter-
vention
64 (16) Not stated Not stated 0/64 (0.
0%)
No Yes 2
Chan
2015
(64)
Silymarin No inter-
vention
64 (not
stated)
64/64
(100.0%)
Yes Not stated Not stated Not stated 11
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Table 1. Characteristics of included studies (by comparison) (Continued)
Aller 2015
(36)
Silymarin
plus an-
tioxidants
No inter-
vention
36 (not
stated)
15/36 (41.
7%)
No 0/36 (0.
0%)
No Yes 3
Bonfrate
2015
(40)
Silymarin
plus an-
tioxidants
No inter-
vention
40 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Lewis
2006
(175)
Statins No inter-
vention
175 (not
stated)
Not stated Not stated Not stated Not stated Not stated 9
Nelson
2009
(16)
Statins No inter-
vention
16 (0) 16/16
(100.0%)
Yes 7/16 (43.
8%)
No No 12
Baranova
2015
(20)
Statins No inter-
vention
20 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Foster
2011
(80)
Statins
plus an-
tioxidants
No inter-
vention
80 (not
stated)
Not stated Not stated Not stated Not stated Not stated Not stated
Uygun
2004
(36)
Sulphony-
lureas
No inter-
vention
34 (2) 34/34
(100.0%)
Yes 0/34 (0.
0%)
No Yes 6
Hauke-
land
2009
(48)
Sulphony-
lureas
No inter-
vention
44 (4) Not stated Not stated 12/44 (27.
3%)
No No 6
Nar 2009
(34)
Sulphony-
lureas
No inter-
vention
34 (not
stated)
Not stated Not stated 34/34
(100.0%)
Yes No 6
Shields
2009
(19)
Sulphony-
lureas
No inter-
vention
19 (not
stated)
19/19
(100.0%)
Yes Not stated Not stated Not stated 12
Garinis
2010
(50)
Sulphony-
lureas
No inter-
vention
45 (5) Not stated Not stated Not stated Not stated Not stated 6
Sofer 2011
(63)
Sulphony-
lureas
No inter-
vention
63 (not
stated)
Not stated Not stated Not stated Not stated Not stated 4
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Table 1. Characteristics of included studies (by comparison) (Continued)
Belfort
2006
(55)
Thiazo-
lidine-
diones
No inter-
vention
47 (8) 47/47
(100.0%)
Yes 0/47 (0.
0%)
No Yes 6
Cui 2006
(124)
Thiazo-
lidine-
diones
No inter-
vention
124 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Aithal
2008
(74)
Thiazo-
lidine-
diones
No inter-
vention
74 (0) 74/74
(100.0%)
Yes 0/74 (0.
0%)
No Yes 12
Ratziu
2008
(64)
Thiazo-
lidine-
diones
No inter-
vention
63 (1) 63/63
(100.0%)
Yes 20/63 (31.
7%)
No No 16
Gastaldelli
2009
(48)
Thiazo-
lidine-
diones
No inter-
vention
48 (not
stated)
48/48
(100.0%)
Yes Not stated Not stated Not stated 6
Yaginuma
2009
(20)
Thiazo-
lidine-
diones
No inter-
vention
20 (not
stated)
Not stated Not stated Not stated Not stated Not stated 12
Jin 2010
(120)
Thiazo-
lidine-
diones
No inter-
vention
120 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Cusi 2013
(101)
Thiazo-
lidine-
diones
No inter-
vention
101 (not
stated)
101/101
(100.0%)
Yes 52/101
(51.5%)
No No 18
Kakazu
2013
(25)
Thiazo-
lidine-
diones
No inter-
vention
24 (1) 24/24
(100.0%)
Yes Not stated Not stated Not stated 24
Sunny
2015
(50)
Thiazo-
lidine-
diones
No inter-
vention
50 (not
stated)
50/50
(100.0%)
Yes Not stated Not stated Not stated 18
Yan 2015
(122)
Thiazo-
lidine-
diones
No inter-
vention
122 (not
stated)
Not stated Not stated Not stated Not stated Not stated 4
Athyros
2006
(186)
Inter-
vention 1:
Statins
Inter-
vention 2:
Other
choles-
terol-
lowering
agents
186 (0) Not stated Not stated 0/186 (0.
0%)
No Yes 12
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Table 1. Characteristics of included studies (by comparison) (Continued)
Statins
plus other
choles-
terol-
lowering
agents
Razav-
izadeh
2012
(100)
Antioxi-
dants
Silymarin 100 (not
stated)
Not stated Not stated Not stated Not stated Not stated 2
Haji-
aghamo-
hammadi
2012
(66)
Interven-
tion
1: Thiazo-
lidine-
diones
Interven-
tion
2: Sulpho-
nylureas
Silymarin 66 (not
stated)
Not stated Not stated 0/66 (0.
0%)
No Yes 2
Siddique
2015
(67)
Thiazo-
lidine-
diones
Statins 67 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Klyaryt-
skaya
2015
(51)
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
plus statins
plus an-
tioxidants
Statins
plus an-
tioxidants
51 (not
stated)
Not stated Not stated Not stated Not stated Not stated 12
Askari-
moghadam
2013
(93)
Sulphony-
lureas plus
antioxi-
dants
Sulphony-
lureas
93 (not
stated)
Not stated Not stated Not stated Not stated Not stated 6
Song 2014
(70)
Sulphony-
lureas plus
other anti-
dia-
betes med-
ication
Sulphony-
lureas
67 (3) Not stated Not stated 67/67
(100.0%)
Yes No 4
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Table 1. Characteristics of included studies (by comparison) (Continued)
Sharma
2012
(60)
Pentoxi-
fylline
Thiazo-
lidine-
diones
59 (1) 59/59
(100.0%)
Yes Not stated Not stated Not stated 6
Omer
2010
(64)
Sulphony-
lureas
Thiazo-
lidine-
diones
64 (not
stated)
64/64
(100.0%)
Yes Not stated Not stated Not stated 12
Razavizade
2013
(80)
Sulphony-
lureas
Thiazo-
lidine-
diones
80 (0) Not stated Not stated 6/80 (7.
5%)
No No 4
Torres
2011
(135)
Interven-
tion
1: Thiazo-
lidine-
diones plus
renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
Interven-
tion
2: Thiazo-
lidine-
diones plus
sulphony-
lureas
Thiazo-
lidine-
diones
89 (46) 89/89
(100.0%)
Yes 18/89 (20.
2%)
No No 11
NASH: non-alcoholic steatohepatitis.
Table 2. Risk of bias (by comparison)
Study
name
Interven-
tion(s)
and con-
trols
Random
sequence
genera-
tion
Alloca-
tion con-
cealment
Blinding
of partici-
pants and
personnel
Blinding
of outcom
assess-
ment
Incom-
plete out-
come data
Selective
reporting
For-profit
bias
Other bias
Fogari
2012
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
Control:
Unclear Low Low Low High High Low Low
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Table 2. Risk of bias (by comparison) (Continued)
Antihyper-
tensives
Ersoz 2005 Bile acids
Control:
Antioxi-
dants
Unclear Unclear High High High High Unclear Low
Harrison
2009
Orlis-
tat plus an-
tioxidants
Control:
Antioxi-
dants
Unclear Unclear Unclear Unclear High High Unclear Low
Kedarisetty
2014
Pentoxi-
fylline plus
antioxi-
dants
Control:
Antioxi-
dants
Unclear Unclear High High Low High Unclear Low
Polyzos
2011
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
plus an-
tioxidants
Control:
Antioxi-
dants
Low Unclear Unclear Unclear Unclear Low Low Low
Bugianesi
2005
Sulphony-
lureas
Control:
Antioxi-
dants
Unclear Unclear High High Unclear High Unclear Low
Sanyal
2010
Thiazo-
lidine-
diones
Control:
Antioxi-
dants
Low Low Low Low Low Low High Low
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Table 2. Risk of bias (by comparison) (Continued)
Basu 2013 Thiazo-
lidine-
diones
Control:
Antioxi-
dants
Unclear Unclear High High Unclear High Unclear Low
Sanyal
2004
Thiazo-
lidine-
diones plus
antioxi-
dants
Control:
Antioxi-
dants
Unclear low Unclear Unclear low High Unclear Low
Parikh
2016
Antioxi-
dants
Control:
Bile acids
Unclear Unclear High High High High Low Low
Copaci
2009
Interven-
tion
1: Pentoxi-
fylline
Interven-
tion
2: Pentoxi-
fylline plus
bile acids
Control:
Bile acids
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Stilidi
2014
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
plus bile
acids
Control:
Bile acids
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Shiffman
2015
Anti-
caspase
Con-
trol: No in-
tervention
Unclear Unclear Low Low Unclear High High Low
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Table 2. Risk of bias (by comparison) (Continued)
Ratziu
2016
Anti-
fibrotic
Con-
trol: No in-
tervention
Low Low Low Low High High High Low
Harrison
2003
Antioxi-
dants
Con-
trol: No in-
tervention
Low Low Low Low High High Unclear Low
Kugelmas
2003
Antioxi-
dants
Con-
trol: No in-
tervention
Unclear Unclear High Unclear Unclear High Low Low
Gomez
2009
Antioxi-
dants
Con-
trol: No in-
tervention
Unclear Unclear Unclear Low Low High High Low
Magosso
2013
Antioxi-
dants
Con-
trol: No in-
tervention
Low Low Low Low Low Low High Low
Basu 2014 Antioxi-
dants
Con-
trol: No in-
tervention
Low Low High High Low High High Low
Santos
2003
Bile acids
Con-
trol: No in-
tervention
Unclear Unclear Low Low Unclear High High Low
Lindor
2004
Bile acids
Con-
trol: No in-
tervention
Unclear Low Low Low High High High Low
Mendez-
Sanchez
2004
Bile acids
Con-
trol: No in-
tervention
Low Unclear Low Low High High Unclear Low
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Table 2. Risk of bias (by comparison) (Continued)
Leuschner
2010
Bile acids
Con-
trol: No in-
tervention
Unclear Unclear Low Low Low Low High Low
Ratziu
2011
Bile acids
Con-
trol: No in-
tervention
Unclear Unclear Low Low Low Low High Low
Mudaliar
2013
Bile acids
Con-
trol: No in-
tervention
Unclear Low Low Low Low Low High Low
Safadi
2014
Bile acids
Con-
trol: No in-
tervention
Unclear Unclear Low Low High High High Low
Neuschwan-
der-
Tetri 2015
Bile acids
Con-
trol: No in-
tervention
Low Low Low Low Low High High Low
Gianturco
2013
Interven-
tion 1: Bile
acids plus
antioxi-
dants
Interven-
tion 2: An-
tioxidants
Interven-
tion 3: Bile
acids
Con-
trol: No in-
tervention
Low Low Low Low High High Unclear Low
Dufour
2006
Interven-
tion 1: Bile
acids plus
antioxi-
dants
Interven-
tion 2: Bile
acids
Con-
Unclear Low Low Low High High High Low
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Table 2. Risk of bias (by comparison) (Continued)
trol: No in-
tervention
Stefan
2014
Glucocor-
ticosteroid
inhibitor
Con-
trol: No in-
tervention
Low Low Low Low High High High Low
Morita
2005
Other
anti-dia-
betes med-
ication
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High Low Low
Armstrong
2016
Other
anti-dia-
betes med-
ication
Con-
trol: No in-
tervention
Low Low Low Low Low Low High Low
Wang
2015
Inter-
vention 1:
Other
anti-dia-
betes med-
ication
Inter-
vention 2:
Sulphony-
lureas plus
other anti-
dia-
betes med-
ication
Interven-
tion
3: Sulpho-
nylureas
Con-
trol: No in-
tervention
Unclear Unclear High High Unclear High Unclear Low
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Table 2. Risk of bias (by comparison) (Continued)
Merat
2003
Other
choles-
terol-
lowering
agents
Con-
trol: No in-
tervention
Low Low Low Low High High Low Low
Loomba
2015
Other
choles-
terol-
lowering
agents
Con-
trol: No in-
tervention
Low Low Low Low Unclear High High Low
Van
Wagner
2011
Pentoxi-
fylline
Con-
trol: No in-
tervention
Low Low Low Low High High Unclear Low
Ratziu
2014
Phospho-
diesterase
type 4 in-
hibitor
Con-
trol: No in-
tervention
Unclear Low Low Low High High High Low
Alam 2016 Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
Con-
trol: No in-
tervention
Low Low High High High Low Low Low
Ha-
jaghamo-
hammadi
2008
Silymarin
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Hashemi
2009
Silymarin
Con-
Unclear Unclear Unclear Unclear Unclear High Unclear Low
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Table 2. Risk of bias (by comparison) (Continued)
trol: No in-
tervention
Taghvaei
2013
Silymarin
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Solhi 2014 Silymarin
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear High High Unclear Low
Chan
2015
Silymarin
Con-
trol: No in-
tervention
Unclear Unclear Low Low Unclear High Unclear Low
Aller 2015 Silymarin
plus an-
tioxidants
Con-
trol: No in-
tervention
Low Unclear Unclear Unclear Low High Unclear Low
Bonfrate
2015
Silymarin
plus an-
tioxidants
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Lewis
2006
Statins
Con-
trol: No in-
tervention
Unclear Unclear Low Low Unclear High Unclear Low
Nelson
2009
Statins
Con-
trol: No in-
tervention
Unclear Unclear Low Low Low High Low Low
Baranova
2015
Statins
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Foster
2011
Statins
plus an-
tioxidants
Unclear Unclear Low Low Unclear High Unclear Low
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Table 2. Risk of bias (by comparison) (Continued)
Con-
trol: No in-
tervention
Uygun
2004
Sulphony-
lureas
Con-
trol: No in-
tervention
Low Unclear High High High High Unclear Low
Hauke-
land
2009
Sulphony-
lureas
Con-
trol: No in-
tervention
Low Low Low Low High High High Low
Nar 2009 Sulphony-
lureas
Con-
trol: No in-
tervention
Unclear Unclear Unclear Low Unclear High Unclear Low
Shields
2009
Sulphony-
lureas
Con-
trol: No in-
tervention
Low Low Unclear Low Low High Unclear Low
Garinis
2010
Sulphony-
lureas
Con-
trol: No in-
tervention
Unclear Unclear Unclear Low High High Unclear Low
Sofer 2011 Sulphony-
lureas
Con-
trol: No in-
tervention
Unclear Unclear Low Low Low High Unclear Low
Belfort
2006
Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Low Low Low Low High High High Low
Cui 2006 Thiazo-
lidine-
diones
Unclear Unclear Low Low Unclear High Unclear Low
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Table 2. Risk of bias (by comparison) (Continued)
Con-
trol: No in-
tervention
Aithal
2008
Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Low Low Low Low Low Low High Low
Ratziu
2008
Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Unclear Unclear Low Low High High High Low
Gastaldelli
2009
Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Unclear Unclear Low Low Unclear High Unclear Low
Yaginuma
2009
Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Jin 2010 Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Cusi 2013 Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High High Low
Kakazu
2013
Thiazo-
lidine-
diones
Con-
Unclear Unclear High Unclear High High Low Low
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Table 2. Risk of bias (by comparison) (Continued)
trol: No in-
tervention
Sunny
2015
Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Unclear Unclear Unclear Unclear Unclear High High Low
Yan 2015 Thiazo-
lidine-
diones
Con-
trol: No in-
tervention
Low Unclear High High Unclear High Low Low
Athyros
2006
Inter-
vention 1:
Statins
Inter-
vention 2:
Statins
plus other
choles-
terol-
lowering
agents
Con-
trol: Other
choles-
terol-
lowering
agents
Low Low High High Low Low High Low
Razav-
izadeh
2012
Antioxi-
dants
Control:
Silymarin
Unclear Unclear Low Low Unclear High Unclear Low
Haji-
aghamo-
hammadi
2012
Thiazo-
lidine-
diones
Sulphony-
lureas
Control:
Silymarin
Unclear Unclear Unclear Unclear Low High Low Low
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Table 2. Risk of bias (by comparison) (Continued)
Siddique
2015
Thiazo-
lidine-
diones
Control:
Statins
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Klyaryt-
skaya
2015
Renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
plus statins
plus an-
tioxidants
Control:
Statins
plus an-
tioxidants
Unclear Unclear High High Unclear High Unclear Low
Askari-
moghadam
2013
Sulphony-
lureas plus
antioxi-
dants
Control:
Sulphony-
lureas
Unclear Unclear High High Unclear High Unclear Low
Song 2014 Sulphony-
lureas plus
other anti-
dia-
betes med-
ication
Control:
Sulphony-
lureas
Low Unclear Unclear Unclear Unclear High Unclear Low
Sharma
2012
Pentoxi-
fylline
Con-
trol: Thia-
zolidine-
diones
Low Low High High High High Unclear Low
Omer
2010
Sulphony-
lureas
Con-
trol: Thia-
Unclear Unclear High High High High Unclear Low
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Table 2. Risk of bias (by comparison) (Continued)
zolidine-
diones
Razavizade
2013
Sulphony-
lureas
Con-
trol: Thia-
zolidine-
diones
Low Low Low Low Low Low Low Low
Torres
2011
Interven-
tion
1: Thiazo-
lidine-
diones plus
renin-an-
giotensin-
aldos-
terone sys-
tem
inhibitor
Interven-
tion
2: Thiazo-
lidine-
diones plus
sulphony-
lureas
Con-
trol: Thia-
zolidine-
diones
Low Low High High High High High Low
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. It was not possible to assess if potential effect modifiers were similar across different comparisons. Therefore, we did not perform
a network meta-analysis, and assessed the comparative benefits and harms of different interventions using standard Cochrane
methodology. The planned future network meta-analysis methodology that would be applied in review updates as data permit is
presented in Appendix 1.
2. We performed Trial Sequential Analysis in addition to conventional methods of assessing the risk of random errors using P values.
3. We included two additional histological outcomes as potential surrogate outcomes (fibrosis score and non-alcohol related fatty
liver disease (NAFLD) activity score) post hoc. We used this only for exploratory purposes because these outcomes are now accepted
by regulatory agencies for expediting drug approval in NAFLD through an accelerated approval pathway (Sanyal 2016) and did not
make any inferences based on the observations in these outcomes.
N O T E S
Considerable overlap is evident between the ’Methods’ sections of this review and those of other reviews written by the same group of
authors.
182Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
